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Summary
A rise in antibiotic resistance has prompted renewed interest in the use of 
phages to treat bacterial infections. This project explored the use of phages to 
treat Ps. aeruginosa infections in the context of potential treatment for Cystic 
Fibrosis patients.
Initial characterisation of phage activity, by both a conventional plaque based 
assay and a novel Bioscreen C assay, revealed that 4 Ps. aeruginosa phages 
could infect multiple strains of Ps. aeruginosa including some clinically 
prevalent strains within the UK. This initial activity was increased in some 
strains following selection with a selective virucidc, and a cocktail was 
designed. The cocktail showed a >2 Logio reduction after 20 h in 10 of 14 
strains. When the cocktail was tested against 4 Ps. aeruginosa strain biofilms, 
only a modest level of activity (<1 Logio) was measured. This was increased 
(>5 Logio) when combined with antibiotics in one bacterial strain in particular; 
i.e. the strain against which the phage were initially propagated. Assessment of 
the endotoxin content of the cocktail showed a level far in excess of acceptable 
levels (approximately 6 Logio EU/mL) that were not reduced sufficiently 
following purification by affinity chromatography (5.81*0.37 Logio EU/mL). 
Delivery of the phage cocktail showed acceptable levels of recovery following 
nebulisahon (approximately 99%).
The methods developed here, particularly the Bioscrecn C assay for the 
assessment of phage lytic activity is applicable to a variety of different arenas 
by the application of standard acceptance criteria on activity levels. The direct 
quantification of the bacterial content of biofilms following the addition of 
phage and virucide treatment is novel and allows a cidal activity to be 
measured.
Results have also highlighted the need for proper quality control within phage 
preparations for chronic infections. This investigation also highlighted the 
need for a standardised in vitro model that is more representative of the 
conditions found within a CF lung.
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Chapter 1
General Introduction
1.1 The human respiratory system
The lungs are the primary site for gaseous exchange within the body and are 
divided into lobes. The left lung comprises of two lobes and the right comprising 
of three lobes. The considerable surface area of the lungs, containing 
approximately 1500 miles of airways and some 300-500 million alveoli (Ochs et 
a/., 2004), allows for efficient gaseous exchange.
The human lung has multiple mechanisms, both generalised and adaptive, that are 
designed to protect it from external contaminants and potential pathogens (Table 
1.1).
While these innate defence mechanisms usually protect the lung from potential 
pathogens and maintain a sterile environment, there exist a number of conditions, 
including cystic fibrosis (CF), infection from the human immunodeficiency virus 
(HIV) and emphysema in which these mechanisms can be compromised and leave 
individuals susceptible to secondary infection from opportunistic pathogens.
2
Mechanism Function Innate/
Adaptive
Upper airway • Speed of air entry and curv e of airways causes Innate
filtering deposition of particles on airw ay surfaces based
on size
Coughing and • Reflex reaction Innate
sneezing o Designed to clear airways
o Works in conjunction with mucocilliary
clearance
Mucocilliary • Mucus is pushed up the respiratory tract by the Innate
clearance cilia beat
• Swallowed and digested
Phagocytosis • Macrophages Innate
o Non-specific degradation of pathogens by
free radicals
• Neutrophils
o Attracted to infection by release of
chemotaxins by macrophages
o Similar degradation to macrophages
Immune • Attraction of B and T cells to site of infection Adaptive
function
Table 1.1: Defence mechanisms possessed by the lung operating to remove 
and destroy bacterial pathogens. Adapted from (Sethi and Murphy, 2008).
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1.2 Cvstic Fibrosis
•r
Cystic Fibrosis (CF) is an autosomal recessive condition (Figure 1.1) that is 
believed to be the most common inherited genetic disease within the Caucasian 
population (Dodge et a l., 2007). Although primarily regarded as a disease o f 
Caucasian populations it has been shown to affect other populations to varying 
degrees (Boyle, 2007), with sub-Saharan Africa (Poolman and Galvani, 2007) 
exhibiting a lower incidence o f CF and those from an Ashkenazi Jewish 
population exhibiting a higher incidence rate (van de Vosse et al., 2005).
P tO , D r»
ddi <$><!> ■
Figure 1.1: Genetic basis of cystic fibrosis. Showing the autosomal recessive 
trait. Diamonds represent male, squares represent female, half shaded represents 
carrier phenotype, clear represents normal and filled represents sufferer.
The average life expectancy of current CF patients is just 31 years old (Ratjen and 
Ddring, 2003) with female sufferers believed to have a higher mortality rate 
(Arrington-Sandcrs et a l., 2006). This is drastically shorter than the average UK 
life expectancy for non-CF patients at 77 years for males and 81 years for females 
(Office of National Statistics, 2010). However, due to improved diagnostic and
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therapeutic strategies, it has been suggested that the average life expectancy for CF 
sufferers bom within the UK in 2003 will be >50 years old (Dodge et a l 2007).
1.2.1 CF pathophysiology
The CF gene defect is carried on chromosome 7 at locus q 3 1.2 and encodes for the 
cystic fibrosis transmembrane conductance regulator (CFTR), an adenosine 
triphosphate (ATP) binding cassette whose structure extends across the cellular 
membrane (Figure 1.2) where it is responsible for the regulation o f chloride ion 
transport across cellular membranes in multiple organs within the human body 
including the lungs, liver, gut and pancreas (Saiman and Siegel, 2004).
MSDM1 M SDM 2
C ell membrane
CFTR 
positioning in 
the cell 
membrane
NH;
NBD
C y t o p l a s m
Figure 1.2: The struc tu re  of the C FTR  protein. The function o f  the protein is to 
bind and hydrolyse ATP at the nucleotide binding domains. Adapted from Gibson 
et al (2003). Membrane spanning domain - MSDM, Nucleotide Binding domain - 
NBD, Regulatory - R domain.
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The most common mutation of the chloride channel associated with CF is the 
result of the deletion of three base pairs encoding for phenylalanine at position 508 
(AF508), which accounts for approximately 66% of mutations (Accurso, 2007).
The AF508 mutation is located within the 14‘ nucleotide binding domain (NBD 1) 
and impacts disease severity. In a homozygous state, the mutation results in 
abnormal protein folding and subsequent degradation that in turn increases the 
severity of symptoms (McCormick et al (2002). However, in a heterozygous state 
the mutation results in a decrease in the ability to regulate chloride ion transport 
across the cellular membrane."
However, it should also be noted that other mutations do exist in varying 
prevalence (Table 1.2) and has been studied in some detail within both UK and 
international populations (McCormick et al., 2002; Hantash et al., 2006).
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Mutation Gene frequency 
per 1000 genes
Effect of Mutation
AF508 752.0 • Classical form of CF
• Deletion of phenylalanine at position 508
• Accounts for approximately 66% of alleles 
in Caucasians
G551D 34.3 • (ilycine to aspartic acid substitution at 
position 551
• Reports of pancreatic insufficiency
• Higher prevalence in French Canadians 
(Gibson et al., 2003)
G542X 18.4 • Premature stop codon mutation (Sennet - 
Gaudclus et al., 2007)
• Halts transcription early
RI17H 12.7 • Substitution of arginine for histidine at 
position 117 (O'Sullivan et al., 2006)
• Missensc mutation in exon 4
• Reduces level of chloride transport
621 + 1G->T 12.7 • Guanine to thymine change at position 621
• Resulting from mRNA splicing defect
• Patients present with high sweat chloride 
levels >100 mmol L (Kercm et al., 1990)
Table 1.2: Breakdown o f the 5 most frequent m utations o f CFTR within the 
genotyped Caucasian UK CF population. Adapted from McCormick et al 
(2002).
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1.2.2 Diagnosis and clinical presentation
Diagnosis of CF patients occurs prenatally or soon after birth (Table 1.3). In older 
patients diagnosis can occur following the onset of unexpected illness.
Age Diagnosis
Prenatal
screening
Screening of chronic villus fluid for the most common mutations 
(Ratjen and DOring, 2003)
<2 Weeks Analysis of dried blood for immune reactive trypsin AND screening 
for common mutations due to the low specificity and sensitivity of the 
trypsin test (Southern et al., 2007)
2-4 Weeks Sweat lest: salt levels in sweat of >60 mmol L arc indicative of 
positive results
Table 1-3: Diagnosis of CF in infants
CF typically and primarily presents as the accumulation of viscous mucus within 
the small airway spaces of the lung (Rubin, 2007) leading to an increased 
susceptibility to bacterial infection (Gomez and Prince, 2007). The presence of 
different phenotypes within the gene mutation itself affects the clinical 
presentation of the disease (Kiesewetter et al., 1993), including the involvement of 
multiple organ systems including the pancreas (Moskowitz et al., 2008) and the 
intestines (Borowitz et al., 2005). Less significant symptoms include the 
deterioration of bone density (King et al., 2005) and the clubbing of joints (Ratjen 
and Ddring, 2003).
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1.2.3 important pathogens of cvstic fibrosis
The establishment of active bacterial infection within the CF patient is perhaps the 
most important pathological feature and is believed to be the leading cause of 
mortality (Rogers et al., 2005).
In the early stages of life numerous bacterial strains, such as Staphylococcus 
aureus and Haemophilus influenzae (Saiman and Siegel, 2004) have been shown 
to establish primary infections within the CF lung. They arc ultimately supplanted 
by Pseudomonas aeruginosa which is believed to be resident within 80% of the 
CF population by the age of 20 (Pritt et al., 2007).
Ps. aeruginosa is arguably the most important pathogen, and will be discussed 
later in greater detail. The increasing prevalence of Burkholderia cepacia complex 
in both single colonization and in co-colonization within CF patients has resulted 
in increased mortality (Courtney et al., 2004). Although co-colonization was 
initially rare, increased co-infection rates could be due to the congregation of 
patients with mixed respiratory infections in CF centres (Wainc et al., 2007) as the 
B. cepacia complex is highly transmissible (McDowell et al., 2004; Festini et al., 
2006).
This practice of congregation of patients with multiple infections has given way to 
the increasing segregation of patients by type of infection (Festini et al., 2006). 
Although both Ps. aeruginosa and B. cepacia complex arc important pathogens 
within the CF patient, a number of new bacterial pathogens such as 
Stenotrophomonas maltophilia, Alcaligenes xylosoxidans and Inquilinus limosus 
(Lambiase et al., 2006; Fierasimenka et al., 2007) are beginning to emerge. In 
addition both fungal e.g. Aspergillus Jumigatus (Lyczak et al., 2002) and viral 
pathogens such as the influenza virus will present new challenges to physicians.
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Currently, and largely due to the voluntary reporting nature of these emerging 
pathogens, no accurate incidence rates exist at this time.
1.2.4 Current CF therapy
Currently no vaccine or cure exists for the underlying genetic defect of CF; 
various therapies exist to treat the symptoms and complications from the 
condition. The accumulation of mucus within the lungs is treated by a 
combination of a physiotherapeutic regime (Osman et al., 2010) and the use of 
anti-mucolytic compounds (Fahy et al., 2010). The former approach (i.e. the 
physiotherapy regime) is often limited in its effectiveness due to poor patient 
compliance (Osman et al., 2010). CF patients arc at increased risk of developing 
respiratory infections (Rogers et al., 2005). Antibiotics arc routinely used to 
control respiratory pathogens and in the case of Ps. aeruginosa infections are used 
to try to eradicate initial infections before a biofilm can be established (Ho et al., 
2009).
13 Pseudomonas aeruginosa
1.3.1 Structure and morphology
Ps. aeruginosa is a motile Gram-negative bacillus (rod) approximately 0.5-0.8 pm 
x 1.5-3.0 pm that belongs to the Pseudomonadaceae family. While this bacterium 
is primarily an opportunistic pathogen, it can establish chronic infections in both 
bum victims (McVay et al., 2007) and those patients with cystic fibrosis (Saiman 
and Siegel, 2004). It is most prevalent in the over 65’s due to immunosenescence 
(Sansoni et al., 2008).
The organism itself is ubiquitous to the environment and is frequently found in 
water reservoirs that have been contaminated by human waste and sewage (Pitt, 
1986). It has also been shown to cause folliculitis in bathers using hot tubs (Yu et 
al., 2007) presumably due to the optimum growth temperatures and poor 
disinfection regimes that are observed in many privately-owned hot tubs.
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In reality it is this ability to grow on numerous surfaces and utilise multiple 
sources of nutrients that allow the organism to present a health risk. When 
compared to other bacterial agents that arc usually associated with CF, namely H. 
influenzae and Staph, aureus, it has been observed that the genome of 
Pseudomonas is larger, 6.26 Mega base pairs (Mbp) with approximately 5567 
genes, than that of both H. influenzae (1.83 Mbp and 1714 genes) and Staph, 
aureus (2.81 Mbp and 2594 genes) (Lambert, 2002). It is also believed that some 
1500 of these genes are needed for metabolism and the production of structural 
proteins, showing a larger than normal capacity for adaptation (Lambert, 2002) 
when compared to other pathogens.
1.3.2 Virulence factors
The Pseudomonas bacterium possesses a number of different mechanisms that 
allow it to establish and maintain chronic infections within both normal patients 
and CF sufferers; bacteracmia associated with Ps. aeruginosa has increased 
between 2006 and 2010 (Figure 1.3). This increase in levels of Pseudomonas 
derived bacteraemia could be the result of a changing hospital population in which 
a greater number of people with deficient immune systems are being treated and 
could also be in part due to better reporting systems.
11
3300
2006 2007 2008 2009 2010
Year
Figure 1.3: N um ber of bacteraem ia cases associated  with Ps. aeruginosa 
between 2006 and 2010 within England and W ales. Based upon voluntary 
laboratory reporting. Adapted from Health Protection Agency (2011).
These factors include the ability to form a biofilm as well as the ability to cause 
tissue damage through the secretion o f proteases and toxins. These various factors 
will play an important role in the clinical outcome and can affect resistance to 
antimicrobials (Figure 1.4).
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Figure 1.4: T rends in the antibiotic resistance of Ps. aeruginosa  im plicated in 
bacteraem ia to antibiotics between 2006 and  2010 w ithin England and W ales.
Based on voluntary laboratory reporting. Health Protection Agency (2011).
1.3.2.1 Alginate production
Alginate is a linear polysaccharide comprised o f [1-D-mannuronic and a-L- 
guluronic acid residues that arc joined in a 1 ,4  linkage (Ertesv&g et a l., 1998). 
The bacterial polysaccharide varies from its algal counterpart through the presence 
of O-acetyl groups on mannuronate residues (Nivens et a l., 2001). In Ps. 
aeruginosa it is synthesised from fructose-6-phosphate in a 7-stage pathway 
(Figure 1.5).
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Alginate overproduction appears to be characteristic of some CF epidemic strains 
but not all. It has also been shown to fulfil a role in biofilm development (Hentzer 
et al., 2001) although not as centrally important as previously believed due to the 
involvement of non-mucoid polysaccharides (Wagner and Iglcwski, 2008).
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Figure 1.5: Alginate biosynthetic pathway as seen in Ps. aeruginosa. Adapted 
from Ertesv&g (1998). Enzymes catalysing reactions arc shown in italics.
The role of alginate within the CF lung is believed to be similar to an adhesin, 
allowing for successful attachment to cells (Kipnis et al., 2006). It is also believed 
that alginate has a protective role in which host defence function is compromised, 
particularly phagocytosis. Also some antibiotics such as the cationic 
aminoglycosides bind to the alginate (Lambert, 2002). However, Moskowitz and 
colleagues (2004) presented contradictory evidence that showed mucoid forms of 
Ps. aeruginosa are found to be fully susceptible to cationic aminoglycosides 
(Moskowitz et al., 2004).
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1.3,2.2 Pvocvanin production
Pyocyanin (N-methyl-l-hydroxyphenazinc) is a redox-active secondary metabolite 
that is secreted by Ps. aeruginosa to produce a blue pigment and is regulated by 
the quorum sensing system (Kipnis et al., 2006).
Pyocyanin production has been shown to play an important part in the virulence of 
Ps. aeruginosa and has been shown to be overproduced in some epidemic strains 
(Fothergill et al., 2007). Pyocyanin can inhibit the beating frequency of cilia on 
respiratory epithelial cells in vivo (Sadikot et al., 2005) and also induce apoptosis 
in neutrophils in culture (Usher et al., 2002; Allen et al., 2005). This apoptotic 
feature could result in the release of other compounds into lung spaces resulting in 
oxidative damage (Kipnis et al., 2006). It may also be responsible for an influx of 
neutrophils into the lung (Lau et al., 2004) which may account for the acidification 
of breath exudates that are observed in CF patients (Tate et al., 2002; Di et al., 
2006).
The presence of pyocyanin has also been shown to depress the host response to Ps. 
aeruginosa bacteria by increasing the levels of IL-8, an immunosuppressive 
cytokine (Allen et al., 2005). This suppression of the host’s immunity could 
provide the Pseudomonas bacterium with a chance to establish itself within the 
lung and protect itself from further interventions. Furthermore, the impairment of 
the host’s immune system has been shown to limit the rate at which apoptotic cells 
are cleared by macrophages (Bianchi et al., 2008).
However, while it has been suggested that pyocyanin may impair CFTR channels 
in CF by disrupting ATPase (Lau et al., 2004), this action is dependent on the 
presence of oxygen which has been shown to be lacking from mature biofilms 
within CF lungs (Worlitzsch et al., 2002).
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1.3.2.3 The Type 111 secretion system and exotoxin production 
Ps. aeruginosa possesses the ability to directly damage the respiratory epithelial 
cells which it binds to, often through the production of exotoxin A. Exotoxin A is 
a proenzyme of molecular weight 66-71 kDa (Pitt, 1986). It enters target cells 
through receptor-mediated endocytosis and inhibits protein synthesis leading to 
cellular death (Sadikot et al., 2005). Death arises because of adenosine 
diphosphate (ADP) ribosylation (Jenkins et al., 2004), a post-transcriptional 
modification of protein occurring through the addition of one or more ADP and 
ribose groups (Sadikot et al., 2005).
Exotoxin has also been shown to be associated w ith high levels of lethality and 
also dissemination of infection in animal models (Kurahashi et al., 2004). The 
toxin can induce apoptosis of human mast cells in culture through capsase- 
dependant mechanisms (Jenkins et al., 2004). which results in down regulation of 
anti-apoptotic pathways. Such down regulation of anti-apoptotic pathways could 
play a significant role in the pathological features that arc observed within the CF 
lung, where the increase of apoptotic cells within the lung, along with other 
factors, could cause a decrease in lung function (Accurso, 2007) and potentially 
the influx of non-specific host defences such as phagocytosis.
The type 111 secretion system possessed by Ps. aeruginosa and other Gram- 
negative bacteria is mediated by pilin and requires contact between the bacterial 
cell and the epithelia in order to function (Sadikot et al., 2005). This system allows 
the production, and injection, of at least four effector proteins (ExoS, ExoT, ExoY 
and ExoU) into host cells. The presence of these effector proteins varies from 
strain to strain and it has been shown that all strains possess ExoT and around 90% 
possess ExoY (Vance et al., 2005).
In the case of the most recently discovered protein, ExoY has been shown to be an 
adenylate cyclase with similar homology to the adenylate cyclase found in
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Bacillus anthracis and Bordetella pertussis (Yahr et al., 1998), but little is known 
about its impact on cellular pathology.
Both ExoT and ExoS have been shown to have a high degree of homology and 
possess both guanine diphosphatase (GDPase) - activating activity and an ADP- 
ribosyl transferase domain (Cuzick et al., 2006). Although both proteins have 
been associated with increasing the level of apoptosis (Alaoui-El-Azher et al., 
2006; Shafikhani and Engel, 2006) it is unclear if this is independent of one 
another, or that ExoT inhibits cellular repair of wounded cells (Geiser et al., 2001) 
and that actual apoptosis is caused by ExoS (Shafikhani and Engel, 2006).
ExoU has been shown to cause high levels of irreversible damage to epithelial 
cells (Sadikot et al., 2005) and could be responsible for the high levels of IL-8 
secretion that are associated with Pseudomonas infection (Cuzick et al., 2006).
1.3.2.4 Elastase and protcase production
Within the normal human lung alveolar cpithelia arc lined with surfactant, a 
complex of lipoproteins that is designed to regulate bacterial clearance and reduces 
surface tension to increase the level of oxygen absorption (Alcorn and Wright,
2004). Surfactant is comprised of around 90% lipids and 10% protein, 
predominantly, Surfactant Protein-A (SP-A), SP-B, SP-C and SP-D (Malloy et al.,
2005).
The two main components that are specifically affected by Ps. aeruginosa 
proteases are SP-A and SP-D which have been shown to be present in decreased 
levels in the lungs of CF patients (Beatty et al., 2005); these two proteins are 
mediators of innate host defences and could be partially responsible for the 
decrease of host immune function in CF lungs. In addition to this Pseudomonas 
also secretes a number of alkaline proteases which circumvent many functions of
17
both the adaptive and innate immune systems by promoting tissue invasion 
(Sadikot et al., 2005).
Ps. aeruginosa also secretes elastasc enzymes which have been shown to cleave 
SP-D (Alcorn and Wright, 2004) resulting in decreased mucocilliary clearance. 
Furthermore, elastasc is responsible for disruption of the epithelial cell lining 
allowing the invasion of lung tissues by Ps. aeruginosa (Sadikot et al., 2005). In 
vitro, it has been shown that inactivation occurs through the disablement of 
proteinase-activated receptor 2, believed to have a role in the innate immunity of 
the lung (Dulon et al., 2005) and is presumably responsible for the loss of lung 
function that is observed in the lungs of CF patients.
1.3.2.5 Other factors
Like many other Gram-negative bacteria Ps. aeruginosa possesses a 
lipopolysaccharide (LPS) layer comprising of a lipid A structure that contains N 
and O acylated diglucosamine biphosphatc backbones. While the same 
fundamental structure is present in Pseudomonas isolated from both CF patients 
and laboratory adapted strains, there is variation in the number of acyl groups as 
well as fatty acid types (Pier, 2007). These side chains have often been the basis 
for serologicical typing due to their antigenic properties (Sadikot et al., 2005).
In the case of CF patients it has been shown that increased inflammation within the 
lung is due to LPS increasing permeability between epithelial cells (Lutamene et 
al., 2005). It has also been shown that direct interaction between bacterial LPS 
and respiratory epithelial cells results in increased uptake and destruction of 
bacteria (Pier, 2007). This increase in destruction is due to a rapid response from 
epithelial cells resulting in the production of many proinflammatory cytokines 
which, in CF lungs, have been shown to be present but in lower levels than those 
of normal patients.
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Ps. aeruginosa expresses a number of pili upon its cell surface. These pili are 
involved in Pseudomonas motility and arc partially responsible for “twitching” 
(Kipnis et al., 2006). This process has been shown to allow the bacterium to travel 
across hydrated surfaces and aids colonization within the CF lung by binding to 
epithelial cell membranes (Sadikot et al., 2005). It has been shown that non-pili 
producing mutants of Ps. aeruginosa are less virulent than those which can 
produce pili, while those which are hypcr-pilatcd mutants (i.e. expressing more) 
form denser biofilms (Chiang and Burrows, 2003).
The single polar flagellum of Ps. aeruginosa has been shown to mediate adhesion 
to asialoGMl residues on pulmonary epithelial cells (Kipnis et al., 2006) which in 
turn allows for initial biofilm formation to occur. Despite playing a role in this 
key pathogenic stage up to 39% of Pseudomonas isolates arc non-motilc (Zhang et 
al., 2007) showing that once biofilms arc formed flagclla arc lost. The loss of 
flagella, following the formation of biofilms, would also account for a lower 
immune response to the bacteria compared to their flagellated counterparts (Tseng 
et al., 2006) enabling the infection to persist and develop.
The effect of Ps. aeruginosa infection on the presentation of CF symptoms are 
summarised in Table 1.4.
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Cause Mode of action Clinical Significance
Pyocyanin • Reduces frequency of cilia • Decreased mucus clearance
production beat • Acidification of lungs
• Induction of neutrophils
apoptosis
Biofilm • Attachment to lung surfaces • Increased resistance to
formation and secretion of antibiotics
exopolysaccharide • Frustrated immune system
Elastase • Disrupts lung epithelial • Increased tissue invasion
production lining • Decreased lung function
LPS release • Interaction between LPS and • Increased bacterial attachment
cell surface structures to lung surfaces
• Inflammation of lung spaces
from immune response
Degradation • Ps. aeruginosa produces a • Further decrease in surfactant
of surfactant number of alkaline fluid levels, resulting in
proteins phosphatases impaired lung clearance
Table 1.4: Summary of the effects of Ps. aeruginosa infection on CF
symptoms.
1.4 Bacterial biofilms
1.4.1 Importance of biofilm associated infection
It is believed that biofilm associated infection accounts for 60% of bacterial 
infections treated within the developed world (Fux et al., 2005). This type of 
infection presents a challenge to physicians when considering therapeutic 
strategies (del Pozo and Patel, 2007) and is primarily resident within medical 
devices (Vickery et al., 2004) and artificial joint replacements (Zimmerli and 
Ochsner, 2003).
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Once established as a biofilm within the lungs of CF patients, Ps. aeruginosa 
proves to be highly resistant to antibiotic therapy, with minimum inhibitory 
concentrations (MIC) increasing by up to 1000 fold (Li et al., 2008). The 
resistance of Pseudomonas bioftlms is in part due to the emergence of persister 
cells that can survive antibiotic treatment (Mulchay et al., 2010).
1.4.2 Model systems of biofilms
Model systems of bacterial biofilms have been developed which aim to provide 
similar conditions to those encountered in vivo. These systems are often based on 
approaches similar to those described below.
Although many biofilm models have been developed in order to best mimic the in 
vivo conditions, these model systems can often be divided into two basic 
categories. Those which are close to in vivo conditions but are often difficult to 
reproduce and those which sacrifice mimicry for reproducibility.
1.4.2.1 Constant depth film fermentor
The constant depth film fermentor (CDFF) (Figure 1.6) functions as a sealed unit 
in which biofilms of a constant depth can be developed and studied. The unit 
operates through the addition of liquid media via a sealed inlet that is protected 
from the outside environment by a bacteria-proof filter (Hope and Wilson, 2006). 
Inside the sealed unit the biofilms are grown on circular discs of a desired material 
(usually polytetrafluoroethyiene (PTFE; Zanin et al., 2005) which can be recessed 
to produce biofilms of a chosen depth (Figure 1.6). Once biofilms have grown to 
the required depth a PTFE scraper removes excess growth which can then be 
discarded leaving an investigable biofilm which can subsequently be removed for 
testing.
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Figure 1.6: Schematic representation of a constant depth film fermentor.
(UCL iiastman Dental Institute, 2010)
This method of biofilm growth has been used in a number of investigations to 
measure the susceptibility profiles of oral biofilms (Hope and Wilson, 2006), 
Candida albicans biofilms (Lamfon et al., 2004), and the effect of photodynamic 
therapy on Streptococcus mutans biofilms (Zanin et al., 2005) primarily within an 
oral environment.
The CDFF possesses a number of advantages over the other model systems which 
are discussed later. Firstly, the CDFF is a sealed environment in which growth 
conditions can be adapted to meet specific requirements (Peters and Wimpenny, 
1988), in terms of both media and atmospheric composition. Secondly, the 
biofilm produced can be altered in terms of depth to possess architecture which is 
unique to its stage of development. These structures will be conserved, 
particularly those of the mature biofilm, in which anaerobic conditions within the 
lower regions have been established.
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1.4.2.2 Flow system
The passage of fluid through tubing at a constant rate allows for the establishment 
of bacterial biofilms while removing unattached bacteria and is the characteristic 
feature of the flow system of biofilm formation.
This system has been used successfully in conjunction with microscopy techniques 
(Lee et al., 2005). Using this approach, Lee and colleagues (2005) have been able 
to directly investigate the microstructurc of a biofilm produced by a non-mucoid 
form of Ps. aeruginosa isolated from a CF patient without disturbing the delicate 
structures contained within, providing an advantage to other systems available. 
However, the flow system model may not provide the best mimic of in vivo 
conditions. This system also requires the sacrificing of tubes for analysis (Kirisits 
et al., 2005) thereby limiting the length of time which films can be consistently 
studied. It has also been reported to be more difficult to use when compared to 
other systems (Fonseca et al., 2007).
1.4.2.3 Sedimentation
A sedimentation biofilm, (Figure 1.7) unlike the other forms of biofilms discussed 
above, uses a singular supply of media and there is no media flow over the surface 
under investigation. Unlike naturally formed biofilms, cells once attached can 
propagate and form mature biofilms which unless disturbed should not slough off 
fiom the attachment surface.
This system has been used as a semi-quantitative method for measuring cell 
propensity to attach to surfaces (Sriramulu et al., 2005) through the use of a crystal 
violet assay. This assay measures cell attachment based upon the association of a 
crystal violet stain to biofilm associated substances (Lee et al., 2005). This 
method provides semi-qualitative data at best and is subject to easy disruption 
when adding or removing reagents, thereby limiting its usefulness.
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Sedimentation biofilms have also been used to measure the effects o f shear stress 
(Fonseca et al., 2007) on Ps. aeruginosa biofilms a simpler manner than with flow 
cell models.
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Figure 1.7: Schematic represen ta tion  o f the developm ent of a biofilm.
1.4.2.4 Model systems of cystic fibrosis
As previously discussed CF patients arc predisposed to multiple bacterial 
infections most notably and prevalent is Ps. aeruginosa. This increased 
susceptibility is due to characteristic CF traits which include both decreased 
mucocilliary clearance and also the production o f  thick mucus. In order to better 
understand the mechanisms and pathogenesis that underpin biofilm associated 
infections, particularly those which are prevalent in CF, in order to increase and 
develop new therapeutic approaches, the development o f  model systems is 
paramount.
The predominant model system that is used in the study o f in vivo conditions o f 
the CF lung appears to be the flow cell model (Krisits et al., 2005), although 
murine models, CDFF models (Hcntzer et al., 2001) and static growth models 
(Fonseca et al., 2007) have been used. Each model possesses particular
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advantages and disadvantages when compared with one another (Table 1.5). In 
particular, flow system models of CF lungs are limited in usefulness by the fact 
that they require a constant flow of medium, while in vivo conditions of the CF 
lung reveal that movement of mucus is frustrated by the defect in the CFTR 
channel resulting in a decreased ciliary beat (Verkman, 2001). Flow system 
models often are difficult to produce (Fonseca et al., 2007) and require the 
sacrifice of portions of biofilm.
In a model system of the CF lung it has previously been shown that Ps. aeruginosa 
exhibits multiple colony morphotypes which could play a role in the establishment 
and persistence of infection (Kirisits et al., 2005). This is further supported in Lee 
et al (2005) in which non-mucoid Ps. aeruginosa isolates from CF patients were 
tested for production of virulence factors and also quorum sensing molecules. 
This study showed that non-mucoid strains of Ps. aeruginosa were able to form 
biofilms that, when assessed by a crystal violet assay, were shown to bind less 
crystal violet than PAOl implying a less complex biofilm.
Other model systems of CF have explored the addition of an artificial mucus 
medium on the formation of micro-colonies (Sriramulu et al., 2005). This study 
found that the addition of artificial mucus supplemented with amino acids 
promotes the growth of micro-colonies within a biofilm and also alters the 
phenotypic presentation of Ps. aeruginosa grown in this manner. This medium 
allows colony phenotypes to be more consistent with those found during the initial 
attachment and invasion phases of Pseudomonas colonisation.
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System of 
Growth
Advantages Disadvantages Possible
applications
Sedimentary • Simplest to • Highly fragile biofilms • Early
produce created screening of
• Poor reproducibility drug
• Difficult quantification of 
bacterial numbers
efficacy
Row Cell • Direct • Difficult quantification of • Biofilms
visualisation bacterial numbers within water
of biofilm • Specialist apparatus systems
structure required
CDFF • Biofilm depth • Difficult quantification of • Efficacy of
reproduction bacterial numbers drugs
• Structure of • Specialist apparatus against
biofilm alters required mature
over biofilms
incubation
period
Table 1.5: Summary of advantages and disadvantages of different biofilm 
producing systems and potential applications.
1.5 Bacteriophage
Bacteriophages (phage) are viruses that specifically target bacterial cells and are 
believed to be amongst the most numerous organisms on Earth (Hanlon, 2007). 
Phages are also environmentally ubiquitous and reside within all reservoirs that are 
populated by potential host bacteria. Initially discovered by Twort and d’Herelle 
in the early part of the 20th century phages have been used to treat a variety of
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bacterial infections (Kutter et al., 2010) and were used in both the First and 
Second World wars (Sulakvelidze et al., 2001).
With the introduction of antibiotics, namely penicillin, in the early 1940s phage 
research and therapy have since been confined to the former Soviet Union and 
Eastern Europe, where phages are currently used in clinical practice. This 
restricted geographical application has primarily been due to Western scepticism 
over the benefits claimed (Barrow and Soothill, 1997) and also due to political 
history (Sulakvelidze et al., 2001).
1.5.1 Structure and replication
The replication of phage centres on one of two cycles, the lytic or the lysogenic 
cycle (Sulakvelidze et al., 2001). In both these cycles viral attachment to host 
cells is the initial stage with host cell lysis being the culmination of replication 
(Figure 1.8). Viral replication is based on the hijacking of the host's metabolic 
machinery to produce and assemble progeny; this self replication makes the phage 
an ideal candidate for antimicrobial therapy as this would reduce the number of 
repeat doses that would be required in order to eliminate a bacterial population.
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Figure 1.8: Lysis and Lysogeny. The lifecycles of phage. In both lysis and lysogeny bacteriophage follow the same process of attachment 
(A), injection of genetic material; (B), replication and packaging of viral progeny; (C-D), before the lysis of the cell (L). However, in the 
lysogenic cycle viral genetic material can be inserted into the host DNA whereby it can lay dormant (lb) until reactivated (la). Adapted 
from Sulakvelidze et al (2001).
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The ability of phage to undergo a lytic lifecycle is the underpinning theory 
behind phage therapy due to the ability of the phage to destroy the host cell 
upon replication (Watanabe et al., 2007).
The use of lysogenic phages is best confined to genetic engineering and gene 
delivery, as genetic material is incorporated into the host genome and is then 
replicated with bacterial growth (Clark and March, 2006) which would allow 
for the successful replication of desired genetic sequences.
Phages are usually between 20 and 200 nm in size and while a great deal of 
morphological variability exists, the majority of phages tend to exhibit some 
structural similarities. The head (or capsid) of phage is a protein structure that 
is usually icosahedral in shape (as in the Pseudomonas phage OKZ; Fokine et 
al., 2005) and contains the viral genome (Hanlon, 2007). In the case of some 
Pseudomonas phages the capsid structure can vary from the icosahedral 
structure (Hanlon, 2007) or be absent altogether, as is the case with the 
Inovirus family, where the primary structure is helical in arrangement and 
consists of coat proteins surrounding the genome (Holland et al., 2006). The 
purpose of the capsid is to protect the genetic material from degradation by the 
extracellular environment. The viral genome can exist as either singfe or 
double stranded DNA or RNA; although it is often double stranded DNA and 
the Caudovirales family (tailed phages) of phages account for approximately 
95% of published literature.
In the case of Ps. aeruginosa specific phages there has been observed a lower 
ratio of guanine to cytosine (G+C) within their genome when compared to the 
host genome of PAOl (54.4:66.6%) and is contrary to the similarities in 
content that is usually observed in other phage/host comparisons e.g. 
Mycobacterium tuberculosis (63.6:65.6%; (Kwan et al., 2006). This 
discrepancy could be accounted for in a number of different ways: 1) recent 
phage invasion from a host with a lower G+C content; 2) genetic conservation 
throughout the evolutionary history of the phage; and, 3) lateral gene transfer
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(Kwan et al., 2006). In the case of Pseudomonas phages, particularly those 
from the Myoviridae family (such as OKZ and EL) (Hertveldt et al., 2005; 
Lavigne et al., 2006) the potential for evolutionary divergence to exist is shown 
by the lack of similar homology to other members of the same family.
In order to mediate attachment to host cells, some phages possess tail fibres 
with the ability to contract. These have been well characterised in the 
Enterobacteria phage T4 of Escherichia coli which possesses a number of tail 
fibres which interact with host cell surface receptors (usually LPS molecules or 
OmpC (surface antigen) proteins) (Rossmann et al., 2004). Once a number of 
tail fibres have bound to the host cell, the tail sheath shortens to allow gp5 
residues on the baseplate (Figure 1.9) to puncture the cell membrane.
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Figure 1.9: Generalised structure of a T4-like bacteriophage.
1.5.2 Bacteriophages as antimicrobial agents
Within Western published literature there seems to be a lack of information 
surrounding the efficacy of phage therapy in humans, although data for both 
animal models and in vitro studies against a variety of organisms exist.
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With the application of phage to the treatment of infection a number of 
variables have to be borne in mind when considering an administration route 
(Table 1.6). Although phages are normally assumed to be highly specific to 
their host, it is possible to develop promiscuous phage under selective 
conditions (Cooper et a l 2011).
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Admin. Route Advantages Disadvantages
Oral
• Economical
• Can be self-administered
• Non-damaging to normal flora
• Sclf-replication of phage
• Neutralisation of gastric 
acid would be necessary
• Endotoxin release from 
lysed bacteria
• Absorption into the body
Ophthalmic • Simple delivery method • Endotoxin release
e.g. eye drops • Self-replication of phage • Could only be used for
• Self-administered eye infections
Topical e.g. • Simple delivery • Poor penetration of phage
cream • Self replication of phage • Limited uses e.g. bums,
• Self administered skin conditions etc
Parenteral • Would require specialist • Clearance by immune
including administration although system
subcutaneous. training could be provided to • Time taken to reach site
intravenous. allow self-administration of infection
intramuscular • Rapid spread throughout body • High levels of purity
and • Self-replication of phage required
intraperitoneal • Endotoxin release
• Highly useful for lung • Loss of dosage in airways
conditions e.g. pneumonia • Endotoxin release
Inhalation • Could be self-administered • Viability of
• Self-replication of phage bacteriophages following 
shear stresses 
• Mucus penetration
Table 1.6: Potential routes of phage administration. A dapted from C lark 
and March (2006).
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In the case of intravenous application, it has previously been shown in a murine 
model of bums that phage therapy can reduce levels of Ps. aeruginosa 
infection and improve survival rates (McVay et al., 2007). In this particular 
case survival rates based upon a single phage dose increased from 6% (in non­
treated mice) to between 22% and 87% (McVay et al., 2007). This study also 
showed that the route of administration proved important to clinical outcome 
with intraperitoneal (i.p.) administration shown to be the most effective. 
However, despite improvement in outcome, the most logical route of 
application for phage in this instance would be topical where it has been 
previously demonstrated in humans that topical application of a phage cocktail 
was effective (Marza et al., 2006).
Although an actively replicating phage would arguably be most effective in 
treating bacterial infections, some studies have used non-replicating phage as 
an alternative (Hagens et al., 2004). The study by Hagens and colleagues 
(2004) showed that a non-replicating phage was effective at reducing the level 
of PAOl infection in mice, although it was less effective than a replicating 
phage, presumably due to the repeated re-infection of PAOl. Perhaps what is 
most striking is the survival rates of mice treated with replicating and pon- 
replicating phage, where in the latter case 70% of mice survived the 
observation period compared to just 20% in the case of a replicating phage. 
This difference in survival rates is assumed to be due to the release of LPS 
from lysed bacteria (Hagens et al., 2004) which has been shown to be 
recognized by TLR4-bearing (Toll like receptor) macrophages, resulting in the 
release of proinflammatory cytokines such as IL-1 and interferon gamma (IFN- 
y) (Gould et al., 2004). However, in the case of the non-replicating phage, host 
cell integrity was maintained despite cell death, therefore preventing the 
release of LPS and allowing the bacterial cell to be phagocytised, which in turn 
will reduce the host response to exopolysaccharide (EPS).
The addition of phage has also shown the ability to reduce the viscoelastic
properties of purified EPS of Ps. aeruginosa from 2.33 mega Pascal (mPA) to
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1.76 mPa after 20 hours while also reducing the bacterial content of these 
biofilms compared to negative controls (Hanlon et al., 2001).
Although phage therapy in humans is unlikely to supplant antibiotic therapy in 
the foreseeable future for a variety of reasons including patient compliance and 
the lack of reliable scientific data surrounding efficacy and side effects, phage 
therapy does present a number of prospective advantages over antibiotic 
therapy (Table 1.7).
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Bacteriophages Antibiotics General Comments
• Highly specific • Often damages microflora • High specificity requires 
pathogen identification for 
phage therapy
• Low level of • Increasing levels of • Phage can be developed
resistance resistance to multiple against a wide range of hosts
antibiotics • Development of resistance will 
be confined to particular 
bacteria for phage
• Actively • Cleared from body • Less frequent dosing of phages
replicating required
• No serious side • Allergic response e.g. • Phage therapy could result in
effects known penicillin toxic shock from bacterial
• Some antibiotics toxic at 
high doses
lysis
• New phage • Development of novel • Believed that every bacterium
isolation - easy antibiotics takes years will possess at least one phage
and relatively • New antibiotics tend to be due to natural selection
simple from structural modifications • Would allow for “custom”
environmental treatments based on organisms
sources present
• Potentially • Small molecules that do • Encapsulated phage
immunogenic not elicit an immune preparations to minimize
response except in cases of 
allergic response
immune system exposure
Table 1.7: Comparison between antibiotics and bacteriophages for 
prophylactic and/or therapeutic use. Adapted from Sulakvelidze et al., 
(2001).
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1.5.3 Current use of bacteriophage
Although usage as a therapeutic agent in humans is primarily confined to the 
former Soviet Union and Eastern Europe, phages have found some applications 
in the West.
One such recent example is the approval by the US Food and Drug 
Administration (FDA) in 2006 for the use of a combination of 6 different 
phages to be added to ready-to-eat meat and poultry products. This was done in 
order to combat the presence of L isteria  m onocytogenes, the causative agent of 
listeriosis which accounts for some 2500 cases per year in the USA with 20% 
of these cases proving fatal (Lang, 2006). Due to the nature of the phage 
preparation it is believed that some 170 strains of L. m onocytogenes  are 
susceptible and the risk of resistance developing in this combination product is 
reduced. While the FDA has authorised the use of this preparation, approval 
from the US Department of Agriculture which oversees the various meat 
inspection industries within the US (Lang, 2006) is still being sought. Phage 
preparations have also been suggested for use in the meat industry against 
Salm onella  species (Atterbury et a l., 2007) and have recently been approved by 
the FDA to combat E scherich ia  co li contamination of cheese in 201 l(Intralytix 
Inc., 2011).
Phage preparations have also found a use in aquaculture and have been 
demonstrated to reduce the appearance of infections in marketable-sized fish in 
the Far East. The most notable of these infections is caused by Lactococcus  
garvieae  in which it was observed that there was no presence of bacteria within 
the spleen of phage treated fish after 48 h (Nakai and Park, 2002).
Haemorrhagic ascites are a significant disease of fish that can strike at any 
stage of development and are the result of infection by Ps. p lecog lossic ida  and 
is particularly prevalent in the Asu region of Japan, a primary area for the
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freshwater culture of fish. The application of phages to this area was found to 
reduce the mortality o f fish from 65% to just 22.5% (Nakai and Park, 2002).
It should also be noted that various phage preparations are licensed for use as 
pesticides within the US (Jones et al., 2007). However, there are currently no 
such preparations available within the UK, although phage based diagnostics 
are being readily investigated (Kalantri et al., 2005; Pai et al., 2005) and may 
possess some advantages over traditional diagnostics. In May 2011, the FDA 
granted clearance for the marketing of the KeyPath MRSA/MSSA Blood 
Culture Test that is based upon phage amplification technology (FDA, 2011).
Due to the well characterised and publicised rise of antibiotic resistance over 
the past decade a number of smaller start up companies have begun 
investigating and developing phage preparations for use on humans. These 
phage preparations are often for topical use only and are currently in clinical 
trials (Table 1.8; Wright et al., 2009) or designed for non-human application.
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Company Product Target Licensing stage
Name/Type organism
lntralytix
Inc.
ListShield™ 
Phage cocktail
Listeria
m onocytogenes
• FDA and USDA 
approved for use direct 
on food
• EPA approved for 
surface applications
• EU approved
EcoShield™ 
Phage cocktail
Escherichia coli 
0157:H7
• No information 
available on company 
website
• Also actively 
researching on other 
bacteria
AmpliPhi
Biosciences
Corp.
BIOPHAGE-PA Pseudom onas
aeruginosa
• Currently undergoing 
Phase III clinical trials
Gangagen
Inc.
StaphTAME: 
recombinant 
phage based 
protein
Mcthicillin resistant 
Staph, aureus
• Pre-phase I
Novolytics N/A1 Mcthicillin resistant 
Staph, aureus
• Research only based 
upon lysogenic phages
Omnilytics a g r ip h a g e ,m Multiple: Including 
Xanthomonas 
campestris pv. 
vesicatoria, or 
Pseudomonas 
syringae pv. tomato
• Commercially 
available
Table 1.8: Commercial companies undertaking phage research including 
licensed products. *: indicates no product name associated with research.
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1.6 Aims and objectives
The aim of this study is to investigate the use of bacteriophages to combat Ps. 
aeruginosa  infections. This will be done in the following manner:
• Characterise 14 Ps. aeruginosa  bacterial isolates and 4 phage strains
•  Investigate the effect of environmental conditions upon bacterial 
content and exopolysaccharide content o f Ps. aerug inosa  biofilms
• Develop and validate biofilm models for the growth of Ps. aeruginosa
•  Develop and validate an alternative method to measure phage activity
•  Assess and enhance the lytic activity of Ps. aerug inosa  phages and 
design a phage cocktail
•  Assess the activity of a phage cocktail against biofilms of Ps. 
aeruginosa  alone and in combination with other components
•  Investigate the delivery, dosing and quality control related issues 
surrounding bacteriophage preparations.
At the end of this investigation it is hoped a phage based preparation that 
possesses activity against both planktonic and biofilm types of Ps. aeruginosa  
will be developed.
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Chapter 2 
General materials and methods
All materials used in this project were obtained from Fisher Scientific 
(Loughborough, UK) or Sigma Aldrich (Dorset, UK) unless otherwise stated in 
the text.
All media and buffers were sterilized by autoclaving at 121°C for 15 min 
(British Pharmacopeia, 201 la) unless otherwise stated in the text.
All deionised water used in the current investigation was prepared on an ELGA 
PURELAB Option BP 15 (Inorganics at 25°C; between 1-15 MQ-cm, total 
organic carbon (TOC) <30 ppb; ELGA Labwater, Marlow, UK).
2.1 Microbial cultures
2.1.1 Bacterial strains
All Ps. aeruginosa strains used in this project were kindly provided by Dr E. 
Mahenthiralingam (School of Biological Sciences, Cardiff University, Cardiff, 
UK). Ps. aeruginosa NCTC 10332 was obtained from the National Collection 
of Type Cultures (NCTC) (Health Protection Agency, London, UK). All strains 
are detailed in Table 2.1.
Ps. aeruginosa cultures were stored at -80°C in 10% glycerol and routinely 
cultured from frozen by streaking to a Tryptone Soy Agar (TSA; Oxoid, 
Cambridge, UK) slope and incubated at 37°C for 24 h. Working slopes were 
stored at 4°C for 2 weeks.
2.1.2 Bacteriophage strains
Bacteriophage strains of GL-1, C 10176 Small (C10176-S), C l0176 Large 
(C10176-L) and L phage Medium (LP-M) used in this project were kindly 
provided by Prof. G.W. Hanlon (School of Pharmacy and Biomolecular 
Sciences, Brighton University, Brighton, UK). Phage cultures were grown 
from frozen stocks by the agar overlay technique (Adams, 1959) using Ps. 
aeruginosa PAOl as a host and were stored at -80°C in 10% glycerol.
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2.2 Culture preparation and standardisation
2.2.1 Bacterial culture
2.2.1.1 Preparation of bacterial cultures
Bacterial growth was washed from the surface of a single overnight TSA slope 
using 5 mL of tryptone sodium chloride (TSC; containing 1 g/L tryptone 
(Oxoid, Cambridge, UK) and 8.5 g/L sodium chloride) and centrifuged at 2600 
x g for 15 min. The supernatant was then discarded and the bacterial pellet 
resuspended in 5 mL of fresh TSC. Overnight bacterial tryptone soy broth 
(TSB; Oxoid, Cambridge, UK) cultures were centrifuged at 2600 x g for 15 
min and then rcsuspendcd in 5 mL of TSC.
2.2.1.2 Standardisation of bacterial cultures bv optical density
Washed bacterial suspensions were then standardised by optical density at 
600nm (ODboonm) to contain between 1 and 5 x 10K colony forming units per 
millilitre (CFU/mL) (Figure 2.1) on a Helios a spectrophotometer 
(ThermoFisher Scientific, MA, USA) that had been previously blanked with an 
appropriate solution (cither TSC or Tryptone soy broth (TSB; Otfoid, 
Cambridge, UK) alone).
2.2.2 Bacteriophage culture
2.2.2.1 Routine culture of bacteriophage suspensions
Five millilitres of phosphate buffered saline (PBS) were pipetted onto the 
surface of prepared phage plates. The 65% (w/v) “sloppy” agar layer was then 
scraped into a 50 mL polypropylene co-polymer (PPCO) centrifuge tube 
(Nalgene, NY, USA). Suspensions were centrifuged at 11000 x g for 15 min at 
4°C then the supernatant was passed through 0.45 and 0.2 pm membrane filters 
(Millipore, Cork, Ireland) to remove bacterial debris. Phage suspensions were 
stored at 4°C for up to 1 month.
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y = 0.1356x + 0.025
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Figure 2.1: R ela tionsh ip  betw een ODmomii an d  v iable count of Ps. 
aeruginosa  s tra in  N C T C  10332. Line represents the best fit by linear 
regression.
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Strain Name Source Comment
PAOl Clinical. non-CF Ps. aeruginosa genome sequencing strain (Stover et al., 2000)
Standard NCTC 10332 NCTC Also known as ATCC 10145. Quality control strain for API products. Alginate non-producing 
strain (Edwards and Saunders, 2001)
C3652 CF Epidemic Manchester CF strain type (Jones et al., 2001)
C3719 CF Epidemic Manchester CF strain type (Jones et al., 2001)
C3786 CF Melbourne Ps. aeruginosa CF strain - unique (Armstrong et al., 2003)
CF LFS-400 (LFS) CF Liverpool epidemic strain - Hypcrvirulent strain predominant epidemic strain in the UK
epidemic (Salunkhc et al., 2005; Fothergill et al., 2007)
Midlands 1-9245 (Mids 1) CF Midlands 1 epidemic strain (Smart et al., 2006)
P8959 CF Liverpool epidemic strain - predominant epidemic strain in the UK (Fothergill et al., 2007)
C1913 CF A55 unique - Unique genotype from Vancouver patients (Lewis, 2005)
CF Non­ C2238 CF A61 unique - Unique genotype from Vancouver patients (Lewis, 2005)
epidemic C2846 CF A55 unique -Unique genotype from Vancouver patients (Lewis, 2005)
C3597 CF Non-epidemic Manchester CF strain type (Jones et al., 2001)
C4503 CF A55 unique - Unique genotype from Vancouver patients (Lewis, 2005)
PAK-SR (PAK) CLIN Streptomycin* parent of Fla-/Pil- mutants of PAK. Sm50. (Ishimoto and Lory, 1989)
Table 2.1: Ps. aeruginosa strains used in the current investigation.
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2.2.22  PEG concentration of phage suspensions
For the preparation of concentrated phage suspensions a polyethylene glycol 
8000 (PEG) concentration step was performed. The sloppy agar layer from 30 
plates of semi-con fluent bacterial lysis was removed with 5 mL PBS per plate 
and transferred to a 50 mL PPCO centrifuge tube. Suspensions were 
centrifuged at 13000 x g  for 15 min at 4°C. The supernatant was passed 
through 0.45 and 0.2 pm membrane filters (Millipore, Cork, Ireland) into a 150 
mL conical flask that contained 8% (w/v) PEG 8000 and 2.3% (w/v) sodium 
chloride and incubated at 4°C overnight with constant mixing. Following 
incubation the solution was centrifuged at 10000 x g  for 30 min at 4°C 
discarding the supernatant upon completion. The resulting pellet was 
resuspended in 1 mL of fresh PBS and centrifuged at 5000 x g  for 20 min at 
4°C after which the supernatant was passed through 0.45 and 0.2 pm filters 
(Millipore. Cork, Ireland).
23  Enumeration techniques
2.3.1 Bacterial enumeration
The total viable count of bacterial suspensions was performed on all 
standardised cultures via the drop count method of Miles and Misra (1938). In 
brief, 100 pL of bacterial suspension was added to 900 pL of TSC buffer and 
then vortexed. This process was repeated until the desired level of dilution was 
reached. Three spots of 10 pL of each dilution were then spotted onto 
duplicate pre-prepared TSA plates. Plates were then incubated at 37°C for 24 
h. The concentration of the suspension was then calculated by counting the 
number of bacterial colonies at a dilution containing 3-30 colonies. This 
process was validated by one way ANOVA at the 95% confidence interval (Cl) 
on 10 separate dilution series (P=0.486).
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2.3.2 Bacteriophage enumeration
Total viable count of phage suspensions were performed according to the agar 
overlay method (Adams, 1959). In brief, 5 mL of 65% (w/v) TSA (26 g/L) 
was prepared and supplemented with 100 pL of 50 mM calcium chloride and 
sterilized. Molten agar was stored at 50°C in a water bath until required. One 
hundred pL of PAOl suspension (containing between 1 and 5 xlO8 CFU/mL) 
was added to the molten agar and gently swirled. To this 100 pL of different 
dilutions of a bacteriophage suspension was added. The molten agar was then 
poured over the surface of a prc-prcpared TSA plate and spread to ensure even 
coverage. The “sloppy” agar layer was allowed to set at room temperature 
before incubation at 37°C for 24 h. Following incubation, plaques (clearing in 
the bacterial lawn) were counted at a dilution containing between 3 and 30 
plaques and the number of plaque forming units per millilitre (PFU/mL) 
determined. This protocol was validated by one way ANOVA at the 95% Cl 
on 10 separate dilution series of phage (/>=0.244).
2.4 Sample preparation for microscopy
2.4.1 Transmission electron microscopy
Concentrated stocks of phage were prepared as previously described (Chapter 2 
Section 2.2.2.2). Five microlitres of concentrated phage suspension 
(approx. 1014 PFU/mL) was added to 3.05 mm copper 200 mesh grids (Agar 
Scientific, Stansted, UK) coated in 0.8% (w/v) pioloform powder in 
chloroform (Agar Scientific, Stansted, UK) and air dried at room temperature 
for 15 min. Copper grids were then stained in 1% (w/v) methylamine tungstate 
(Agar scientific, Stansted, UK) for 15 min. Samples were viewed on a Phillips 
CM 12 Transmission electron microscope (TEM; Phillips Healthcare, MA, 
USA) and imaged on a Megaview III TEM digital camera (Soft Imaging 
System GmbH, MUnstcr, Germany) using iTEM software (Soft Imaging 
System GmbH, MUnstcr, Germany). Representative images were taken based 
upon 15 fields of observation.
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2.4.2 Scanning electron microscopy
Bacterial biofilms that had been cultured either as sedimentary biofilms or as 
CDFF biofilms were prepared for scanning electron microscopy (SEM) 
imaging as follows. Samples were gently rinsed in 5 mL PBS to remove any 
loosely adherent cells before fixation in 2 mL of 2% glutaraldehyde (GA) in 
PBS for 1 h. Samples were rinsed twice in PBS, and then stained with 1% 
osmium tetroxide (Agar Scientific, Stansted, UK) in PBS for 1 h. Following 
staining, samples were sequentially dehydrated in ethanol for 5 min at each of 
the following concentrations, 50% (v/v), 70% (v/v), 90% (v/v) and twice in 
absolute ethanol.
Samples were dried by critical point drying then affixed to carbon discs and 
mounted on aluminium studs (Agar Scientific, Stansted, UK). Samples were 
gold coated and imaged using a Phillips XL20 SEM (Phillips Healthcare, MA, 
USA) at an accelerating voltage of 20 or 30 kilovolts (kV). Representative 
images were taken based upon 15 fields of observation.
2.S Biofilm preparation
2.5.1 Sedimentary biofilms
Ps. aeruginosa strains were prepared and standardised as previously described 
(Chapter 2; Section 2.2.1). To each well of a 6-well tissue culture plate 
(Coming Inc., NY, USA) that contained 4 mL of growth medium, either a 
polytetrafluoroethylenc (PTFE) disc (Goodfellow Cambridge Ltd, Huntingdon, 
UK) or a No. 2 glass coverslip (Mcnzel-Glaser, SaarbrUckener, Germany) was 
added followed by 1 mL of bacterial suspension (containing between 1 and 
5xl08 CFU/mL). Culture plates were then incubated at 37°C in normal air or 
95% air: 5% CO2 depending on experimental protocol. Prior to use biofilms 
were gently rinsed in 5 mL PBS.
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2.5.2 Constant depth film fermentor (CDFF) biofilms
2.5.2.1 CDFF arrangement
Previously autoclavcd CDFF components were removed from the autoclave 
bags inside of a Hcrasafe Category 2 biosafety cabinet (Thermo Scientific, 
MA, USA) and subjected to UV irradiation for 1 h as an additional precaution. 
PFTE holders were inserted into the rotating platform before the addition of 
rods and discs. Discs were recessed to the required depth (between 10 and 160 
pm) using the tools supplied, subjected to UV irradiation for 1 h and then 
mounted onto a rotating axle. The glass chamber was then added to the 
apparatus and the base scaled using silicone grease (Dow Coming, Ml, USA). 
The scrapers, lid. and HFPA filters (Whatman Pic, Maidstone, UK) were then 
added.
2.5.2.2 Culture conditions
The assembled CDFF apparatus (Figure 2.2) was transferred to a 37°C 
incubator with a 95% air: 5% CO: atmosphere. Bacterial suspensions in TSB 
(containing between 1 and 5 xlO8 CFU/mL) were perfused in at a rate of 1 
mLmin for 15 min using a B. Braun Melsungen Ag perfusor (B. Braun 
Melsungen AG, Melsungen, Germany). Once dispensed, bacterial suspensions 
were allowed to attach for 15 min prior to the perfusion of TSB at 0.2 mL/min 
using a Watson Marlow 502S peristaltic pump (Watson-Marlow Pumps Group, 
Cornwall, UK). Medium was then continually perfused into the CDFF for 96 h 
at a rate of 0.2 mL min.
2.5.2.3 CDFF decontamination
Upon cycle completion biofilm samples were removed and stored in sealed 
containers for up to 1 h. The base apparatus containing the motor and 
electrical components was removed and sprayed with 70% v/v ethanol. The 
CDFF apparatus was dismantled and autoclaved at 121°C for 15 min (British 
Pharmacopeia, 2011a). The base, lid and glass cylinder of the CDFF were 
rinsed with water and dried overnight. PTFE discs, rods and holders were
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washed in w ater and then soaked for 1 h in 70% (v/v) ethanol and then dried 
overnight. All tubing and rem aining com ponents were treated by the passage 
o f  (0.2 m L  min for media inlet tubing and bacterial tubing), or immersion in 
(waste tubing), 2.5%  Steris HAM O PAA solution (Steris, Biel, Switzerland) 
for 1 h before rinsing with w ater and overnight drying. All components were 
re-autoclaved prior to use.
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Figure 2 .2 : C o n stan t d ep th  film fe rm e n to r  a p p a ra tu s  used in the cu rren t 
investigation, a) shows schem atic representation o f  apparatus and b) shows 
apparatus in situ.
2.5.3 Quality control
In order to ensure purity, sam ples from biofilm s and waste containers were 
streaked to TSA plates and Kings m edium  A (Fluka, WI, USA) and then 
incubated overnight at 37°C. The run was deem ed to be successful if only one 
colony type was present and the Kings m edium  had turned blue/green.
Media
Rotating
platform
Rotating aidp
Waste pipe
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2.6 Statistical analysis
All data were statistically analysed in the Minitab 15 Statistical Software 
(Minitab Ltd, UK) by either a one way ANOVA or a Tukey-Kramer A 
posterior test at the 95% Cl unless otherwise stated in the text.
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Chapter 3
Characterisation of bacterial and bacteriophage 
strains and the quantification of 
exopolvsaccharide in biofilms
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3.1 Introduction
Ps aerug inosa  is of particular importance to CF patients as it is the primary 
cause of respiratory infection with around 80% of patients colonized by the age 
of 20 (Saiman and Siegel, 2004). The organism is able to survive and persist 
despite intervention in the lung due to the ability to form complex biofilms 
with characteristic mucus build-up, resulting in an increase in minimum 
inhibitory’ concentration (MIC) of numerous antibiotics up to 1000 fold greater 
than when grown as planktonic cultures (Li et a l ., 2008). This is in part due to 
the production of large quantities of exopolysaccharide (EPS) containing 
alginate, which coats the Ps. aeruginosa  preventing the uptake of some 
cationic antibiotics (llaagensen et al., 2007; Platt et a l., 2008).
Alginate is a linear polysaccharide consisting of P-D-mannuronic and a-L- 
guluronic acid residues that arc joined in a 1-4 linkage and has been shown to 
be an important part o f Ps. aerug inosa  biofilms (Hentzer et al., 2001) making it 
a useful target for quantification of biofilm formation. Currently the main 
method of biofilm quantification is the crystal violet assay (Gooderham et al., 
2008). This method is based on the adherence of bacterial cells to a surface 
and the interaction of crystal violet stain with the EPS of the established 
biofilm. This unfortunately is an indirect method of EPS quantification and is 
highly variable due to the fragile nature of the biofilm produced. The 
carbazolc assay relies on the acidic degradation of the alginate polysaccharide. 
This forms a 5-formylfuran-2-carboxylic acid intermediate which then reacts 
with the carbazolc to produce the characteristic purple colour (Usov, 1999). 
Although a direct measurement of the amount of uronic acid within a 
Pseudom onas  biofilm is provided by the carbazole assay, it is reliant on EPS 
production to be consistent, which is known not to be the case (Purevdorj-Gage 
e t a l ,  2005).
The current literature describes numerous conditions and media that are 
designed to mimic the in vivo  conditions of the CF lung (Worlitzsch et al.,
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2002; Brennan et a l.y 2007). It is of great importance to create a standard set of 
conditions that will mimic as closely as possible this environment for testing of 
the effectiveness of future therapeutics. The synthetic media that are currently 
available vary greatly in composition and also in their ability to accurately 
model the in vivo  CF lung conditions. Perhaps the forerunner of these 
synthetic media that most closely models the in vivo  conditions is the artificial 
sputum medium (Sriramulu et a/., 2005). However, this medium is too 
expensive to scale up to larger applications such as biofilm growth within a 
CDFF.
This chapter seeks to characterise 14 strains of Ps. aerug inosa  including some 
of the more clinically-relevant strains within the UK upon multiple criteria and 
to also characterise 4 strains of Ps. aerug inosa  phage. In addition the effect of 
varying environmental conditions upon the bacterial content and BPS content 
of Ps. a erug inosa  biofilms will also be investigated.
3.2 Materials and methods
3.2.1 Bacterial strains
All Ps. aerug inosa  strains (Chapter 2; Table 2.1) were used for initial 
characterisation. For subsequent testing of the effects of media 
supplementation on the rate of growth and EPS production strains P8959, 
C2238, NC'TC 10332 were used. Bacterial strains were prepared and 
standardised as previously described (Chapter 2; Section 2.2.1).
3.2.2 Characterisation of bacterial strains
3.2.2.1 Gram stain
Ps. aerug inosa  strains were suspended in a drop of deionised water on a glass 
slide using a flame-sterilised inoculating loop. The bacterial growth was 
spread, air dried and then heat fixed. Slides were covered in crystal violet for 1 
min and washed in deionised water. Gram’s iodine was added for 1 min before
53
decolourization with 70% (v/v) ethanol. Safranin was then added for 45 s to 
counter-stain before the addition of deionised water.
Slides were blotted dry and viewed under oil immersion at xlOOO 
magnification using an Olympus BX50 Microscope (Olympus, Watford, UK). 
Images were taken using an Olympus DP 10 camera (Olympus, Watford, UK) 
and visualised using Corel Paint Shop Pro (Corel Corp, Maidenhead, UK).
3.2.2.2 Exopolvsaccharide stain
The follow ing methodology was adapted from Harrison-Balestra et al. (2003). 
Glass coverslips 18 x 18 x 0.17 mm (Menzel-GlSser, Saarbriickener, Germany) 
that had been previously cleaned with absolute ethanol were added to 6 well 
tissue culture plates (Coming Inc., NY, USA). One hundred microlitres of 
bacterial suspension (containing between 1 and 5 x 108 CFU\mL) and 900 pL 
fresh TSB were added to each well and then incubated at 37°C for 6 h.
Coverslips were removed with flame sterilised tweezers and one side of the 
coverslip was then washed with ethanol using a sterile cotton wool swab, 
attached to a slide and allowed to air dry before being heat fixed.
Once cooled, the slides were stained with a 2:1 mixture of aqueous Congo red 
(Bios Europe, Lancs, UK) and 10% Tween 80 for 15 min before being washed 
with deionised water. Slides were then stained with Zeihl carbol fuschin (Pro- 
Lab Diagnostics, South Wirral, UK) for 6 min before being washed in 
deionised water and allowed to air dry. Slides were then blotted dry and 
viewed as above.
3.2.2.3 BBL crystal identification
Ps. aeruginosa strains were characterised by the use of the BBL™ Crystal™ 
Enteric/Nonfermenter ID Kit (BD, NJ, USA). Ps. aeruginosa strains were 
streaked to blood agar plates (containing 10 g of Number 2 Blood agar base
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(Oxoid, Cambridge, UK) and 7% (v/v) defibrinated sheep’s blood (Oxoid, 
Cambridge, UK) per 250 mL deionised water) to check culture purity.
Singular Ps. aeruginosa colonies were added to the inoculum fluid provided 
with the BBL crystal kit (BD, NJ, USA) from overnight blood plates. The 
suspension was then vortexed and turbidity checked against a McFarland 
standard. The inoculum fluid was then poured into a labelled sample tray and 
swirled to ensure all wells were filled with fluid before the addition of the test 
strip. The completed test was then returned to the tray provided, placed inside 
a plastic bag with a damp piece of tissue and incubated at 37°C overnight.
Following incubation kits were read in a positive/negative manner (Figure 3.1) 
according to BD specifications that were included with the test kits. The code 
generated was then inserted into the BBL Crystal MIND Software (BD, NJ, 
USA) and then identified.
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AB
Score A B C D E F G H I J
2
1 + - + + + + + + + +
CODE 3 0 3 3 i i i 3 1 T
F igure  3 .1 : E xam ple  o f BBL crysta l. Strain NCTC 10332 was used and 
shows characterisation as Ps. aeruginosa  Biotype 1561. A) Shows completed 
BBL crystal. B) Shows BBL crystal as a positive/negative result and the code 
generated.
3.2.2.4 Antibiotic susceptibility
The antibiotic susceptibility profile o f  all 14 Pseudomonas strains was 
evaluated using the disc diffusion m ethod (Andrews, 2009). Iso-Sensitest agar 
(ISA) plates (Oxoid, Cam bridge, UK) were prepared according to 
m anufacturer’s instructions.
Bacterial suspensions o f  all strains were prepared as previously described 
(Chapter 2; Section 2.2.1) to contain between 1 and 5 x 108 CFU/mL, then 
further diluted by a ratio o f  1:100 and enum erated (Chapter 2; Section 2.3.1).
The standardised suspension was spread onto pre-poured ISA plates in three
directions using a sterile cotton wool swab. The inoculum was then dried at
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room temperature for up to 15 min before the addition of antibiotic discs 
(Oxoid, Cambridge, UK). The antibiotics used (Table 3.1) were chosen on the 
basis of current NHS usage against Ps. aeruginosa in the Heath Hospital in 
Cardiff (Hoscin, 2007). To ensure compliance with standard methodology 
(Andrews, 2009) plates were incubated within 15 min of disc addition. ISA 
plates were incubated at 37°C in air for between 18 and 24 h.
Once checked for semi-confluent growth as described in Andrews (2009), the 
diameters of the zones of inhibition were measured to the nearest millimetre 
using a ruler. A mean of triplicate plates was then taken and the results 
compared to standard diameters (Andrews, 2009) to determine susceptibility.
Antibiotic Disc Contents (pg)
Colistin (as Colistin sulphate) (CT) 25
Ciprofloxacin (C'lP) 1
Ticarcillin (TIC') 75
Ceftazadime (CAZ) 30
Tobramycin (TOB) 10
Table 3,1: Antibiotics used in antibiotic susceptibility testing of Ps. 
aeruginosa strains.
3.2.3 Characterisation of Ps. aeruginosa bacteriophages 
Structural characterisation and DNA/RNA determination was performed in 
conjunction with Ms Helen Jones (final year undergraduate student, Welsh 
School of Pharmacy, Cardiff, UK).
3.2.3.1 Visual characterisation
Concentrated stocks of phages GL-1, C10176-S, C10176-L and LP-M were
prepared and concentrated as previously described (Chapter 2; Section 2.2.2)
then diluted 1:10 in PBS. Samples were then prepared for TEM imaging as
previously described (Chapter 2; Section 2.4.1). Representative images were
taken based upon 15 fields of observation. The 4 phage strains used in the
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current investigation were classified on the basis of morphology (Figure 3.2; 
Hull et al., 1989). Phage size was calculated based upon the means of 15 
phage particles using iTEM software (Soft Imaging System GmbH, MUnster, 
Germany).
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X X X
A1 A2 A3
B1 B2 B3
FI
Morphotype Family Comment
Tailed Phage
AI to A3 Myoviridae Tails long and contractile
B1 to B3 Siphoviridae Tails long and non-contractile
Cl to C3 Podoviridae Tails short
Cubic Phage
D1 Microviridae Small unenveloped phages containing
ssDNA
D2 Unclassified Large unenveloped phages containing
dsDNA
D3 Corticoviridae Large containing dsDNA and internal
lipid layer
D4 Tectiviridae Large containing dsDNA, double
capsid structure and internal lipid
El Leviviraidae Small naked phages containing ssRNA
E2 Cystoviridae Large isometric phages with
segmented dsRNA and lipid envelope
Rod shaped or Filamentous phage
FI
F2
F3
Inovirus
Plectrovirus
Unclassified
Long flexible rods containing ssDNA 
Short straight rods containing dsDNA 
Enveloped rigid rods of variable length 
dsDNA
Pleomorphic phage
G Plasmavirus Rounded phage with flexible envelope
Figure 3.2: S tru c tu ra l characterisa tion  of Ps. aeruginosa  phages. Images not to scale. Adapted from Hull et al. (1989).
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3.2.3.2 DNA/RNA characterisation
The following protocol was adapted from Bradley (1967). Ten microlitres of a 
concentrated phage suspension (prepared as in Chapter 2; Section 2.2.2) was 
spotted onto the surface of a glass slide and air dried at room temperature for 
1 h.
Phage drops were fixed for 3 h in Camoy’s fluid (containing 60% (v/v) 
absolute ethanol, 30% (v/v) chloroform and 10% (v/v) glacial acetic acid). 
Once fixed, coverslips were stained in 1% (w/v) acridine orange (Invitrogen, 
CA, USA) in Mcllvaines buffer at pH 3.8 (containing 35.5% (v/v) 0.2 M 
Na:HP0 4  and 64.5% (v/v) 0.1 M citric acid). Slides were then soaked in 0.15 
M Na:HP0 4  for 15 min and examined under ultraviolet light (UV) (Figure 
3.3a).
DNA/RNA content was then determined on the basis of emitted fluorescence 
(Table 3.2). DNA and RNA were distinguished by the addition of 0.1 M 
molybdic acid (Figure 3.3b).
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F igure  3 .3 : R ep resen ta tive  im age o f DNA/RNA ch arac te risa tio n . Phage 
used was LP-M a) Green fluorescence after staining with acridine orange and 
b) show s retention o f  green fluorescence after addition o f molybdic acid 
show ing presence o f  dsDNA. Images not to scale.
S taining with acrid ine Addition of molybdic acid
orange
dsDNA Green
dsRNA Green
ssDNA Red
ssRNA Red
T ab le  3 .2 : D eterm ination  o f D N A /RN A  con ten t of bacteriophages using 
a c rid in e  o ran g e  sta in ing . dsDN A; double stranded DNA, dsRNA; double 
stranded RNA, ssDNA; single stranded DNA, ssRNA; single stranded RNA. 
(Bradley, 1967).
Green 
Green fades 
Paler green 
Paler red
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3-2.4 Effect o f  media supplem entation on Ps. aeruginosa  growth 
Ps aeruginosa  strains were prepared and standardised as previously described 
(C hapter 2; Section 2.2.1).
3 -2.4.1 Bioscrccn C analysis o f growth under aerobic conditions 
The Bioscrccn C analyzer (Figure 3.4) is an automated spectrophotometer that 
can directly measure bacterial growth o f up to 200 samples at a wide range o f 
tem peratures based on sample turbidity over a period o f  time. Upon 
com pletion data are presented in a M icrosoft Excel document as optical density 
per time point sampled.
Figure 3.4: The Bioscreen C analyser.
To each well o f  a 100 well honeycom b plate (6 y  Growth Curves AB Ltd, 
Helsinki, Finland) 350 pL o f  growth medium was added. To test wells (5 per 
strain tested) 50 pL o f  Ps. aeruginosa  culture (containing between 1 and 5 x 
108 CFU/m L) was added. A negative control containing growth medium (TSB 
or Luria-Bertani broth (LB) broth at pH 7, 6.5, 5 in the presence or absence o f 
10% (w /v) glycerol) and 50 pL o f  TSC was also performed.
The assessm ent o f  bacterial growth was then undertaken over 20 h using a 
wideband filter (420-580 nm) with readings taken every 15 min in a Bioscreen 
C analyzer (Oy Growth Curves AB Ltd, Helsinki, Finland) at 37°C using the
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EZExperim cnt software Version 1.26 (Oy G rowth Curves AB Ltd, Helsinki, 
Finland). Each reading was preceded by shaking cycle o f  10 s.
Experim ents were perform ed in triplicate using a fresh bacterial suspension for 
each run.
3.2 4.2 A nalysis o f  growth in a 95%  air 5% C O  atm osphere
Upon standardisation 31.25 mL o f Ps. aeruginosa  culture (containing between 
1 and 5 x 108 CFU/m L) w as added to 250 mL o f media (TSB, LB or LB Final) 
and incubated at 37°C in a 95%  air: 5% C O 2 atmosphere. Culture flasks were 
shaken gently by hand prior to sam pling in order to adequately mix the sample. 
GDhoonm was determ ined every hour using un-inoculated media as a negative 
control on a Hc/.ios a  spectrophotom eter (Therm oFisher Scientific, MA, USA).
3.2 .4.3 Data analysis o f  grow th curves
Data was analysed in M icrosoft Excel (M icrosoft, MA, USA) whereby optical 
density at each time point was averaged. Optical density was then adjusted by 
subtracting the optical density o f  the blank from optical density o f  the cultures. 
Bacterial growth was measured indirectly as the time taken to enter a log 
grow th phase and as an expression o f  increase in OD (xlO"4) per min during the 
log phase o f  grow th (AOD/min; Figure 3.5).
Logio
Adjusted
OD
Figure 3.5: The different phases of bacterial growth.
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Stationary Phase
Death Phase
Exponential (Log) Phase
Lag Phase
Tim e (min)
3.2.5 Effect of media supplementation on EPS production of Ps. aeruginosa 
biofilms
3.2.5.1 Biofilm preparation
Sedimentary biofilms of Ps. aeruginosa strains NCTC 10332, P8959 and 
C2238 were prepared on 18 x 18 x 0.17 mm glass coverslips (Menzel-GlSser, 
Saarbrilckcncr, Germany) as previously described (Chapter 2; Section 2.5.1).
3.2.5.2 Separation of EPS from bacterial biofilms
Coverslips were added face down to a 100 mL glass bottle containing 5 g of 3 
mm borosilicatc glass beads and 4 mL sterile deionised water (SDW). Glass 
bottles were then shaken at 200 RPM for 2 min on a Grant Bio POS-300 
Orbital shaking platform (Keison UK, Chelmsford, UK). The bacterial 
suspension was removed, retained and then the process repeated. Coverslips 
were then removed and rinsed with 1 mL fresh SDW and total viable count 
(TY'C) performed on the combined suspensions. This process was validated on 
10 replicates (P=0.066).
Bacterial suspensions were transferred to 50 mL PPCO centrifuge tubes and 
centrifuged at 13750 x g for 30 min at 15°C. The supernatant was poured off 
and retained while the bacterial pellet was resuspended in 5 mL of fresh SDW. 
The centrifugation was repeated and the supernatants combined. The 
combined supernatant was then centrifuged at 13750 x g  for 15 min at 4°C to 
remove any further bacterial debris and seeded with 0.1 g sodium acetate and 
stored on ice. Three volumes of ice cold absolute ethanol (stored at -20°C) 
were then added to the final solution and then centrifuged as before.
The solution was transferred to a 100 mL glass round bottom flask, attached to 
a Biichi rotavapor R-114 (Biichi Laboratory-Techniques, Switzerland) and 
partially immersed into a Biichi waterbath B4-80 (Biichi Laboratory- 
Techniques, Switzerland) that was preheated to 20°C. Removal of the ethanol
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was achiev ed through the use of a Droi 2-2L vacuum pump and dry ice. Total 
volume of remaining solution was then recorded for future analysis.
3.2.5.3 Quantification of uronic acid content
A modified carbazolc assay was used (Knutson and Jeanes, 1968) to quantify 
the uronic acid level (alginate) from Ps. aeruginosa biofilms cultured under 
different conditions.
Briefly, 140 pL of the uronic acid sample (Chapter 3; Section 3.2.5.2) was 
layered on top of 1.2 mL borate working solution (1:40 ratio of borate stock 
solution (containing 24.7 g of boric acid and 45 mL 4 M KOH per 100 mL): 
concentrated sulphuric acid) that was prepared fresh daily. The solution was 
cooled briefly on ice, vortexcd for 4 s and then returned to an ice bath. Forty 
microlitrcs of a 0.1% (w/v) solution of carbazole in absolute ethanol was then 
added prior to repetition of the cooling and vortexing procedure. Once 
processed, samples were placed into a 55°C waterbath for 30 min.
Absorbance at 530nm (Asjonm) was determined on a Helios a 
spectrophotometer (Unicam, Cambridge, UK) that had been previously blanked 
with deionised water. Uronic acid content was deemed to be positive when the 
reaction mixture turned purple upon heating. The quantity of uronic acid was 
calculated based upon the mean absorbance of five replicates compared to 
standard alginic acid (Acros Organics, Geel, Belgium) solutions ranging from 
0.1 m gm L to 1.0 m gm L (Figure 3.6). The overall process was validated using 
a Kruskal-Wallis test on 10 replicates (/*=0.437) based upon the quantity of 
uronic acid TO6 CFU.
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F igure  3.6: R ela tionsh ip  betw een the  u ro n ic  acid content of alginic acid 
s ta n d a rd s  and  ab so rp tio n  at 530 nm . Line represents the best fit by linear 
regression. Data are the mean o f  three replicates ±1SD.
3.2.6 I-fleet o f  m edia supplem entation on sedim entary biofilm structure 
Sedim entary biofilm s o f  Ps. aeruginosa  strains NCTC 10332, P8959 and 
C2238 were cultured as previously described (Chapter 2; Section 2.5.1) in TSB 
for 24 and 96 h and also in LB final broth for 96 h. Samples were then 
prepared for SEM as previously described (Chapter 2; Section 2.4.2)
3.2.7 Bacterial content o f  CDFF grown biofilm s
PA O l cultures were prepared and standardised as previously described 
(C hapter 2; Section 2.2.1). PTFE discs were recessed to depths ranging from 
10 to 160 pm. B iofilm s were then cultured as previously described (Chapter 2; 
Section 2.5.2) and bacterial content calculated.
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3.3 Results
3.3.1 Characterisation of Ps. aeruginosa strains
3.31.1 Characterisation of EPS production, biotvoe and Gram type
All strains were shown to be Gram-negative (Figure 3.7a), with EPS 
production characterised as either positive or negative using the method of 
Harrison-Balestra et al. (2003) (Figure 3.7b,c). It should be noted that this 
method is purely qualitative and EPS production was characterised on 
representative images from 15 fields of vision. Although characterised on a 
positive negative basis, varying levels of EPS were seen to be produced 
between the strains, with P8959 and C2238 appearing to produce the most.
Two biotypes, 7 and 58 dominated the 14 Pseudomonas strains (Table 3.3) that 
were observed when characterised with the BBL crystal system. However, 
both C4503 and NCTC 10332 were shown to be of a unique biotype (Table 
3.3). It was also observed that biotype 7 was predominantly an EPS producer 
w ith the exception of PAK-SR, while biotype 58 had no such similarities.
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Figure 3.7: O ptical m icroscopy testing used in the initial characterisa tion  of Ps. aeruginosa  strains, a) Gram stain o f  C4503, b) 
EPS positive strain from C2238 and c) EPS negative stain from C3652. Black bar represents 10 pm.
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Bacterial strain EPS
stain1
BBL Crystal Results—" ' — ■ — " —■ —m
Biotype Probability^
Standard NCTC 10332 Neg 1561 .9998
PA01 Pos 7 .9989
C3652 Neg 58 .9999
C3719 Neg 58 .9999
C3786 Pos 58 .9999
CF epidemic
LBS Pos 58 .9999
Midsl Pos 7 .9989
P8959 Pos 7 .9989
C 1913 Neg 58 .9999
C2238 Pos 7 .9989
CF non-
epidemic C2846 Pos 7 .9989
C3597 Pos 58 .9999
C4503 Pos 5495 .9939
PAK Neg 7 .9989
Table 33 :  Summary of initial screening of Ps. aeruginosa strains.
presence or absence of exopolysaccharide as described in (Chapter 3; Section 
3.2.2.2). : : Biotype probability determined by BBL Crystal Mind Software as 
the probability of correct biotype.
3.3.1.2 Antibiotic susceptibility profiles
While each strain has a unique resistance profile it should be noted that strains 
isolated from CF patients were resistant to multiple antibiotics. Resistance 
levels were determined based upon the British Society for Antimicrobial 
Chemotherapy (BSAC) methodology (Andrews, 2009).
All strains with the exception of NCTC 10332 showed resistance or 
intermediate levels of resistance to at least one antibiotic (Table 3.4), which
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varied between strains. Ticarcillin was shown to be the least active against all 
the Pseudomonas strains with 8 strains showing resistance. Colistin was 
shown to be the most active with only 5 strains showing resistance. With 
ciprofloxacin, there were only 4 strains with complete resistance but 7 strains 
with intermediate resistance. This intermediate level of resistance is of clinical 
relevance as it would suggest that a number of strains are developing resistance 
to ciprofloxacin.
Bacterial strain TIC
Antibiotics
CIP TOB CT CAZ
Standard strains NCTC 10332 S S S s S
PAOl S S R R s
C3652 R R S R s
C3719 R R R S R
CF F.pidcmic C3786 S I R s s
LBS R I S s R
Midsl S R R s S
P8959 R R R R R
C 1913 R I R R R
C2238 R I S S R
CF Non-epidemic C2846 S I S S S
C3597 S S s R S
C4503 R I s S R
PAK R I s s R
No. of Resistant Strains 8/14 4/14 6/14 5/14 7/14
Table 3.4: Summary of antibiotic susceptibility profiles of Ps. aeruginosa 
strains. TIC-Ticarcillin, CIP-Ciprofloxacin, TOB-Tobramycin, CAZ- 
Ceftazadime, and CT-Colistin (as Colistin Sulphate). R-Resistant, I- 
Intermediatc, S-Susceptible. Resistance levels determined based upon BSAC 
methodology (Andrews, 2009).
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3.3.2 Growth and EPS production of Ps. aeruginosa strains
3.3.2.1 Unsupplemented TSB
When grown in unsupplemented TSB at 37°C and in full aerobic conditions, 
the rate of bacterial growth varied significantly (P=0.017) between strains 
(Table 3.5).
In 50% of the strains tested there was no clear log growth phase observed by 
20 h, the other 50% exhibited a more consistent linear growth (Figure 3.8). In 
general it was observed that more non-epidemic CF strains of Ps. aeruginosa 
were able to enter a log phase of growth within 20h compared to non-epidemic 
strains (Table 3.5).
The change in OD min was shown to vary between strains with all CF non- 
epidemic strains exhibiting a higher rate of growth during log phase than both 
CF epidemic and standard strains (Tabic 3.5). However, strain C3597 
exhibited the slowest growth rate of all the strains that exhibited a log phase of 
growth.
A 96 h incubation provided the highest total uronic acid content (Figure 3.9), 
hence this incubation time was chosen to compare different growth conditions 
on the production of uronic acid by the different strains. It was surprising to 
observe that the non-mucoid strains, NCTC 10332 and PAOl, also produced 
some uronic acid (Figure 3.9). However, this was considerably less than the 
clinical strains.
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Figure 3 .8 : G row th of Ps. aeruginosa strains under full areobic conditions in TSB at pH 7. Data are the mean o f three replicates.
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Figure 3.9: Effect of time on total uronic acid content (UAC) of Ps, 
aeruginosa hiofilms grown in non-supplemented TSB under full aerobic 
conditions. Data arc the mean o f  three replicates ±1SD .b 24 h, ■ 48 h and 
96 h.
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Bacterial strain  Growth slope_____
________________  Time1 (min) AOD/min3
Standard NCTC 10332 45 51.7
strains PAOl 45 37.5
C3652 2 -
C3719 2 -
CF epidemic C3786 30 41.5
strains LES 2 -
Midsl 2 -
P8959 _2 -
C1913 45 62.3
CF non­ C2238 _2 -
epidemic C2846 45 93.1
strains C3597 45 7.72
C4503 _2 -
PAK 45 11.5
Table 3.5: Summary table of the growth of Ps. aeruginosa strains grown 
under full aerobic conditions. Data are the mean of three replicates. Time 
lapse from inoculation to log phase. no log phase of growth observed. 3: 
grow th expressed as an increase in OD42o-580nm per min (x 1 O'4) during log phase 
of growth.
3.3.2.2 Effect of media supplementation
The growth of all strains was shown to be lower in unsupplemented LB broth 
compared to TSB (Table 3.6). Incubation in a 95% air 5% C 0 2 atmosphere 
resulted in a decrease in growth for all strains. However, clinical strains 
appeared to be more tolerant of diminished oxygen content (Table 3.6).
The clinical strains of Ps. aeruginosa (P8959 and C2238) were shown to 
produce more uronic acids at all conditions (with the exception of C2238 at pH 
5) compared to the standard strain (NCTC 10332; Table 3.7). Under full aerobic 
conditions at pH 7, both TSB and LB were shown to produce among the highest
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levels of uronic acid (Table 3.7) with the exception of NCTC 10332 that showed 
the highest levels of uronic acids at pH 5 in TSB compared to the other 
conditions tested.
Media supplementation resulted in no significant change (P>0.05) of total uronic 
content for the clinical strains, with the standard strain NCTC 10332, showing a 
significant increase of total uronic acid content in TSB at pH 5 and a significant 
decrease in TSB when incubated in a 5% C 0 2 atmosphere (P<0.05; Table 3.7). 
It is interesting to observe that NCTC 10332 biofilms contained 50% or less of 
the total uronic acid content compared to the clinical strains with the exception 
of TSB at pH 5.
Supplementation with 10% glycerol resulted in a higher bacterial yield for all 
strains in both TSB and LB (/*<0.05; Table 3.7) compared to unsupplemented 
TSB. P8959 showed significantly (P<0.05) increased levels of bacteria for all 
media supplementations with the exception of unsupplemented LB which 
showed significantly less bacteria per biofilm (Table 3.7).
The rate of growth was shown to vary by strain and also condition tested with 
both P8959 and C2238 showing few log growth phases (Table 3.6). The overall 
level of growth did not appear to change between pH 7 (Figure 3.10) and pH5 
(Figure 3.11), however some differences between TSB and LB were observed 
with LB showing lower rates of growth and lower overall growth.
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Tim e  (min)
F igure 3.10: Exam ple of Bioscreen C  da ta  for the assessm ent o f bacteria l g row th  u n d er full aerobic conditions at pH 7.
Data are the mean o f three replicates. ♦ NCTC 10332, A P8959 and ■ C2238. Solid lines indicate TSB growth. Dashed lines 
indicate LB broth growth.
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T im e  (min)
F igure 3.11: E xam ple of Bioscreen C da ta  for the assessm ent of b ac teria l g row th  u n d er full aerobic conditions at pH 5. Data 
are the mean o f three replicates. ♦ NCTC 10332, ▲ P8959 and ■ C2238. Solid lines indicate TSB growth. Dashed lines indicate LB 
broth growth.
TSB LB
pH 5 pH 6.5_____________ pH_7____________ pH 5 ______________ pH7____________  10%
10%
Glycerol
5% C 02 10% 5% C 02 
Glycerol
Glycerol, 
pH 5 and
5% C 02
NCTC 10332 Tim e1 60 60 45 90 60 45 15 -
AOD /m in2 94.8' 49.8 49.7 33.2 - 13.2 17.8 11.8 -
P8959 Tim e1 - - - 30 - - - 15 -
AOD/min - - - 2.81 - - - 1.9 -
C2238 Tim e1 - - - 45 - - - 15 -
AOD/min - - - 6.36 - - - 5.21 -
Table 3.6: Effect of media supplementation on Ps. aeruginosa growth over 20 h. Data are the mean of three replicates Time taken to 
reach log growth,2: AOD/min is expressed as an increase in OD42o-580nm per min (x lO"4) during the log phase 3: no log phase observed.
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TSB LB
pH 5 pH 6.5 pH 7 pH 5 pH 7 10%
10%
Glycerol
5% C 02 10%
Glycerol
5% C 02 Glycerol, pH 
5 and 
5% C 02
NCTC 10332
TUC 1.24 (0.21) 0.56 (0.08) 0.41 (0.10) 0.45 (0.05) 0 0.31 (0.10) 0.42 (0.07) 0.37(0.32) 0.54 (0.08) 0.57 (0.06)
Log,0
CFU/mL 7.81 (0.04) 7.56 (0.09) 7.36 (0.46) 8.27 (0.19) 7.34 (0.14) 7.58 (0.17) 7.49 (0.09) 8.16(0.22) 8.30 (0.07) 8.73 (0.19)
P8959
TUC 1.34 (0.64) 1.17(0.29) 2.10(1.35) 1.17(0.53) 0.75 (0.20) 1.11 (0.30) 0.87 (0.09) 0.74 (0.02) 0.90 (0.06) 1.13(0.33)
Logio
CFU/mL 7.85 (0.13) 7.68 (0.05) 7.03 (0.30) 8.28 (0.25) 7.64 (0.10) 7.57 (0.22) 6.20 (0.20) 8.03(0.11) 8.16(0.08) 8.63 (0.06)
C2238
TUC
I
0.54 (0.07) 1.27 (0.16) 1.12(0.27) 1.19(0.36) 1.18(0.32) 0.95 (0.38) 0.80 (0.21) 0.61 (0.03) 1.04 (0.23) 0.94 (0.05)
Logio
CFU/mL 7.90 (0.09) 7.87 (0.27) 7.59 (0.46) 8.31 (0.34) 7.80 (0.05) 7.41 (0.25) 7.31 (0.19) 8.58 (0.12) 8.27 (0.19) 8.52 (0.15)
Table 3.7: EfTect of media supplementation on total uronic acid content (mg) and bacterial content of 96 h old Ps. aeruginosa biofilms.
Data are the mean of three replicates (±SD). TUC: total uronic acid content (mg). Bold typeface indicates significant differences compared to 
unmodified TSB by one way ANOVA at the 95% Cl.
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3.3.2.3. Effect of media supplementation upon biofilm structure 
Investigation by electron microscopy provided clear evidence of the production 
of EPS in sedimentation biofilms of both clinical isolates and the standard 
strain grown for 96 h in TSB under full aerobic conditions (Figure 3.12). A 24 
h biofilm showed little evidence of EPS production in all strains (Figure 3.12) 
with the exception of C2238 (Figure 3.12) where clumps of EPS and bacteria 
were observed to remain on the glass surface. The growth of the sedimentation 
biofilm for 96 h under 5% CO2 in LB media (pH 5) supplemented with 10% 
glycerol showed a more complex and compact structure with a visually 
increased amount of EPS (Figure 3.12) in all strains when compared to 
unsupplemented TSB in full aerobic conditions. When grown for 96 h under 
both full aerobic conditions (Figure 3.12) and in a 5% CO2 atmosphere the 
biofilm appears to take on a honeycomb type structure (Figure 3.12). It is also 
interesting to note that in 96 h incubation bacterial size also appears to 
decrease.
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NCTC
10332
P8959
C2238
Figure 3.12: Effect of media supplem entation on sedim entary bioFdms of Ps. aeruginosa  strains. Images are representative o f 15 
fields o f vision that remained attached to the coverslip. Scale bars are included on each image.
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3.3.3 Phage characterisation
All 4 phages were found to contain ds-DNA (Table 3.8). Both phage GL-1 and 
C10176-S were found to possess A1 structure (Figure 3.13a, d) whereas 
C10176-L possessed Cl structure (Figure 3.13b) and LP-M possessed B1 
structure (Figure 3.13c). All phage possessed capsid diameters of approx. 50 
nm while tail domains in GL-1 and C10176-S were approx. 100 nm in length.
An initial morphological characterisation was given to each of the phages using 
the images shown (Figure 3.13). However, due to the poor image quality and 
time constraints of an undergraduate project, TEM characterisation should be 
repeated in order to confirm the initial characterisation.
Phage Structure Family Length (nm) DNA1
Capsid Tail RNA
GL-1 A1 Myoviridae 49.3(5.2) 106.3(9.1) 2-DNA
C10176-L Cl Podoviridae 49.6(6.1) NC1 2-DNA
CI0176-S A1 Myoviridae 57.4(6.2) 116.6(15.5) 2-DNA
LP-M B1 Siphoviridae 80.0(5.7) 126.6(13.2) 2-DNA
Table 3.8: Summary table of characterisation data of Ps. aeruginosa 
phages used in the current investigation. Data are the mean of 15 phage 
particles (±SD) and structural characterisation based upon Figure 3.2. NC 
indicates not calculated, 2-DNA - double stranded DNA. Due to breakage 
caused by preparation not enough tail domains were observed.
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Figure  3.13: T ransm ission  e lectron  m icroscopy  im ages of the four phages 
used in the c u rre n t investigation  a) C10176-S, b) C10176-L, c) LP-M, d) 
GL-1. Images are representative o f  15 fields o f vision. Black Bar is 
representative o f  100 nm.
3.3.4 LfTect o f  biofilm depth on the bacterial content o f biofilms 
As the depth o f  biofilm was increased the number o f bacteria recovered 
increased significantly (Figure 3.14; P=0.007). The increase in depth o f  the 
biofilm  to 160 pm  produced the largest recovery o f bacterial number while 10 
pm  produced the lowest yield o f  bacteria. However, this increase was non­
linear in nature.
10 20 40 80 120 160
Depth o f  Biofilm (pm)
Figure 3.14: Effect of varying depth on the bacterial content of 96 h old 
CDFF cultured biofilms of Ps. aeruginosa strain PAOl. Data arc the mean 
o f  three replicates ± SD.
3.4 D iscussion
3.4.1 Initial characterisation o f  Ps. aeruginosa  bacterial strains 
The colonization o f  CF patients with Ps. aeruginosa  is a major pathological 
feature o f  the disease and can lead to increased mortality and morbidity (Pritt et 
a l., 2007). The production o f  EPS within biofilms has been shown to increase 
resistance to antibiotic therapy (Li et al., 2008), which is reflected by the 
therapeutic antibiotic resistance profiles generated here (Table 3.4). Antibiotic 
therapy in CF patients colonised with Ps. aeruginosa  varies depending on the 
stage o f  infection and often centres on the use o f nebulised tobramycin and 
colistin or oral ciprofloxacin o f  which approximately 30% or more o f the 
strains tested show some level o f  resistance to at least one o f these antibiotics. 
O f particular interest is the high level o f  intermediate resistance that is
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observed with ciprofloxacin (Table 3.4) as this would suggest the development 
of resistance.
On the whole, the epidemic strains possess a greater degree of antibiotic 
resistance than those isolated from single patients, which would allow strains to 
persist within individuals. The congregation of CF patients at dedicated CF 
centres (McDowell et al., 2004) led to the development of epidemic strains 
such as LES-400 that infect multiple individuals at multiple centres (Jones et 
al.% 2001).
The presence of EPS within 8 of the 11 strains from CF patients shows the 
importance of biofilm formation to persistence as the most resistant strain 
(P8959) is one of the largest If PS producers. However, there are a couple of 
notable exceptions to this (C3719 and C 1913) that showed resistance or 
intermediate resistance to 4 or more antibiotics, although their lack of EPS 
production here (Table 3.3) does not mean they are incapable of doing so.
3.4.2 Initial characterisation of Ps. aeruginosa phage strains 
The characterisation of the 4 phages described here revealed that all phages 
belonged to tailed phage families (Table 3.8) and contain ds-DNA. This is 
consistent with what is seen in the literature (Miles et al., 1995; Kwan et al.,
2006).
When comparing the sizes of previously published Ps. aeruginosa phages, the 
phages described here appear to be slightly smaller in size (Ceyssens et al., 
2008). However, although suitable for initial identification, further 
characterisation work based upon genomic and proteomic analysis would need 
to be performed (Kwan et al.y 2006; Lavigne et al.y 2006).
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3.4.3 Effects of media supplementation on Ps. aeruginosa growth. EPS 
production and biofilm formation
This investigation has used a simple sedimentation biofilm to assess the 
production of uronic acids and also bacterial content under differing culture 
conditions.
Ps. aeruginosa strain NCTC 10332 has previously been described as a non­
mucoid strain (Edwards and Saunders, 2001). In our studies it was observed to 
produce uronic acid levels comparable to clinical strains under certain 
conditions (Table 3.7). However, a previous investigation by Edwards and 
Saunders (2001) showed the presence and expression of alginate genes within 
NCTC 10332.
The production of alginate by Ps. aeruginosa is believed to be part of a 
“coping” mechanism designed to protect against detrimental environmental 
conditions which could, in part, help to explain increased uronic acid levels at 
lower pH levels. This has been discussed in greater detail for a variety of 
stimuli including antibiotics (Wood et al., 2006) and environmental stimuli, 
including both pH and nitrate concentration (Platt et al., 2008).
The addition of 10% glycerol was chosen as both a secondary source of carbon 
and also as an aid in the initial attachment o f bacteria to a surface (Jesaitis et 
al., 2003). Although the addition of glucose could have aided in the 
attachment of bacteria, and hence the increase in the bacterial content of 
biofilms that has been demonstrated here, (Table 3.7), it is more likely that this 
was due to the extra nutrients provided by the glycerol.
While no conclusive value exists for the inter-pulmonary pH of CF patients 
studies have suggested it to be an acidic environment (Tate et al., 2002). When 
colonized with Ps. aeruginosa the natural pH of the lung (approx. 6.15) is 
altered and decreases to approx. 5.88 in stable CF patients (Tate et al., 2002) 
and therefore the lower pH values were chosen to reflect both stable and
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exacerbated CF patients. This investigation has shown that a decrease in pH 
had no significant impact on the total content of uronic acids produced by two 
clinical strains (P8959 and C2238). However, the bacterial content of 96 h old 
biofilms significantly increased for the CF epidemic strain (P8959) for both pH 
values when compared to pH 7 TSB, but did not significantly alter for the CF 
non-epidemic strain (C2238), suggesting that CF epidemic strains are better 
suited to the acidic environment of the CF lung.
The presence of the characteristic mucus layer and the availability of oxygen 
w ithin it is a source of much debate, with some groups demonstrating that the 
mucus layer is anaerobic (Worlitzsch et al., 2002) and that Ps. aeruginosa can 
grow' anaerobically in this environment utilizing nitrate as an alternative 
electron acceptor (O’May et al., 2006). However, more recently it has been 
suggested that the mucus layer is actually microaerophilic (Alvarez-Ortega and 
Harwood, 2007). The existence of an environment which possesses a greater 
accessibility to oxygen is more likely than a true anaerobic environment as any 
physiotherapy regime that the patient underwent would limit the depth of the 
mucus layer within the lungs of CF patients.
In this investigation the presence of a 5% CO2 atmosphere was included in an 
attempt to mimic a decreased oxygen atmosphere that may be included within 
the CF lung. Although the bacterial content of both clinical and standard 
biofilms was shown to increase substantially (Table 3.7), the total uronic acid 
content did not vary greatly compared to fully aerobic growth. As such it 
could be suggested that Ps. aeruginosa clinical strains are better adapted to a 
diminished oxygen environment than their standard strain counterpart.
3.4.4 The quantification of uronic acid content as a method of quantifying 
biofilm formation
In most cases, the static formation of biofilms and the efficacy of treatments 
are assessed using a crystal violet assay that measures bacterial adhesion to a 
surface (Hentzer et al., 2001). In this assay the crystal violet is retained by
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exopolysaccharides such as alginate and then optical density measured to 
provide an indication of the level of biofilm. In this investigation, the total 
uronic acid content of Ps. aeruginosa biofilms has been measured along with 
the bacterial content of biofilms to investigate the effects of media 
supplementation on Ps. aeruginosa biofilms.
The total uronic acid content assay was chosen as alginate is accepted as one of 
the key components within the EPS matrix of Ps. aeruginosa biofilms and is 
comprised of mannuronic and guluronic acid residues. However, this method 
of quantification does not take into account some of the other Ps. aeruginosa 
polysaccharides that are encoded for by the pel and psl gene loci (Ryder et al.,
2007). The presence of extracellular DNA has been shown to be present as 
part of the EPS of Ps. aeruginosa and has been suggested to interfere with the 
uronic acid assay (Whitchurch et al., 2002) although it is still widely used 
(Kills and Ddnmcz, 2008). In this investigation the presence of extracellular 
DNA was tested for against NCTC 10332 under full aerobic conditions in TSB. 
This showed that the DNA content o f extracted EPS accounted for approx. 
10% of total uronic acid content, potentially explaining some of the variability 
observed.
From the work carried out here, the quantification of uronic acids is not 
sensitive or specific enough to quantify biofilm formation. As such the 
bacterial content of biofilms will be used as the method of assessment for 
future work.
3.4.5 Use of sedimentary biofilms
The production of sedimentation biofilms described here, and other biofilms 
cultured on abiotic surfaces, are believed to differ from those found in the CF 
lung (Moreau-Marquis et al., 2008) in both complexity and structure.
It is believed that the primary attachment Ps. aeruginosa takes place in the 
presence of lung epithelial cells. The initial attempts to co-culture Ps.
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aeruginosa in the presence of lung epithelial cells in vitro failed within 3-4 
hours due to the accumulation of secondary metabolites and lack of oxygen 
resulting in cellular death. This was overcome in subsequent refinements 
(Carterson et al., 2005). Despite the ability to co-culture epithelial cells and 
Ps. aeruginosa there is still no consensus on whether Ps. aeruginosa binds 
directly to epithelial cells, with some groups advocating that biofilm formation 
and growth takes place entirely within the mucus layer in the CF lung 
(Worlitzsch et al., 2002) and some groups suggesting that direct binding and 
even cellular internalisation play a role (Garcia-Medina et al., 2005).
Here, we have shown that the supplementation o f media does alter both the 
uronic acid content and the total bacterial content of sedimentary biofilms of 
Ps. aeruginosa (Table 3.7). However, the differences were often insignificant. 
Here sedimentary biofilms have been shown to be easy to culture and 
reproducible. As such sedimentation biofilms that show complex structures 
and LPS production are still valid as an initial method of testing potential 
therapeutics while more complex and representative models are developed.
The presence of the mucus layer itself is also believed to aid in the initial 
colonization of CF patients (Landry et al., 2006); the addition of mucin to 
media (Sriramulu et al., 2005) and the pre-treatment of abiotic surfaces with 
pig mucin has been shown to increase biofilm complexity and also formation 
(Landry et al., 2006) as the addition of glycerol demonstrated. The simple 
media (LB broth, pH 5 10% glycerol and 5% CO2) described here has also 
shown to produce biofilms (Figure 3.12) of similar levels of complexity and 
structure to those produced from more complex media (Sriramulu et al., 2005). 
This media could therefore be suitable for larger experiments for the culture of 
Ps. aeruginosa biofilms such as those found in CDFF apparatus, as the media 
is a fraction of the cost of the artificial sputum media.
89
3.4.6 Summary
This chapter has characterised 14 strains of Ps. aeruginosa on the basis of EPS 
production by light microscopy and antibiotic susceptibility profiles 
determined using BSAC methodology. From this, 3 strains of Ps. aeruginosa 
were chosen for subsequent testing. A number of Ps. aeruginosa phages were 
structurally characterised using TEM and type of genetic material determined.
The quantification of the total uronic acid content as a measure of Ps. 
aeruginosa biofilms has been shown here to be highly variable, with no 
significant differences existing between the different conditions tested (with 
the exception of NCTC 10332 in TSB at pH 5 and 5% CO2). As such the use 
of uronic acid content to quantify biofilms is not sensitive or specific enough to 
determine the effects of environmental and nutritional supplementation.
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Chapter 4
Assessment and enhancement 
of the lvtic activity of 
Ps. aerueinosa bacteriophages
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4.1 Introduction
With the rise in the level of antibiotic resistance in bacteria there has been an 
increased interest in alternatives to antibiotic therapy. Although in clinical use 
in Eastern Europe bacteriophage therapy has only recently begun to attract 
attention in the West with a number of new products being licensed or 
currently in clinical trials (Merabishvili et al., 2009).
To produce successful whole-phage based therapeutics a number of criteria 
must be met. These include the ability to infect a range of strains as well as the 
ability to reduce the overall level of infection (Hanlon, 2007). Such a phage 
preparation requires one of two approaches to be undertaken: genetic 
modification (GM) of the phage genome to broaden specificity and to increase 
activity or selective breeding for the most infectious phage. The former of 
these two approaches might be more efficient allowing for the ability to not 
only contain elements that would enhance penetration of biofilms e.g. such as 
the production of an alginate lyase (Hanlon et al., 2001), but also to increase 
the rate and overall level of bacterial kill. In reality, products based on 
genetically modified phages are probably more difficult to bring to market due 
to the amount of regulation surrounding GM organisms. The latter approach 
on the other hand allows for the selection of more virulent phage on the basis 
of time required to infect the host organism (Jassim et al., 1995), which should 
lead to an increase in level and rate of bacterial lysis.
This chapter seeks to assess the lytic activity o f 4 Ps. aeruginosa phages using 
a qualitative streak test (Merabishvili et al., 2009). In addition, a Bioscreen C 
based-assay was developed to provide more reliable quantitative data on phage 
activity and increase the effectiveness of screening. The lytic activity of phage 
strains was enhanced using a pomegranate rind extract (PRE) (Jassim et al., 
1995). This chapter also sought to design and assess the lytic potential of a 
bacteriophage cocktail.
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4.2 Materials and methods
4.2.1 Bacterial and bacteriophage strains
Fourteen bacterial strains and 4 phage strains were routinely cultured as 
previously described (Chapter 2; Section 2.2). Prior to use bacterial 
suspensions were standardised as previously described (Chapter 2; Section
2.2.1). Fresh phage cultures were prepared using the agar overlay technique 
(Adams, 1959) with PAOl as a host.
4.2.2 Streak test for phage activity and host range
The following method was adapted from Merabishvili et al. (2009). Bacterial 
suspensions were prepared and standardised as previously described (Chapter 
2; Section 2.2.1). Ten microlitres of bacterial suspension (containing between 
I and 5 xlO8 CFU/mL) were streaked over the surface of a 100 x 100 mm 
square pctri dish (Stcrilin Ltd, Caerphilly, UK) that had previously been 
divided into a 5 x 5 grid and air dried at room temperature for 15 min.
Ten microlitrcs o f bacteriophage solution (approx. 107 PFU/mL) was then 
spotted at each intersection and air dried at room temperature for 1 h. PBS was 
used as a negative control. Plates were incubated at 37°C for 3 h and assessed 
visually for phage activity on the basis of a positive/negative reaction of the 
bacteria to the phage. Plates were then re-incubated at room temperature in the 
dark for a further 18-21 h after which a secondary reading (Figure 4.1) was 
scored from 0 to +5 on the basis of the plaque formed by bacteriophage (Table
4.1).
93
Figure  4.1: F xam ple  of a phage s tre a k  test p la te  a t secondary  reading  
stage. Labels on the plate correspond to Table 4.1.
O bservation Score
Confluent lysis - bacterial streak completely broken, no bacterial
colonies present at spotted intersection +5
Overgrowth - bacterial streak completely broken, presence of singular +4
bacterial colonies on spot
Semi-confluent lysis - bacterial streak incompletely broken +3
Multiple small phage plaques +2
Bacterial streak just affected i.e. little observable disruption to bacterial + 1
growth
Negative reaction - no lysis 0
T ab le  4.1: Scoring  system  fo r assessm en t o f bacteriophage activity using a 
s tre a k  test. Based on M erabishvili et al. (2009).
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4.2.3 Bioscreen C assessment of phage activity
4.2.3.1 Culture preparation
Bacterial and phage suspensions were prepared from working stocks as 
previously described (Chapter 2 Section 2.2.1 and Chapter 2 Section 2.2.2 
respectively); with the exception that bacterial standardisation was performed 
in TSB. Experiments were performed in triplicate using fresh phage and 
bacterial suspensions.
4.2.3.2 Plate layout and experimental conditions
Three hundred and fifty microlitres of bacterial suspension (containing 
between 1 and 5 xlOK CFU/mL) in TSB was added to each well of a 100 well 
honeycomb plate (Oy Growth Curves AB Ltd, Helsinki, Finland), followed by 
the appropriate volume of phage suspension (50 pL unless otherwise stated). A 
non-phage treated control containing 350 pL of bacterial suspension and 50 pL 
PBS was performed. A negative control containing TSB alone and 50 pL of 
PBS was also performed.
The assessment of phage lytic activity was then performed over 20 h using a 
wideband filter (420-580 nm) with readings taken every 15 min in a Bioscreen 
C analyzer (Oy Growth Curves AB Ltd, Helsinki, Finland) at 37°C using the 
EZExperiment software Version 1.26 (Oy Growth Curves AB Ltd, Helsinki, 
Finland). Each reading was preceded by a 10 s shaking cycle.
4.2.3.3 Data analysis and interpretation
Data were analysed in Microsoft Excel (Microsoft, MA, USA) whereby O D 4 2 0 -  
5sonm at each time point was averaged. OD420-580nm was then adjusted for the 
contribution of TSB. From this the assessment criteria for phage activity were 
calculated (Figure 4.2). “Acceptance” criteria were established for two main 
criteria (Table 4.2): 1) a measurement of bactericidal activity (i.e. activity >2 
Logjo decrease in bacterial number after 8 or 20 h) and 2) a measurement of
bacterial regrowth following phage infection (i.e. time taken to reach an O D 4 2 0 -  
580nm of 0.1 units above the original O D 42o-580nm) of >480 min.
Bactericidal activity was calculated by measuring the bacterial content of test 
wells and untreated controls, based on O D 42o-580nnv O D 42o-580nm was converted 
to Logio CFU from O D / T V C  graphs of individual strains and subtracting tests 
from controls.
Other measurements of phage activity were also calculated but not used for the 
calculation of phage activity. These included: 1) the initial lytic activity
indicated by a decrease in OD42o-580nm within 30 min of phage addition (Figure
4.2) and 2) the calculation of the lytic slope as an indication of the rate of 
bacterial lysis. The set “acceptance” values (Table 4.2) were derived from the 
literature for phage activity (Hanlon et al., 2001; Atterbury et al., 2007; Fu et 
al.. 2010) and antibiotic dosing times (van Zanten et al., 2007; McCoy et al., 
2008).
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Figure 4.2: A ssessm ent criteria  for Bioscreen C analysis. Data used are the treatment o f Ps. aeruginosa strain PA01 against 
PRE and non-PRE treated GL-1. Assessment criteria based on: a) time taken to induce lysis; the level o f bacterial reduction at 8 
and 20 h (b and c respectively), d) level o f bacterial regrowth (time taken to increase OD42o-580nm 0.1 units above the initial O D 420- 
580nm)- ♦ , untreated culture; • ,  non-PRE treated phage; ▲, PRE treated phage.
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Evaluation criteria Additional criterion
Logio reduction Time1 Lysis2
8 h_______ 20_h_____ (min)_________ (min)______
“Acceptance” value >2 >2 >480 <30
Table 4.2: Standard criteria for the assessment of the lytic activity of Ps. 
aeruginosa bacteriophages in the Bioscreen C analyzer. Bacterial 
regrowth (time taken to increase OD42o-$80nm 0.1 units above the initial OD420- 
580nm) and 2: time taken to induce lysis.
4.2.4 Enhancement of bacteriophage activity
Pomegranate rind extract stock (PRE) was kindly provided by David Houston 
(Welsh School of Pharmacy, Cardiff University, Cardiff, UK). The PRE was 
prepared as described in Jassim et a l., (1995). In brief, pomegranate rind (25% 
w v) was boiled in distilled water for 30 min then centrifuged at 20000 x g  for 
30 min at 4°C. The supernatant was then autoclaved at 121°C for 15 min and 
then further purified by membrane ultra filtration (molecular weight cut off 10 
kDa) and stored at -20°C.
4.2.4.1 Chemical preparation
A 0.53% (w/v) stock solution of ferrous sulphate in X buffer (containing 6 
mL L of 1 M Tris-HCl at pH 8.0 (Invitrogen, CA, USA), 5 g/L gelatine and 1.2 
g/L MgS0 4 .2 H20 ) was prepared and sterilized by filtration with a 0.45 pm 
filter (Millipore, Cork, Ireland). A working solution of ferrous sulphate was 
prepared by adding 4.1 mL stock solution to 14 mL A, buffer. A working 
solution of PRE was prepared by adding 1.3 mL stock PRE to 8.7 mL X buffer.
Composition A (CompA) was prepared 1-2 min prior to use by mixing 16.74 
mL of ferrous sulphate working solution to 8.3 mL PRE working solution. The 
solution turned black after approximately 30 s and was protected from light.
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4.2.4.2 Phage enhancement
The phage enhancement protocol has been adapted from Jassim et al., (1995). 
In brief, phage strains were treated with PRE as in Figure 4.3 for 15 min. 
Subsequent enhancements at 10, 5 and 2.5 min were also performed. By 
reducing the time allowed for phage infection it is believed that this will 
increase the infcctivity of subsequent phage progeny. The addition of CompA 
to the phage/host suspension will act as a selective virucide removing phages 
which have not infected the host.
Controls containing approximately 10s PFU/mL and CompA solution were 
assessed for lytic activity following 20 min at room temperature in the dark. 
No plaques were detected when regrown using PAOl as a host. There was no 
significant difference in plaque numbers between phages treated with PRE 
containing 2% tween 80 and those treated with PBS (P>0.05).
4.2.5 Assessment of Ivtic activity in a phage cocktail
Phage Cocktails containing up to five Ps. aeruginosa phages were tested for 
lytic activity against all strains of Ps. aeruginosa using both the streak test and 
the Bioscreen C Assay. Phages were chosen on the basis of the streak test 
assay performed on all enhancements. Phage cocktails containing GL-1, GL-1 
2.5, LP-M 10, C10176-S 15 and LP-M 5 (figure in italics represent 
enhancement time chosen) were prepared by mixing phage suspensions in 
equal volumes (containing approx. 10n PFU/mL). The streak test and the 
Bioscrcen C assay were then performed as previously described (Chapter 4; 
Section 4.2.2 and 4.2.3)
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Bacterial host suspension 
(PA01) 10pL of 109 CFU/mL
Initial phage suspension 
(unenhanced) 10 pL of 1012 
PFU/mL
15 min enhancement time1
\
SELECTION STEP
Addition of PRE (144 pL)
I
2-3 min contact time
_______________________ i ___________________________
Neutralisation of PRE
Addition of 2% (v/v) Tween 80 in A-buffer (144 pL)
 i_ _ _ _ _ _
PROPAGATION OF “ENHANCED” PHAGES
Addition of0.1 mLPAOl (10® CFU/mL) and 2.3 mL TSB
*
Incubation for 3-5 h at 37°C
i
ISOLATION OF PHAGES
(in this schematic 15 min enhancement time)
Figure 43; Schematic representation of phage enhancement using PRE.
'iContact time between phages and bacterial suspension varied (i.e. 
enhancement time of 15, 10, 5 and 2.5 min were used; see text).
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4.3 Results
4.3.1 Assessment of the lytic activity of Ps. aeruginosa pha2es against the host 
strain
4.3.1.1 Effect of multiplicity of infection on the lvtic activity of non-PRE 
treated phages
Following the addition of phage suspensions at different multiplicities of 
infection (MOI) to Ps. aeruginosa strain PAOl, all concentrations between 
10'‘ and 10‘ PFU/mL (MOI approx. 1400:1 at 1012 PFU/mL) caused a decrease 
in OD420 580nm (Figure 4.4). However, the time taken to induce this lytic curve 
varied depending on the phage inoculum size (Table 4.3). No lytic slope was 
detected in the lowest inoculum size for all phages (101 PFU/mL; Table 4.3).
In terms of the reduction of bacterial number at 8 h, phages GL-1 and C 10176- 
S showed a general trend of decreasing activity as phage inoculum size was 
decreased (1012 to 102 PFU/mL; Table 4.3). However, LP-M and C10176-L 
showed the highest reductions at 108 or 109 PFU/mL (Table 4.3). The MOI 
( 1012 to 103 PFU/mL) was shown to have no significant impact (/^0.05) on the 
level of bacterial lysis (i.e. no difference in bacterial kill). A phage 
concentration of 101 PFU/mL showed a significantly lower reduction (P<0.05; 
Table 4.3) implying that the MOI only impacts on the overall level of bacterial 
lysis at extremely low phage levels.
As the MOI was decreased, the amount of time taken for the phages to induce 
lysis increased (Table 4.3). The rate of lysis (i.e. the slope of the linear 
decrease in O D 420-580nm) was found to vary significantly (7^0.05) for all phages 
with the exception of LP-M (Table 4.3; P=0.452).
When using the “acceptance” criteria (Table 4.2) all phages met the required 
level of bacterial reduction above a concentration of 103 PFU/mL (Table 4.3).
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However, all phages failed to meet the acceptable level for time taken to induce 
lysis.
4.3.1.2 Enhancement of lvtic activity following treatment with PRE 
The streak test showed an increase in the level of plaque formation in all 4 
phages (Table 4.4) following the enhancement process. The largest increase in 
streak score was between no PRE treatment (i.e. unenhanced) and the 15 min 
contact time. Subsequent enhancements led to smaller increases to a maximum 
level in all phages except GL-1 where a maximum activity was achieved 
following a 5 min enhancement. Both C10176-L and GL-1 showed the largest 
overall increase in score and LP-M showed the smallest increase (Table 4.4).
When analysed on the Bioscreen C, a phage-treated culture of PAOl produced 
lysis within 30 min for all non-PRL treated phages and immediately with PRE- 
trcatcd phages, with the exception of C10176-L (data not shown). Following 
enhancement there was a decrease in the gradient of the slope (implying a 
slower rate of bacterial lysis) for all phages and enhancement times, but this 
was not statistically significant (/’^O.OS; Table 4.4). Only C10176-L after a 15 
min enhancement time showed a non-significant increase in slope gradient 
(/M ).05) when compared to non-PRE treated phage (Table 4.4).
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Figure 4.4: Effect of phage multiplicity of infection on the growth of Ps. aeruginosa  strain PAOl. Phage used was LP-M. Data shown 
are the mean o f 5 replicates (SD not shown as this would over complicate the figure). 1012 (♦), 10n (■), 10,0( A ), 109 (x), 108 (x), 107 (•), 
106(+), 105 (-), 104(-), 103 (♦), 102(b), 10'(A), Untreated (x) PFU/mL.
Bacteriophage
Phage
concentration
(PFUmL1)
GL-14 C10176-S4 C10176-L*......... LP-M
Time* Slope2 Log,0
Reduction3
Time* Slope2 Log,.
Reduction3
Time1 Slope2 Log,0
Reduction3
Time1 Slope2 Log,0
Reduction3
1012 40(10) 20.2 >2 35(25) 20.0 >2 45(0) 25.9 >2 30(15) 20.0 >2
10" 45(15) 20.6 >2 55(10) 21.7 >2 45(0) 24.1 >2 40(10) 25.2 >2
1010 60(15) 25.5 >2 55(10) 26.9 >2 55(10) 29.9 >2 55(10) 26.8 >2
10g 65(10) 22.3 >2 70(10) 25.6 >2 65(10) 25.7 >2 60(0) 30.1 >2
10* 75(0) 25.2 >2 85(10) 23.6 >2 75(0) 27.9 >2 70(10) 33.1 >2
107 85(10) 4.01 >2 85(15) 24.4 >2 90(0) 22.9 >2 75(0) 34.8 >2
106 95(10) 20.9 >2 90(10) 25.3 >2 95(5) 23.5 >2 90(0) 27.7 >2
105 105(0) 37.2 >2 110(10) 28.5 >2 105(0) 25.1 >2 105(0) 29.4 >2
104 115(10) 30.8 >2 130(15) 36.0 >2 120(0) 31.7 >2 120(0) 35.1 >2
103 130(10) 32.3 >2 145(15) 28.5 >2 130(10) 30.3 >2 140(10) 30.9 >2
102 410(530) 6.38 1.34(0.87) 165(15) 16.8 1.10(0.97) 600(400) - 1.14(0.71) 390(455) 6.45 1.01(0.58)
101 - - 0.38(0.54) - - 0.29(0.19) - - 0.39(0.50) - - 0.15(0.43)
Table 4.3: Summary of the effect of multiplicity of infection on the growth of Ps. aeruginosa strain PAOl. Time (min) taken to induce 
a lytic slope (±SD).2: Slope is expressed as a decrease in OD42o-580nm per minute (xlO"4) .3: Log to reduction in bacterial number at 8 h .4: n=4.5: 
n=5. Bold typeface indicates significant differences at the 95% Cl by one way ANOVA.
1 0 4
Phage
Treatment
(min1)
Streak Bioscreen C
Test
(max.50)
Slope2 Logio Reduction
8 h 20 h
Time3
Phage GL-I
0 20 22.0 1.95(0.51) 1.24(1.10) 815±670
15 40 19.9 1.98(0.68) >2 >1200
10 45 17.5 >2 >2 >1200
5 46 16.0 >2 >2 >1200
2.5 43 16.3 >2 >2 >1200
Phage C10176-S
0 29 22.1 >2 >2 >1200
15 40 19.6 1.99(0.73) >2 >1200
10 44 18.8 >2 >2 >1200
5 43 16.0 >2 >2 >1200
2.5 47 17.1 >2 >2 >1200
Phage C10176-L
0 20 21.5 >2 >2 >1200
15 40 23.1 1.99(0.69) >2 >1200
10 44 16.4 >2 >2 >1200
5 45 16.9 >2 >2 >1200
2.5 48 17.0 >2 >2 >1200
Phage LP-M
0 30 21.5 >2 >2 >1200
15 40 19.3 1.99(0.70) >2 >1200
10 44 17.3 >2 >2 >1200
5 45 16.3 >2 >2 >1200
2.5 45 16.2 >2 >2 >1200
Table 4.4: Summary of the lytic activity of Ps. aeruginosa phages treated 
with PRE against Ps. aeruginosa strain PAOl. Data shown are the mean of 3 
replicates (±SD). Phage-bacteria contact time before exposure to PRE (see 
text). 2: Slope is expressed as a decrease in OD420-580nm per minute (xlO-4). 3: 
Time taken to increase OD420-580nm by 0.1 above the original OD420-580nm* Bold 
typeface indicates significant differences at the 95% Cl by one way ANOVA 
when compared to non-PRE treated phage.
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The level of reduction in bacterial number was calculated from OD42o-580nm as 
previously described (Chapter 4; Section 4.2.3.3), PRE-treated phages (2.5 min 
enhancement time) showed a significantly higher level of reduction than non- 
PRE treated phages (P<0.05; Table 4.4) at 8 h. This difference was not 
significant by 20 h, with the exception of GL-1 (Table 4.4). All PRE-treated 
phages showed a continuation of the reduction in bacterial number between 8 
and 20 h; with the exception of LP-M these increases were not significant 
(P>0.05; Table 4.4).
When comparing the lytic activity of PRE and non-PRE treated GL-1 phage 
using a streak test, it was observed that the highest level of activity was 
following a 5 min contact time (Table 4.4). However, the highest level of lytic 
activity (i.e. Logio reduction in bacterial number) when assessed with the 
Bioscreen C was observed with a 2.5 min contact time (Table 4.4). The 
difference in Logio reduction using the Bioscreen C between these two contact 
times was not significant (P>0.05).
In the host strain, PAOl, all PRE treatment times showed the induction of a 
lytic slope in <30 min, thereby meeting the “acceptance” criteria set out in 
Table 4.2 (data not shown).
Overall GL-1 phage showed the greatest difference between the Logio 
reduction in bacterial number when comparing untreated and PRE treated 
samples.
When comparing the time taken for PAOl to re-grow to an OD420-580nm value 
of 0.1 higher than the initial O D 420-580nm, it was found that for all phages, 
except GL-1, both PRE and non-PRE treated phages took >1200 min to reach 
this value (Table 4.4). When compared against the “acceptance” criteria 
(Table 4.2) for all phages, both PRE and non-PRE treated exceeded the 
“acceptance” criteria for regrowth of >480 min.
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4.3.2 Assessment of the lytic activity of Ps. aeruginosa phages against strains 
isolated from CF patients
Enhanced phages were chosen on the basis of streak test analysis. Where there 
was no increase or decrease in activity the final stage (2.5 min) of enhancement 
was chosen in order to provide a comparison between PRE treated and non 
PRE-treated phages.
The treatment of phages with PRE, when assessed using the streak test method, 
led to an increase in phage activity with C10176-L and LP-M showing the 
largest increases and GL-1 showing the smallest (Tables 4.5 a-d). Ps. 
aeruginosa strain C4503 showed increased susceptibility to infection in only 
the LP-M phage (Table 4.5d). However, some strains, most notably the Midsl 
strain (a CF epidemic strain) showed no increase in susceptibility to any of the 
phages tested (Table 4.5a-d).
Assessment using the Bioscreen C revealed that some of the bacterial strains 
exhibited no clear lytic slope when challenged with non-PRE treated phages 
and that following PRE treatment the lytic slope either decreased in gradient 
(i.e. slower rate of lysis) or ceased to be present (Table 4.5 a-d), and thus failed 
to meet “acceptance” criteria in almost 50% of strains (Table 4.6). Despite 
this, the growth pattern of the bacteria varied drastically between PRE and non- 
PRE treated phages (Figure 4.5).
The activity of the phages based on the “acceptance” criteria described earlier 
(Table 4.2), the level of bacterial lysis at 8 h (i.e. reduction in bacterial number 
calculated from O D 420-580nm) showed no significant difference between non- 
PRE and PRE treated phages with the exceptions of C3786 and C 1913 treated 
with C10176-S (Table 4.5b) and C1913 and C2846 treated with GL-1 (Table 
4.5a). All bacterial strains showed some level of reduction by 8 h with the 
exception of Mids 1.
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Following exposure to phages, all bacterial strains exhibited an eventual 
increase in OD420-580nm (Table 4.5a-d) which is indicative of bacterial regrowth, 
and potentially the presence of phage resistant bacteria. This increase varied 
between the bacteria/phage combinations. In the vast majority of cases the 
level of regrowth (time taken to increase OD420-580nm by 0.1 above the original) 
met the required acceptance criteria (i.e. >480 min).
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Non-PRE treated phage PRE Treated phage
Bacterial Streak Bioscreen C Streak Bioscreen C
strain test Logio reduction Time* test Logio reduction Time1
(max.50) 8 h 20 h (max. 50) 8 h 20 h
NCTC 35 0.99(0.74) 0.72(1.22) 230(35) 2 >2 1.51(1.68) 180(25)
C3652 34 1.23(0.17) 1.70(0.71) 885(295) 38 10* 0.90(0.20) 1.21(0.70) 505(140)
C3719 46 0.93(0.17) 0.97(0.06) 585(130) 2 0.79(0.20) 1.39(0.50) 455(160)
C3786 44 0.77(0.67) 0.05(0.95) 110(30) 2 >2 1.57(1.07) 145(10)
LES 30 1.09(0.13) >2 1185(25) 34 2.5' 0.97(0.21) 1.25(0.09) 940(80)
Midsl 30 _4 1.22(0.76) 85(20) 4 1.12(0.69) 140(25)
P8959 35 1.79(0.34) >2 905(175) 2 1.95(0.07) >2 915(25)
C1913 6 >2 0.21(0.63) 310(20) 22 2.5' >2 >2 345(90)
C2238 23 0.51(0.08) 0.73(0.51) 765(70) 40 / O' 0.57(0.16) >2 840(240)
C2846 35 0.97(0.50) 0.48(0.71) 240(15) 2 >2 >2 345(275)
C3597 50 >2 0.89(1.32) 560(185) 2 >2 >2 495(300)
C4503 34 4 0.10(0.35) 140(20) _2 0.90(1.52) 0.99(2.06) 350(400)
PAK 30 >2 >2 >1200 46 2.53 >2 >2 1020(40)
Table 4.5a: The lytic activity of PRE and non-PRE treated Ps. aeruginosa phage GL-1 when tested against strains isolated 
from CF patients. Data shown are the mean of 3 replicates (±SD). Time taken to increase OD420-580nm by 0.1 above the 
original OD42o-580nm- 2' No increase in score 3: time: phage-bacteria contact time (min) before exposure to PRE (See text) 4: No 
reduction in bacterial number observed. Bold typeface indicates significant differences at the 95% Cl by one way ANOVA.
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Non-PRE treated phage PRE Treated phage
Bacterial Streak Bioscreen C Streak test Bioscreen C
strain test Logio reduction Time* (max. 50) Logio reduction Time1
(max.50) 8 h 20 h 8 h 20 h
NCTC 14 0.47(0.78) _4 220(30) 27 15' 1.64(1.20) 1.32(1.52) 180(25)
C3652 30 0.97(0.24) >2 900(520) 40 10s 0.95(0.37) 0.93(0.37) 558(200)
C3719 30 0.89(0.24) 1.87(0.71) 890(540) 31 /53 0.77(0.31) 1.39(0.79) 485(170)
C3786 9 0.87(1.31) 0.58(1.04) 100(25) 45 2.5' >2 1.90(1.11) 145(10)
LES 14 0.91(0.24) 1.46(0.36) 805(280) 30 2.5i 1.50(1.21) 1.27(0.40) 980(330)
Midsl 18 _4 0.68(0.58) 95(30) 2 4 1.55(0.73) 140(25)
P8959 22 1.96(0.20) >2 1100(85) 2 1.81(0.08) 1.91(0.48) 825(145)
C1913 30 1.50(0.33) 0.03(0.16) 200(30) 2 >2 >2 425(285)
C2238 8 0.56(0.11) 1.02(0.27) 805(50) 40 /O3 0.62(0.13) >2 865(340)
C2846 25 0.76(0.67) 0.59(0.77) 215(25) 30 10s >2 >2 215(50)
C3597 2 >2 1.78(1.24) 500(280) 46 53 >2 >2 895(295)
C4503 30 4 0.01(0.12) 140(10) 2 0.81(1.63) 0.83(1.92) 370(435)
PAK 24 >2 >2 1095(160) 46 53 >2 >2 1025(100)
Table 4.5b: The lytic activity of PRE and non-PRE treated Ps. aeruginosa phage C10176-S when tested against strains 
isolated from CF patients. Data shown are the mean of 3 replicates (±SD). Time taken to increase OD42o-580nm by 0.1 above 
the original O D 42o-580nm-2: No increase in score3: time: phage-bacteria contact time (min) before exposure to PRE (See text)4: No 
reduction in bacterial number observed. Bold typeface indicates significant differences at the 95% Cl by one way ANOVA.
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Non-PRE treated phage PRE Treated phage
Bacterial Streak Bioscreen C Streak test Bioscreen C
strain test Logio reduction Time* (max. 50) Logio reduction Time'
(max.50) 8 h 20 h 8 h 20 h
NCTC 10 0.90(0.78) 0.99(0.99) 205(10) 21 101 1.90(0.65) 1.46(0.89) 180(40)
C3652 10 0.94(0.14) 1.79(0.64) 590(85) 36 10s 1.06(0.15) 1.76(0.88) 1005(340)
C3719 0 0.85(0.05) 1.59(0.46) 565(10) 25 l t f 1.05(0.15) >2 >1200
C3786 44 >2 >2 130(10) >2 1.51(0.87) 140(10)
LES 10 1.09(0.18) >2 1155(80) 29 2.53 0.88(0.27) 1.04(0.43) 860(280)
Midsl 10 4 1.12(0.63) 105(45) 2 4 1.43(0.69) 140(25)
P8959 10 1.99(0.20) >2 1180(35) 27 1& 1.72(0.46) 1.86(0.60) 770(285)
C1913 0 >2 0.10(0.55) 345(55) 22 2.53 >2 >2 240(50)
C2238 0 0.59(0.07) 1.48(0.23) 865(135) 49 53 0.59(0.14) >2 790(325)
C2846 20 >2 >2 305(30) 24 l& >2 >2 205(40)
C3597 47 >2 1.34(1.67) 570(210) 50 l& >2 >2 185(40)
C4503 20 0.07(0.04) 0.30(0.27) 130(10) 1 0.95(1.70) 0.35(0.99) 380(440)
PAK 16 >2 >2 1085(150) 40 /53 >2 >2 1000(165)
Table 4.5c: The lytic activity of PRE and non-PRE treated Ps. aeruginosa phage C10176-L when tested against strains 
isolated from CF patients. Data shown are the mean of 3 replicates (±SD). Time taken to increase OD42o-580nm by 0.1 above 
the original OD42o-580nm.2: No increase in score3: time: phage-bacteria contact time (min) before exposure to PRE (See text)4: No 
reduction in bacterial number observed. Bold typeface indicates significant differences at the 95% Cl by one way ANOVA.
I l l
Bacterial
strain
Non-PRE treated phage PRE Treated phage
Streak test
(max.50)
Bioscreen C Streak Bioscreen C
Logio reduction Time* test Logio reduction Time*
8 h 20 h (max. 50) 8 h 20 h
NCTC 32 0.87(0.56) 1.00(0.62) 200(20) 1 >2 1.76(1.18) 170(30)
C3652 22 1.08(0.02) >2 880(280) 35 HP 0.92(0.32) 1.54(0.79) 505(275)
C3719 20 0.95(0.24) >2 >1200 31 I03 0.76(0.29) 1.94(0.08) 450(250)
C3786 40 >2 >2 130(20) 42 2.53 >2 1.17(1.36) 140(10)
LES 30 1.08(0.19) >2 1155(80) 2 0.91(0.23) 1.22(0.42) 940(320)
Midsl 10 4 1.56(0.60) 115(40) 7 4 1.04(1.19) 135(15)
P8959 20 >2 >2 >1200 26 I03 1.76(0.28) 1.99(0.73) 830(285)
C1913 0 >2 >2 545(115) 22 I01 >2 >2 350(205)
C2238 20 0.77(0.09) >2 >1200 50 J 3 0.51(0.17) >2 705(370)
C2846 43 >2 >2 305(10) 50 103 >2 >2 200(40)
C3597 43 >2 1.84(0.64) 605(85) 50 10s >2 >2 220(60)
C4503 10 4 _4 130(10) 21 i d 0.83(1.54) 0.72(1.89) 335(360)
PAK 4 >2 >2 995(75) 42 2.53 >2 >2 950(55)
Table 4.5d: The lytic activity of PRE and non-PRE treated Ps. aeruginosa phage LP-M when tested against strains isolated 
from CF patients. Data shown are the mean of 3 replicates (±SD). Time taken to increase OD42o-580nm by 0.1 above the 
original OD42o-580nm-2-' No increase in score 3: time: phage-bacteria contact time (min) before exposure to PRE (See text) 4: No 
reduction in bacterial number observed. Bold typeface indicates significant differences at the 95% Cl by one way ANOVA.
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Time (min)
Figure 4.5: R epresentative change in bacterial grow th patterns of Ps. aeruginosa  s tra in  C1913 following trea tm en t with 
PRE trea ted  and non-PRE treated  C10176-S bacteriophage. Phage treated samples are the mean o f 3 replicates; untreated 
samples are the mean o f 6 replicates.*, Untreated bacteria; », non-PRE treated; A,  PRE treated.
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Evaluation criteria Additional
criterion
r
00 
o
 
ST
© reduction 
20 h
Time (min)1 Lysis2
Phage Treatment No. of bacterial strains where phage “acceptance” 
criteria was met (out of 14)
GL-1 3 3 8 7
C10176-S Non-PRE 3 4 8 7
C10176-L treated 6 6 8 7
LP-M 7 10 8 7
GL-1 7 7 7 4
C10176-S PRE treated 6 6 8 4
C10176-L 6 7 6 4
LP-M 7 6 6 4
Table 4.6: Summary of the lytic assessment criteria of single Ps. 
aeruginosa phages from Bioscreen C assessment. Time taken to increase 
O D 420-580nm by 0.1 about the original O D 42o-580nm .2: Time taken to induce a lytic 
slope.
4.3.3 The lvtic activity of phage cocktails against strains of Ps. aeruzinosa 
When the lytic activity of Ps. aeruginosa phage cocktails was assessed by the 
streak test method, all phage cocktails exhibited a score of >30 against all 
strains with the exception of Midsl and it was not possible to distinguish 
between the different phage cocktails (Table 4.7a-b).
When analyzed by the Bioscreen C method the lytic activity of phage cocktails 
(containing between 2-5 phages) varied depending on the bacterial strain that 
was challenged (Tables 4.7a-b).
Once again, Ps. aeruginosa strain C4503 exhibited the least sensitivity to
phage infection over all the criteria measured. CF epidemic strains showed
less sensitivity to phage infection (i.e. lower “kill”) compared to CF non-
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epidemic strains (Tables 4.7a-b). In the case of PAOl, all phage cocktails met 
or exceeded the activity of at least two of the individual phage components.
When assessed using the “acceptance” criteria as previously described (Table
4.2) approximately 50% of strains met the required standard for Logio 
reduction at 8 h (Table 4.8), although this increased to above 50% for all phage 
cocktails tested. For the level of bacterial regrowth 50% or above of strains 
met the required criterion.
Although the 5 phage cocktail (containing GL-1, GL-1 2.5, LP-M 10, C 10176- 
S 15 and LP-M 5) met the most “acceptance” criteria, both this cocktail and the 
3 phage cocktail (containing GL-1, GL-1 2.5, and LP-M 10) showed no 
significant differences in terms of activity (/*>0.05; i.e. no greater reduction in 
bacterial number etc).
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Phage Cocktail
Bacterial GL-1 and GL-1 2.5 GL-1, GL-1 2.5 and LP-M 10
strain Streak test Logio reduction Time1 Streak test Logio reduction Time*
8 h 20 h 8 h 20 h
PAOl 50 >2 >2 >1200 50 >2 >2 1195(10)
NCTC 40 1.41(0.15) 1.16(0.44) 220(20) 40 >2 >2 175(35)
C3652 50 1.06(0.20) >2 >1200 50 1.02(0.18) >2 >1200
C3719 50 0.92(0.09) >2 >1200 50 1.03(0.16) >2 >1200
C3786 50 1.91(0.98) 1.03(1.33) 140(10) 50 >2 1.81(1.39) 140(10)
LES 40 0.95(0.21) 0.99(0.44) 750(225) 40 0.98(0.12) 1.05(0.31) 795(140)
Midsl 4 2 >2 165(55) 0 2 >2 150(40)
P8959 50 1.50(0.36) 1.66(0.41) 855(85) 50 1.66(0.30) 1.51(0.82) 785(205)
C1913 44 >2 >2 255(65) 44 >2 >2 225(60)
C2238 50 0.64(0.22) 3.02(1.11) 860(295) 50 0.70(0.24) >2 735(220)
C2846 42 >2 >2 510(325) 42 >2 >2 465(255)
C3597 50 >2 1.03(1.96) 535(295) 50 >2 >2 365(245)
C4503 30 0.33(0.54) 0.86(0.88) 120(15) 30 0.25(0.55) 0.46(0.87) 125(10)
PAK 50 >2 >2 745(320) 50 >2 >2 755(320)
Table 4.7a: Summary table of the lytic activity of phage cocktails against Ps. aeruginosa assessed using the Bioscreen C. Phage 
cocktails contained equal parts GL-1, GL-1 2.5 and LP-M 10. Data shown are the mean of 3 replicates (±SD). Time taken to increase 
OD42o-580nm by 0.1 above the original OD42o-580nm.2: No reduction in bacterial number observed. Bold typeface indicates significant 
differences at the 95% Cl by one way ANOVA.
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Phage Cocktail
Bacterial GL-1, GL-1 2.5, LP-M 10 and C10176-S 15 GL-1, GL-1 2.5, LP-M 10, C10176-S 15 and LP-M 5
strain Streak test Logio reduction Time1 Streak test Logio reduction Time1
8 h 20 h 8 h 20 h
PAOl 50 >2 >2 >1200 50 >2 >2 >1200
NCTC 40 >2 >2 200(25) 40 >2 >2 210(15)
C3652 50 1.18(0.06) >2 >1200 50 1.15(0.08) >2 >1200
C3719 50 1.04(0.05) >2 >1200 50 1.03(0.04) >2 >1200
C3786 50 >2 1.49(0.87) 135(0) 50 >2 1.43(0.49) 125(10)
LES 40 0.96(0.16) 0.99(0.32) 755(140) 40 0.95(0.09) 0.96(0.23) 740(75)
Midsl 0 0.57(0.77) >2 150(30) 0 _2 >2 160(40)
P8959 50 1.60(0.09) 1.82(0.21) 860(150) 50 1.56(0.08) 1.67(0.19) 755(130)
C1913 44 >2 >2 240(95) 44 >2 >2 195(65)
C2238 50 0.64(0.30) >2 835(355) 50 0.68(0.31) >2 840(345)
C2846 42 >2 >2 580(415) 42 >2 >2 545(395)
C3597 50 >2 >2 605(350) 50 >2 >2 600(315)
C4503 30 0.19(0.45) 0.79(1.32) 125(10) 30 0.26(0.49) 0.56(0.88) 125(10)
PAK 50 >2 >2 785(345) 50 >2 >2 785(340)
Table 4.7b: Summary table of the lytic activity of phage cocktails against Ps. aeruginosa assessed using the Bioscreen C.
Phage cocktails contained equal parts GL-1, GL-1 2.5 and LP-M 10. Data shown are the mean of 3 replicates (±SD). Time 
taken to increase OD42o-580nm by 0.1 above the original OD42o-580nm-2- No reduction in bacterial number observed. Bold typeface 
indicates significant differences at the 95% Cl by one way ANOVA.
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Evaluation Criteria Additional
Criterion
Logio reduction 
8 h 20 h
Time
(min)1
Lysis2
Phage Cocktail No. of bacterial strains where phage 
“acceptance” criteria was met (out of 14)
GL-1 and GL-1 2.5 5 8 9 6
GL-1, GL-1 2.5 and LP-M 10 7 10 7 6
GL-1, GL-1 2.5, LP-M 10 and 
C10176-S 15
7 9 9 6
GL-1, GL-1 2.5, LP-M 10, 
C10176-S 15 and LP-M 5
7 10 9 6
Table 4.8: Summary of the lytic assessment criteria of Ps. aeruginosa 
phage cocktails from Bioscreen C assessment. Numbers in brackets represent 
enhancement time *: Time taken to increase OD420-580nm by 0.1 about the 
original OD42o ssonm.2' Time taken to induce a lytic slope.
4.3.4 Comparison between the streak test and Bioscreen C assessment 
In the host strain (PAOl), there was a good level of correlation between the 
Bioscreen C and the streak test assessment, where PRE treated phages showed 
the highest level of bacterial reduction corresponding with the highest scores 
achieved on the streak test (Table 4.4), with the exception of GL-1. When 
comparing the level of regrowth, there was no discemable difference between 
PRE and non-PRE treated phages.
The level of correlation between streak test and Bioscreen C method depended 
on the phage/bacterial strain. A good correlation (based upon meeting two or 
more of the “acceptance” criteria) was observed with LP-M, 2 strains; CIO 176- 
L, 5 strains; GL-1, 6 strains; C10176-S, 7 strains (Table 4.6). For all other 
phage/bacteria combinations, the level of reduction in bacterial number at 8 h 
was not significantly different (P>0.05) between PRE and non-PRE treated 
phages.
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The differences exhibited between the Bioscreen C and streak test analysis of 
phage cocktails further highlights the need for a more discriminatory test for 
phage activity than the current streak test method, as in this situation it has 
been shown to be unable to distinguish between different phage cocktails.
4.4 Discussion
4.4.1 Effect of PRE enhancement on lvtic activity of Ps. aeruzinosa phages 
In this investigation 4 phages were confirmed, by both an established streak 
test assay (Merabishvili et al., 2009) and a novel Bioscreen C assay, to possess 
activity against multiple strains of Ps. aeruginosa including some of the more 
prevalent clinical strains within the UK (Jones et al., 2001; Fothergill et al.,
2007). All bacterial strains, irrespective of treatment by wild or PRE treated 
phage, show some regrowth after 20 h, inferring the presence of either 
uninfected or resistant bacteria.
Although the treatment of phages with PRE was shown to increase lytic 
activity in the host strain (PAOl) and in some of the clinical strains, this 
increase in activity (either by increase in Logio reduction or bacterial regrowth) 
was often not significant.
Result variability in the Bioscreen C assessment of lytic activity is most 
probably caused by the inherent variability that is associated with both 
bacterial and bacteriophage growth, despite initial standardization of bacterial 
concentration. The differences in susceptibility of the bacteria may be a result 
in part to the binding efficacy of the phage to the target cell (Comolli et al, 
1999) and also the growth rates of the strains tested.
The PRE treatment was originally conceived as a selective virucide and has
been demonstrated to have no effect on bacterial or fungal cells (Jassim et al.,
1995), and was designed as a mechanism for bacterial detection (Stewart et al.,
1998). Here we have adapted this process to remove phages that have been
unable to infect a bacterial host within a specified amount of time. The exact
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mechanism for the action of the PRE/ferrous sulphate complex still needs to be 
elucidated. It is possible that the function would be around the interaction of a 
phenolic compound with the binding sites of phage. Phenol itself has 
previously been shown to damage the tail fibres of the Ps. aeruginosa phage 
FI 16 (Maillard et al.y 1995; Maillard et al., 1996). Damage to tail fibres would 
be consistent with the phages used in this investigation which have all been 
shown to be tailed (Chapter 3; Section 3.3.3). Although PRE treatment could 
potentially damage phage DNA preventing successful transcription and 
replication, phenol has been shown to not significantly impair Ps. aeruginosa 
phage FI 16 replication (Maillard et al., 1995).
4.4.2 Bioscreen C vs. streak test for the measurement of phage activity 
With a renewed increase in bacteriophage therapy (Merabishvili et al., 2009) 
there is a need for a high throughput method that is both sensitive and 
quantitative. The successful selection of a phage does not hinge on the initial 
activity screening; the selection process can be enhanced by efficient and 
quantitative screening methods that will ensure the widest host range and 
maximum activity.
Mere it has been shown that both the Bioscreen C and the streak test can be 
used to assess the lytic activity of phages and that the Bioscreen C method 
possesses a number of advantages in terms of both the quantity and type of data 
generated.
The set “acceptance” values used in this investigation were based upon the 
literature for other phage based products. The reduction of bacterial number 
(i.e. Logio reduction) at 8 h and 20 h was based upon reductions that were 
reported from the literature for other Ps. aeruginosa phages (Hanlon et al., 
2001; Fu et al., 2010). Regrowth criteria were based upon antibiotic dosing 
times for CF patients i.e. 2 or 3 times daily dosing (van Zanten et al., 2007; 
McCoy et al., 2008). This reflects a minimum amount of time (i.e. 480 min)
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between dosings that any potential treatment developed would have to maintain 
activity over.
The streak test provides adequate data for initial screening in terms of yes/no 
activity; the Bioscreen C method allows for a quantitative assessment of the 
lytic activity of phages to be made based upon different criteria (i.e. reduction 
in bacterial number at set time points and bacterial regrowth) that would be 
useful in phage based products, such as the reduction in bacterial number and 
also the development of resistance. These criteria, however, should not be 
used individually but assessed as an amalgamation to reflect the real lytic 
ability of phages.
The key difference between the two methods is one of throughput. With the 
streak test a maximum of 4 phage combinations plus one set of controls 
(assuming 5 replicates per line) can be tested per experiment against a single 
bacterial strain. In the case of the Bioscreen C method, however, up to 18 
combinations can be tested per run assuming the same conditions as the streak 
test.
4.4.2.1 Limitations of the current Bioscreen C assay
Although the Bioscreen C assay described in the current investigation 
represents a step towards a standardised, rapid and quantitative method for the 
assessment of phage activity, a number of drawbacks still need to be resolved.
Perhaps the biggest limitation of the Bioscreen C  assay is the conversion of 
O D 420-580nm to a C F U  value from an O D / T V C  graph for each bacterial strain, 
which in turn limits the sensitivity of the assay. At O D  values above ~0.8 it is 
well established that a non-linear relationship between C F U  and O D  exists, 
therefore at O D  values >0.8 the bacterial content may have been 
underestimated. This underestimation of bacterial content would also be 
evident at O D  values <0.1 whereby turbidity caused by bacteria would be 
difficult to distinguish from the background O D .  Therefore, a narrow range of
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approx. 2 Logio exists in which lytic activity can be calculated accurately using 
the current method. The use of an OD based system is further complicated by 
the contribution of bacterial debris to the total OD, which may also further 
reduce any detection limits.
In order to confirm the lytic activity of phages following initial assessment by 
Bioscreen C Assay, aliquots should be removed at required time points (i.e. 8 
and 20 h as in the current investigation) and assessed for both bacterial and 
viral content.
Although the Bioscreen method currently possesses a number of flaws which 
limit its usefulness, these flaws could be addressed by the incorporation of 
metabolic assays that would allow for the assessment of the level of bacterial 
viability (Kuda and Yano, 2003; Cerca et al., 2005) or potentially 
bioluminescent mutants (Marques et al., 2005; Jassim et al., 2007; Thom et al.,
2007) providing direct measurement of bacterial viability, ultimately increasing 
the sensitivity of this OD-based assay.
4.4.3 Single bacteriophaee preparations vs. phage cocktails 
This chapter has demonstrated the effectiveness of both individual phage and 
also phage cocktails against Ps. aeruginosa strains. The choice of a phage 
cocktail over a single phage was based upon the current literature where phage 
preparations currently undergoing clinical trials (Rhoads et al., 2009; Wright et 
al., 2009) are cocktails targeting multiple species.
Here, the phage cocktails described have shown some increased lytic activity 
(i.e. increased Logio reduction and reduced bacterial regrowth) as well as a 
broader host range compared to their individual counterparts, however most 
increases observed were not significant.
The choice of a 3 phage cocktail (containing equal parts of GL-1, GL-1 2.5 and 
LP-M 10) for future testing over the other cocktails described here was based
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upon Bioscreen C assessment of lytic activity. Although more complex phage 
cocktails met more of the “acceptance” criteria, the 3 phage cocktail exhibited 
similar levels of activity.
4.4.4 Summary
This investigation has established the host range and overall level of lytic 
activity for 4 Ps. aeruginosa phages against 14 strains of Ps. aeruginosa 
including some clinically relevant strains from CF patients within the UK 
(Salunkhe et al., 2005; Fothergill et al., 2007).
An alternative assay for the investigation of the lytic activity of Ps. aeruginosa 
phages, based upon optical density reading, was also developed to address 
some of the deficiencies of current protocols and to further characterise the 
lytic activity of Ps aeruginosa phages.
The optical density assay compared to a currently adopted traditional plaque 
based assay has shown that the lytic activity of phages can be increased 
through selective breeding of phages with PRE (Chapter 4.3.1). It is 
interesting to note that not only did the lytic activity of phages increase against 
the chosen strain (in this case PAOl) but activity was also increased against a 
number of other strains. The enhancement of the PRE treated (2.5 min) phages 
was repeated, this time using Ps. aeruginosa strain C4503 as the host. It was 
observed that where activity had been decreased during the first cycle of 
enhancement (using PAOl as a host), the activity against C4503 could be 
increased again using the enhancement procedure described above (Bhogal, 
2010).
The cocktail of 3 phages created (containing GL-1, GL-1 2.5 and LP-M 10) 
will be used for subsequent testing based upon Bioscreen C analysis of activity 
as it was shown to have a broad range of activity that exceeded the individual 
components.
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Chapter 5
The efficacy of a 
bacteriophage cocktail 
against biofilms of Ps. aerueinosa
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5.1 Introduction
Within the clinical setting, bacterial biofilms present a considerable challenge 
to physicians (Hall-Stoodley et al.y 2004) with approx. 60% of infections 
treated believed to involve biofilms (Fux et al., 2005). In the clinical setting 
this type of infection predominates around catheter use (Williams and Stickler,
2008), other medical devices such as endoscopes (Vickery et al., 2004) and 
artificial joint replacements (Zimmerli and Ochsner, 2003). Once established 
within biofilms Ps. aeruginosa infections prove more difficult to clear with 
antibiotic therapy resulting from MIC levels that increase by up to 1000 fold 
when compared to planktonic cultures (Li et al., 2008). In order to 
successfully treat biofilm associated infections both drug penetration and 
biofilm disruption need to take place (Smith, 2005). Both mucolytics and 
nebulised antibiotics are used to treat pulmonary infections in CF patients and 
enjoy some success in treating early stage Ps. aeruginosa colonisation (Ho et 
a l 2009). In chronic CF patients where biofilms are well established the 
success rates of these therapies declines dramatically (Boe et al., 2004).
Alginate lyase (ALG) enzymes have been isolated from a variety of sources 
including marine molluscs (Iwamoto et al., 2001). The majority fit into one of 
two main groupings based upon substrate specificity. The first is poly (M) 
lyase (E.C.4.2.2.3) and the second poly (G) lyase (E.C. 4.2.2.11) (Shimizu et 
a l 2003). A notable exception is the commercially available alginate lyase 
used in the current investigation which has been previously noted to possess bi­
functional activity (Iwamoto et al., 2001). The enzyme depolymerises the 
polysaccharide via a 3 stage (3 elimination reaction (Figure 5.1) in which the
1,4 linkage binding the monomer units is severed (Gacesa, 1992) forming 
optically-active isomers which can then be spectrophotometrically detected.
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Figure 5.1: Mechanism of alginate degradation by alginate lyase. Thick 
arrow indicates site of cleavage, thin arrow indicates progression of reaction. 
Taken from (Yamasaki et al., 2004). A, B and C indicate cleavage of different 
disaccharide blocks.
Ambroxol hydrochloride (AMB) is a mucolytic compound (Seifart et al., 2005) 
and also sodium channel blocker (Gaida et al., 2005) that is currently 
unlicensed for use in the UK (British National Formulary, 2011) and has been 
shown to affect the structure of Ps. aeruginosa biofilms (Li et al, 2008). 
Although the exact mechanism behind the disruption of biofilms is unknown, it 
is thought to be through the reduction of viscosity (Malerba and Ragnoli,
2008).
Since the mid 20th Century the treatment of bacterial infections has relied upon 
the use of antibiotics. The widespread use and misuse of these drugs, since 
their introduction, has led to the development of phenotypes that are resistant 
to multiple classes, most notably in Staphylococcus aureus, Clostridium 
difficile (Taori et al., 2010) and Mycobacterium tuberculosis (O’Sullivan et al., 
2010).
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Increased susceptibility to bacterial infection is one of the characteristic traits 
of CF in which sufferers are colonized in early childhood by organisms such as 
H. influenzae or Staph, aureus (Valenza et al., 2008). However, these 
organisms are eventually supplanted by Ps. aeruginosa by the age of 20 (Pritt 
et al., 2007).
The treatment of Ps. aeruginosa infection in CF patients varies depending on 
the stage of infection and these different strategies are summarised (Table 5.1).
Stage of 
Infection
Treatment Typical Duration
Initial Oral ciprofloxacin 30-40 mg/kg/day 2-3 weeks or until
colonisation + negative sputum
Inhaled tobramycin 80-300 mg/12 h 
Or
Inhaled colistin 1-3 million U/12 h
results
Chronic Inhaled tobramycin 80-300 mg/kg/12 h Inhaled antibiotics
colonisation Or permanently,
Inhaled colistin 1-3 million U/12 h Ciprofloxacin 2-3
+
Oral ciprofloxacin 30-40 mg/kg/day
weeks
Exacerbation IV ceftazidime,50-70 mg/kg/8 h + IV
(or antibiotic tobramycin, 5-10 m g/kg/24 h
resistance) (NB, This is an example of a typical 
regime, but alternatives can be used)
Table 5.1: Treatment regimes and doses for the various stages of Ps. 
aeruginosa infection in CF patients. Adapted from Canton et al., (2005).
This chapter evaluates the effectiveness o f a previously described cocktail 
(Chapter 4; Section 4.3.3) against biofilms of Ps. aeruginosa. The addition of 
other components to the cocktail will be investigated to see if the activity of the 
cocktail can be increased.
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5.2 Materials and methods
5.2.1 Bacterial and bacteriophage strains
Ps. aeruginosa strains PAOl, NCTC, P8959 and C2238 were prepared and 
standardised as before (Chapter 2; Section 2.2.1). The phage cocktail 
containing equal parts GL-1, GL-1 2.5 and LP-M 10 was prepared as 
previously described (Chapter 4; Section 4.2.5).
Phage cocktails containing either alginate lyase (ALG; 200 mg/L) or ambroxol 
hydrochloride (AMB; 200 mg/L) and ciprofloxacin (CIP) or tobramycin (TOB) 
at MIC concentrations (1 mg/L and 4 mg/L respectively; based upon Andrews,
2009) were prepared fresh prior to use. Antibiotics were chosen on the basis of 
NHS usage for Ps. aeruginosa infection at the University Hospital of Wales 
(Cardiff, UK; Iloscin, 2007).
5.2.2 Assessment of the activity of a phage cocktail alone and in combination 
with other components
5.2.2.1 Bioscreen C assessment
The activity of the phage cocktail alone or in combination with other 
components was assessed using the Bioscreen C analyser as previously 
described (Chapter 4; Section 4.2.3).
52.2.2 Biofilm assessment
Sedimentary and CDFF biofilms were prepared as before (Chapter 2; Sections
2.5.1 and 2.5.2 respectively). Samples were then treated with 5 mL of phage 
cocktail alone or in combination with ALG or AMB at final concentrations of 
200 mg/L and incubated at 37°C in a 95% air: 5% CO2 atmosphere.
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For the assessment of activity in combination with CIP or TOB biofilms were 
exposed to phage cocktails, TOB (4 mg/L) and CEP (1 mg/L) alone or in 
combination for 20 h before the bacterial content of biofilms was calculated.
The bacterial content of biofilms was then quantified as follows. PTFE discs 
were removed and rinsed gently with TSC buffer. Discs were then immersed 
in 1.2 mL of CompA that had been prepared as previously described (Chapter 4 
Section 4.2.4) for 20 min in the dark. Samples were then sonicated on a MSE 
Soniprep 150 (MSE, Lower Sydenham, UK) for 30 s with a wavelength 
amplitude of 2 pm. Bacterial numbers were then quantified (Chapter 2 Section
2.3.1). This process was validated on 10 replicates using a one way ANOVA 
at the 95% Cl (P=0.083).
5.3 Results
5.3.1 Assessment of the Ivtic activity of a phage cocktail alone or in 
combination with other components
5.3.1.1 Bioscreen C assessment
The mixture o f phage cocktails with either CIP or TOB at MIC concentrations 
of (1 mg/L and 4 mg/L respectively) were shown to be the most effective 
treatment for the 4 strains tested by showing the highest bacterial reduction 
(Table 5.2) at 8 h. There were no significant differences in reduction over the 
period 8 to 20 h for any cocktail (/*>0.05; Table 5.2).
The addition o f ALG or AMB at a final concentration of 200 mg/L to cocktails 
of phage also had no significant impact upon the time taken for bacterial 
regrowth (P>0.05; Table 5.2). At MIC concentrations the cocktail of phage did 
not result in a significant difference in bacterial reduction at 8 h for all the 
strains tested (P>0.05; Table 5.2). At 20 h, phage showed no significant 
difference in reduction (P>0.05) in both standard strains (PAOl and NCTC; 
Table 5.2). With the clinical strains (P8959 and C2238), CIP showed
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significant differences (PcO.OS) in reduction compared to the phage alone that 
was not consistent between 8 and 20 h. TOB only showed significant 
differences in C2238 (Table 5.2). Analysis also showed no significant 
differences ( />>0.05) in reduction between the CIP and TOB at either 8 or 20 h.
When comparing the cocktail of phage and either CIP or TOB to antibiotics 
alone, no strain showed a significant difference in reduction at 8 and 20 h 
(P>0.05; Table 5.2) compared to antibiotic treatment alone.
However, when comparing the cocktails on the basis of the assessment criteria 
previously described (Chapter 4; Section 4.2.3), it was observed that phage 
cocktails in conjunction with CIP and TOB at MIC concentrations (1 mg/L and 
4 mg/L respectively) proved to be the most effective (Table 5.3).
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Logio reduction (± SD) Time1
Treatment 8 h 20 h
PAOl
Cocktail only >2 >2 1195(10)
Cocktail + ALG 1.78 (0.35) >2 1150 (90)
Cocktail + AMB 1.82 (0.34) >2 1180 (35)
Cocktail + CIP >2 >2 >1200
Cocktail + TOB >2 >2 >1200
CIP >2 >2 70 (25)
TOB 1.80 (0.39) >2 455 (645)
NCTC 10332
Cocktail only >2 >2 175 (35)
Cocktail + ALG 1.10(0.95) 0.81 (0.97) 160 (40)
Cocktail + AMB 0.34 (0.44) 0.10(0.60) 160 (40)
Cocktail + CIP >2 >2 565 (550)
Cocktail + TOB >2 >2 755 (465)
CIP >2 >2 180 (25)
TOB >2 >2 1075 (220)
P8959
Cocktail only 1.66 (0.30) 1.51 (0.82) 785 (205)
Cocktail + ALG 1.21 (0.22) 0.60 (0.97) 545 (35)
Cocktail + AMB 1.24 (0.25) 0.74 (0.58) 560 (75)
Cocktail + CIP >2 >2 >1200
Cocktail + TOB >2 >2 >1200
CIP 0.73 (0.36) >2 155(10)
TOB 1.77 (0.20) >2 >1200
C2238
Cocktail only 0.70 (0.24) >2 735(220)
Cocktail + ALG 0.70 (0.17) >2 745(180)
Cocktail + AMB 0.66 (0.21) >2 740 (220)
Cocktail + CIP 0.97 (0.16) >2 >1200
Cocktail + TOB 1.09 (0.06) >2 >1200
CIP 0.39 (0.10) >2 230 (25)
TOB 0.87 (0.07) >2 >1200
Table 5.2: Bioscreen C assessment of a phage cocktail in conjunction with 
other components. Phage cocktails contained equal parts GL-1, GL-1 2.5 and 
LP-M 10. Data for Bioscreen analysis are the mean of three replicates (±SD). l: 
Time taken to increase OD420-580nm by 0.1 above the original OD42o-580nm- Bold 
typeface indicates significant difference at the 95% Cl by one way ANOVA to 
cocktail only.
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Treatment Evaluation Criteria
Logio 
8 h
Reduction 
20 h
Time1
No. Strains meeting acceptance criteria (max. 4)
Cocktail only 2 3 3
Cocktail + ALG 2 2 3
Cocktail + AMB 2 2 3
Cocktail + CIP 3 4 4
Cocktail + TOB 3 4 3
CIP 2 4 0
TOB 1 4 2
Table S 3 : Summary of the lytic assessment criteria of a phage cocktail in 
conjunction with other components from Bioscreen C assessment. Phage 
cocktails contained equal parts GL-1, GL-1 2.5 and LP-M 10. Time taken to 
increase O D 42o-580nm by 0.1 above the original O D 420-580nm .2’. No strains met the 
required level.
5.3.1.2 CDFF grown biofilms
Following exposure of CDFF cultured biofilms to a phage cocktail (containing 
equal parts GL-1, GL-1 2.5 and LP-M 10) or mixtures of phage cocktail with 
ALG or AMB, all strains showed a significant reduction in bacterial content at 
8 h (P<0.05) compared to a PBS treated control (Table 5.4). However, at 20 h 
only PAOl and P8959 (P<0.05; Table 5.4) showed a significant reduction, 
while NCTC showed a small but statistically insignificant change in bacterial 
content (P>0.05; Table 5.4) compared to PBS controls.
In both PAOl and P8959 there was no significant difference between biofilms 
treated with the phage cocktail or the phage ALG/AMB combination at 8 h and 
20 h (P>0.05; Table 5.4).
At 8 h NCTC 10332 showed no significant differences between the cocktail
only treated biofilm and the phage cocktail in combination with ALG (P>0.05;
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Table 5.4), a significant difference was observed between the phage cocktail 
only and phage cocktail in combination with AMB (P<0.05; Table 5.4). At 20 
h, there were no significant differences between each treatment (P>0.05; Table
5.4). There was also a significant level of bacterial regrowth between 8 and 20 
h for each of the treated biofilms (P<0.05; Table 5.4).
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Bacterial strain (Logio CFU ± SD)
Treatment PAOl NCTC P8959
8 h 20 h 8 h 20 h 8 h 20 h
Untreated 8.86(0.27) 8.87(0.46) 8.81(0.07) 8.93(0.23) 8.11(0.11) 8.39(0.14)
Phage cocktail only 8.16(0.19) 8.17(0.13) 8.30(0.14) 8.87(0.07) 7.38(0.07) 7.71(0.11)
Phage cocktail +ALG 8.13(0.18) 8.10(0.11) 7.86(0.30) 8.83(0.05) 7.42(0.05) 7.39(0.23)
Phage cocktail +AMB 8.31(0.14) 8.24(0.11) 7.24(0.23) 8.64(0.14) 7.47(0.03) 7.18(0.23)
Table 5,4: Activity of bacteriophage cocktail on 96 h CDFF cultured biofilms of Ps. aeruginosa at 20 h post phage cocktail 
addition. Data are the mean of three replicates (±SD). Phage cocktails contained equal parts GL-1, GL-1 2.5 and LP-M 10. Bold 
typeface indicates significant difference at 95% Cl by one way ANOVA compared to untreated control.
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5.3.1.3 Sedimentary biofilms
The exposure of sedimentary biofilms to a phage cocktail (containing equal 
parts of GL-1, GL-1 2.5 and LP-M 10) resulted in a significant reduction 
(P<0.05) in the bacterial content of PAOl biofilms. However, the reduction in 
bacterial number was not statistically significant (P>0.05) in the other strains 
(Table 5.5).
When the reduction in bacterial number of Ps. aeruginosa sedimentary 
biofilms was assayed using phage in combination with antibiotics both 
standard (PAOl and NCTC 10332) and clinical (P8959 and C2238) strains 
showed a significant reduction in biofilm bacterial content compared to an 
untreated control (P<0.05; Table 5.5). In combination with ALG and AMB 
only PAOl showed a significant reduction (P<0.05) in biofilm bacterial 
content and NCTC 10332 and P8959 showed an increase in bacterial content 
that was not statistically significant (P>0.05).
Phage cocktails alone, and in conjunction with other components showed 
significant differences with both ALG/AMB addition in PAOl biofilms as well 
as antibiotics in all strains (P<0.05; Table 5.5).
Both CIP and TOB at MIC concentrations proved to be the most effective of 
the strategies employed in this investigation following 20 h of exposure against 
all strains with the exception of PAOl (Table 5.5). A significant reduction 
(P<0.05) in bacterial content compared to untreated controls was observed, 
whereas there was no significant reduction in bacterial content for those strains 
tested with ALG or AMB alone (P>0.05 with the exception of PAOl Table
5.5).
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Bacterial strain (Logio CFU ± SD)
Treatment PAOl NCTC P8959 C2238
Untreated 7.47 (0.21) 7.35 (0.27) 7.47 (0.15) 7.35 (0.29)
Cocktail only 3.99 (1.29) 6.84(1.69) 7.33 (0.16) 7.19(0.29)
Cocktail +ALG 5.22 (039) 8.24 (0.17) 7.86 (0.06) 6.97 (0.10)
Cocktail +AMB 5.61 (0.27) 7.96 (0.21) 7.93 (0.21) 6.96 (0.01)
Cocktail+ CIP <2 4.66 (0.15) 6.23 (0.20) 6.33 (0.28)
Cocktail +TOB <2 4.65 (0.31) 6.08 (0.07) 5.35 (0.05)
ALG only 7.55 (0.16) 7.31 (0.21) 7.12(0.27) 7.58 (0.08)
AMB only 6.70 (0.06) 6.96 (0.24) 6.53 (0.40) 7.13(0.13)
CIP only 3.36 (0.05) 4.65 (0.59) 4.19 (0.31) 4.81 (0.26)
TOB only 3.62 (0.48) 4.47 (0.35) 3.49 (0.30) 5.45 (0.16)
Table 5.5: Activity of phage cocktail with other components on 96 h 
sedimentary biofilms of Ps, aeruginosa at 20 h post cocktail addition. Data 
are the mean of three replicates (±SD). Phage cocktails contained equal parts 
GL-1, GL-1 2.5 and LP-M 10. Untreated and cocktail only are means of six 
replicates. Bold typeface indicates significant difference at 95% Cl by one way 
ANOVA compared to untreated control.
5.3.1.4 Effects of extra components on the activity of a phage cocktail 
When evaluating the overall effect of extra components on the activity of the 
phage cocktail used here it was found that the combinations of phage and 
antibiotics led to the highest activity (i.e. Logio reduction at 20 h) in both 
Bioscreen and biofilm assessment (Figure 5.2). However, this was often a 
marginal increase over the other tests.
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F igure 5 .2 : R epresen ta tion  o f the re la tive  activ ities o f testing in this 
c h ap te r . Ranking is based upon Logio Reduction at 20 h. ■ Bioscreen C 
assessm ent and ■ Sedim entary biofilm assessm ent. *: no strains.
5.4 D iscussion
5.4.1 The activity o f  a phage cocktail against biofilm s o f  Ps. aeruginosa 
Bacterial biofilms present an existing and developing challenge to clinicians 
trying to use successful therapeutic regimes. In the case o f CF patients, the 
formation o f  Ps. aeruginosa  biofilms is one o f  the key pathological features o f 
disease progression, with the biofilm  o f  Ps. aeruginosa  surviving aggressive 
antibiotic therapy (Hoiby et a l ., 2010). The cocktail o f  multiple antibiotics 
(colistin and tobramycin; Herrmann et a l., 2010) increased the survival o f mice 
and reduced Ps. aeruginosa  content within sputum samples taken from CF 
patients.
In this investigation a previously described cocktail o f phages, containing equal 
parts GL-1, GL-1 2.5 and L P -M  10 (Chapter 4; Section 4.3.3) has been shown
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to possess activity against both sedimentary and CDFF cultured biofilms 
derived from multiple strains of Ps. aeruginosa including clinical strains 
isolated from CF patients. This activity extends to cocktails containing 
antibiotics (ciprofloxacin and tobramycin), alginate lyase and ambroxol 
hydrochloride. However, the observed reduction in bacterial content was 
modest when compared to phage cocktails reported in the literature (Wright et 
al., 2009; Fu et al., 2010).
The two different models of Ps. aeruginosa described here (CDFF and 
sedimentary biofilms) have shown sizable differences in their susceptibility to 
phage infection. In comparison to the Ps. aeruginosa biofilm layers within the 
CF lung, the biofilm layers employed here are simplistic and lack components 
such as an existing layer of mucin (similar to the thick sticky mucus that is 
found in CF patients; Sriramulu et al., 2005). This has been shown in a 
previous chapter (Chapter 3; Section 3.3.2.3) to possess similar levels of 
structural complexity to images from the literature. There is some variation 
between the bacterial content of biofilms between sedimentary and CDFF 
cultured models. This is due to the denser packed nature and near consistent 
nutrient flow that the CDFF method provides, whereas in the sedimentation 
model, access to nutrients was limited. In the CDFF model in particular 
biofilms were often more densely packed and visible on the PTFE discs 
(unpublished observation) compared to their sedimentation counterparts, 
raising the bioburden, reducing any potential phage penetration and limiting 
reduction in bacterial content.
The combination of alginate lyase and ambroxol hydrochloride to phage 
preparations derives from the need to disrupt the biofilm layer and increase 
penetration not only by phage cocktails but potentially by other therapeutic 
compounds. The case of alginate lyase reveals an interesting situation in which 
both enzyme specificity, and also conditions of use, can play a role in activity. 
The enzyme used here, while suggesting bifunctional activity (Iwamoto et al., 
2001), may lack in activity compared to other alginate lyases isolated from
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both Ps. aeruginosa phages (Glonti et al., 2010) and bacterial spp. (Ma et al., 
2008; Uchimura et al., 2010).
Here we have described a method for the direct quantification of the bacterial 
content of biofilms following the addition of phage. This method contests with 
the crystal violet method which is often used for biofilm quantification 
(Knezevic and Petrovic, 2008) and was designed to measure the ability of 
bacterial cells to bind to a surface, rather than as a quantification of bacterial 
numbers. The direct quantification method not only neutralises any surviving 
phage, following transfer to the activated PRE allowing for the “surviving” 
bacterial content of biofilms to be enumerated, but also does not rely upon the 
uptake of crystal violet into the exopolysachharide matrix and contains fewer 
stages, reducing potential disruption caused to the biofilm.
5.4.2 The use of antibiotics in combination with a phage cocktail
For the current investigation both Ciprofloxacin and Tobramycin have been
used alone and in combination with a phage cocktail and assessed against both
biofilms and planktonic Ps. aeruginosa. These antibiotics are currently
primarily used to combat Ps. aeruginosa infection within CF patients via
nebulisation.
Both Ciprofloxacin and Tobramycin are non-lytic antibiotics, acting against 
DNA gyrase and the bacterial 30S and 50S ribosome respectively. Although 
this will have little impact on the level of activity exhibited in biofilms, due to 
the direct quantification of activity by TVC.
However, in the Bioscreen C assay, due to the nature of activity calculation 
from OD, the level of reduction calculated may under estimate the level of 
activity o f both the cocktail alone and also the activity of the cocktail in 
combination with antibiotics, due to the contribution of unlysed bacterial cells 
to the overall OD.
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5.4.3 Summary
This investigation has established the activity of a cocktail of phages against 
biofilms of 4 Ps. aeruginosa strains in cocktail with a number of different 
components designed to increase phage penetration of a biofilm and to increase 
the level of bacterial kill. Although a modest level of activity against the 
bacterial strains was detected any potential therapeutic agent would need to 
increase this activity substantially to remain commercially viable.
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Chapter 6
Delivery of a bacteriophage cocktail 
and quality control issues
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6.1 Introduction
The nebulisation of antibiotics for the treatment of respiratory infections has 
been in clinical use since the introduction of penicillin to treat pneumonia. 
Today the nebulisation of antibiotics is the primary method of treating Ps. 
aeruginosa infections of CF patients (Ho et al., 2009). Although many 
companies produce nebulisers they fall into one of two broad categories based 
upon the method of aerosol production; jet or ultrasonic nebulisers.
The production of an aerosol in the jet nebuliser relies upon the passage of a 
compressed air stream to create a negative pressure state which draws liquid 
from a reservoir. Depending on the flow rate of compressed air, particle size 
can vary and is controlled by the addition of baffles which result in the 
condensation of larger particles (Boe et al., 2004).
Ultrasonic nebulisers however, produce aerosols of a uniform particle size 
(Boe et a l 2004) via the vibration of a mesh with specific sized holes with 
piezoelectric actuators.
The different delivery vectors for potential phage therapeutics have been 
discussed in greater detail elsewhere (Chapter 1; Section 1.5.2). The 
advantages and disadvantages of the different type of nebulisers are 
summarised below (Table 6.1).
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r
Nebuliser
type
Advantages Disadvantages
Jet • Widely used for the 
delivery of antibiotics
• Low operational cost
• Shear stress could destroy 
biological components
• Requires a compressor pump to 
create aerosols
• Loss of nebulised product in the 
airways
Ultrasonic • More portable than jet 
nebulisers
• Lower shear stress to 
nebulised product could 
increase availability to 
target site
• Higher initial cost of 
manufacture
• Loss of nebulised product in the 
airways
Table 6.1: Summary table of the advantages and disadvantages of
different forms of nebulisation.
With renewed interest in the use of phage to treat bacterial infection, attention 
will have to be drawn to the production of phage preparations in order to 
ensure they meet regulatory requirements. These requirements will vary 
depending on the type of application and route of administration, with topical 
applications requiring little in the way of microbial compliance and intravenous 
injections requiring strict control (British Pharmacopeia, 201 If)- As such, 
many of the commercially produced phage preparations currently undergoing 
trials are of a topical nature (Wright et al., 2009).
This chapter seeks to investigate the use of a jet stream nebuliser for the 
delivery of a cocktail of phages via nebulisation and the stability of the 
individual phage components. Pharmacopeial requirements, including bacterial 
content for non-sterile products and endotoxin content will also be 
investigated.
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6.2 Materials and methods
Ps. aeruginosa strains PAOl, NCTC 10332, C2238 and P8959 were routinely 
cultured for 24 h prior to use in 10 mL of TSB at 37°C and standardised as 
previously described (Chapter 2; Section 2.2.2).
The phage cocktail, containing equal parts GL-1, GL-1 2.5 and LP-M 10 was 
routinely cultured and enumerated as previously described (Chapter 2; Section
2.3.2).
6.2.1 Calculating the efficacy of phage cocktail delivery via a nebuliser into a 
simulated lung
A cocktail of Ps. aeruginosa phages (containing equal parts of GL-1, GL-1 2.5 
and LP-M 10) was prepared in 0.9% (w/v) saline as previously described 
(Chapter 2; Section 2.2.2.1) and quantified.
Ten mL of the phage cocktail was transferred to the Ventstream drug chamber 
of a Porta-neb nebuliser (Respironics Resipiratory Drug Delivery Ltd, 
Chichester, UK). The nebuliser was connected to a Anderson cascade 
impactor (Figure 6.1) and air was drawn through the impactor at a rate of 
approx. 28 Umin. The phage suspension was then nebulised for 10 min after 
which the remaining phage suspension was recovered and quantified by the 
agar overlay method (Chapter 2; Section 2.3.2).
Steel sampling plates were removed from the cascade impactor using flame 
sterilized tweezers and transferred to sterile petri dishes. To each petri dish 10 
mL of sterile PBS was added and the plates shaken at 150 RPM for 15 min. 
PBS was then pipetted into sterile centrifuge tubes and vortexed. The phage 
content of each impactor stage was then determined by the agar overlay 
method (Chapter 2; Section 2.3.2).
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Figure 6.1: Schem atic rep resen ta tion  of the cascade im pactor used to 
sim ulate depth  of lung penetration .
6.2.2 Zcta potential characterisation o f Ps. aew ginosa  phages
6.2.2.1 Phage preparation
Phage suspensions (GL-1, GL-1 2.5 LPM, LPM 10, C10176-S and C10176-L) 
were prepared as previously described using sterile deionised water to wash the 
overlay agar from the surface o f  the plate (Chapter 2; Section 2.2.2).
6.2.2.2 Calibration o f the Zetasizer 2000
The Zetasizer 2000 (Malvern Instruments Ltd, Malvern, UK) was calibrated 
daily by the passage o f  zeta potential transfer standard solution (Malvern 
Instruments Ltd, Malvern, UK). In order to be successfully calibrated the zeta 
potential had to fall within the range o f  68 ± 6.8 mV.
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6.2.2.3 Determination of the Zeta potential of Ps. aeruginosa phages
The zeta potential of phage suspensions was determined by passing 2.5 mL of 
phage suspension into the flow cell of a Zetasizer 2000 (Malvern Instruments 
Ltd, Malvern, UK) and five readings were taken. Between each sample the 
flow cell was flushed with 30 mL of sterile deionised water before the injection 
of the next sample.
6.2.3 Effect of purification on activity and endotoxin levels in a phase cocktail 
All glassware and containers where possible were depyrogenated by dry heat 
sterilization at 200°C for 1 h (British Pharmacopeia, 2011a). Buffers and 
reagents were made in cell culture grade water.
6.2.3.1 Cocktail preparation
The phage cocktail containing equal parts of GL-1, GL-1 2.5 and LP-M 10 
(Chapter 4; Section 4.2.5) were prepared in 0.9% (w/v) saline and 50 pM 
CaCh using PAOl as a host.
6.2.3.2 Purification of a phage cocktail
Endotoxin was removed from the crude phage cocktail preparation via the 
Endotrap Blue Chromatography system (Hyglos, Germany) as follows. The 
prepacked column was drained and regenerated using the regeneration buffer 
supplied. Following regeneration the column was washed twice in 0.9% (w/v) 
saline with 50 pM CaCh (equilibration buffer). The sample was added and 
flushed through with equilibration buffer. The column was then washed and 
regenerated prior to the addition of the next sample. Once finished the column 
was stored in 0.2% (w/v) sodium azide at 4°C. Samples of purified phage 
cocktail were assessed within I h of generation.
6.2.3.3 Endotoxin determination of Ps. aeruginosa phage cocktails 
Endotoxin levels in suspensions of Ps. aeruginosa phage cocktails were 
determined via a Limulus amebocyte lysate (LAL) kinetic chromogenic
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method on an Endosafe*-PTS (Figure 6.2; PTS; Charles River Laboratories 
International Inc., MA, USA) according to manufacturer’s instructions 
(Charles River Laboratories International Inc., MA, USA) on a PTS testing 
cartridge (0.05 endotoxin units per millilitre (EU/mL); Charles River 
Laboratories International Inc., MA, USA). Experiments were performed in 
triplicate. Controls were also perform ed on 0.9% (w/v) saline. Where 
appropriate samples were diluted in LAL reagent grade water (Charles River 
Laboratories International Inc., MA, USA).
F igure 6.2: Endosafe PTS LAL kinetic assay for the detection of
endotoxin  and  schem atic rep resen ta tio n  of the test cartridge, a) Endosafe 
PTS machine and b) schematic representation o f a PTS testing cartridge.
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6.2.3.4 Activity determ ination o f  phase cocktails against Ps. aeruginosa 
The lytic activity o f  both purified and non-purified Ps. aeruginosa phage 
cocktails was assessed using the Bioscreen C method against PAO l as 
previously described (Chapter 4; Section 4.2.5).
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6.2.4 Stability of Ps. aeruginosa phages
Crude Ps. aeruginosa phage suspensions of GL-1, GL-1 2.5 and LP-M 10 were 
prepared in PBS as previously described (Chapter 4; Section 4.2.5). Following 
initial quantification of phage content, triplicate samples were stored at 2-8°C 
or room temperature (approx. 22°C). Samples were then quantified at 7, 30, 
60, 90 and 180 days for phage content by the agar overlay method (Chapter 2; 
Section 2.2.2) using PAOl as a host.
6.2.5 Testing phage cultures for microbial contamination
The level of microbial contamination in both purified and crude phage 
cocktails was assessed in accordance with Pharmacopoeial requirements for 
non-stcrile respiratory products as follows (British Pharmacopoeia, 201 Id and 
201 le).
6.2.5.1 Total aerobic viable count
One millilitre of Ps. aeruginosa phage cocktail was used to inoculate 20 mL of 
TSA or 20 mL of Sabouraud Dextrose agar (SAB; Oxoid, UK). This was 
repeated for triplicate plates. TSA plates were incubated at 37°C for 5 days 
and SAB plates were incubated at 30°C for 5 days. Plates were checked for 
growth every 24 h.
6.2.5.2 Absence of Ps. aerusinosa
One millilitre of Ps. aeruginosa phage cocktail was incubated into 100 mL 
TSB and incubated at 37°C for 48 h. If no microbial growth was detected after 
48 h the product was streaked to Cetrimide agar (Oxoid, UK) and incubated at 
41-43°C for 24 h.
6.2.5.3 Absence of Staphylococcus aureus
One millilitre o f Ps. aeruginosa phage cocktail was incubated into 100 mL 
TSB and incubated at 37°C for 48 h. If no microbial growth was detected after 
48 h the product was sub-cultured to Baird-Parker Agar (Oxoid, UK) and 
incubated at 37°C for 72 h.
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6.3 Results
6.3.1 Characterisation of Ps. aeruginosa bacteriophage charge 
When the zeta potential (i.e. surface charge) of phages was assessed both 
enhanced and unenhanced phages were shown to be negatively charged (Figure
6.3 and Table 6.2). There was no significant difference (P>0.05) in the surface 
charge of the non-PRE treated phages (Table 6.2) with C10176-L showing the 
least negative charge. Following treatment with PRE the surface charge of 
phages (GL-1 and LP-M) was increased (Table 6.2). However, this increase 
was not significant (P>0.05) when compared to the non-PRE treated 
counterparts. It should also be noted that the conductivity (Cond.) value for 
GL-1 was increased following treatment with PRE (Table 6.2), however 
C10176-L possessed the highest conductance value.
Bacteriophage _________________ Charge Detail______________
________________ Mean (mV) Width (mV) Cond. (mS/cm)
Non-PRE treated
GL-1 -16.35(3.36) 4.98(4.73) 6.96(0.14)
C10176-S -17.11(3.39) 4.05(2.48) 8.34(2.42)
C10176-L -14.35(2.35) 3.47(1.00) 11.58(3.68)
LP-M -17.07(2.78) 2.43(1.36) 8.73(2.80)
PRE-treated
GL-1 2.5 -15.20(3.39) 2.85(1.63) 10.18(3.82)
LP-M 10 -16.76(2.32) 2.40(1.39) 8.87(3.43)
Table 6.2: Zeta potential characterisation of PRE and non-PRE treated Ps. 
aeruginosa bacteriophages.
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F inure 6.3: Lxam ple of the d a ta  ou tpu t from  the Zetasizer 2000 showing 
the negative su rface charge of phage LP-M .
6.3.2 Nebulisation o f  Ps gerusinoaphaec cocktails
When quantified there was no significant difference (P=0.848) between the 
total number o f nebulised phage and the total number o f phage recovered. By 
stage 7 o f the impactor 99.2% (±4.2%) o f all phage had been recovered (Figure
6.4). As the nebulised droplets penetrate the cascade impactor they are sorted 
by size, with larger particles (between 10 and 3.3 pm) being retained by the 
earlier levels (stages 0-3). Stages 0-3 represent impact with the throat and 
upper airw ays and show approximately 75% o f the total deposited phage. The 
remainder o f the deposited phage occurs within the later stages (stages 4-7), 
representing the secondary bronchi to the alveoli (droplet sizes approximately
3.2 to 0.4 pm).
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F igu re  6.4: N ebulisation  o f  a b a c te r io p h a g e  cocktail. Data are the mean o f 3 
replicates ±SD. Each im pactor s ta g e  corresponds to a particular particle size 
(Figure 6.1).
6.3.3 Stability o f  Ps. aeruginosa  p h ase
There was no significant d iffe re n c e  in viable phage at both room temperature 
and 4°C (P>0.05) for all 3 p h a g e s  over a period o f  180 days. Also there was no 
significant difference in loss o f  phage viability due to storage conditions at 
either 4°C or room tem perature (F ig u re  6.5; P>0.05) with the exception o f  LP- 
M 10 at 180 days storage (P < 0 .0 0 3 ). In general phage LP-M 10 was most 
susceptible to loss o f  v iability  fo llow ing  storage (Figure 6.5c) and GL-1 least 
susceptible to loss follow ing s to ra g e  (Figure 6.5a).
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Figure 6.5: Stability of phage cocktail components over a period of 180 
days, a, GL-1; b, GL-1 2.5 and c, LP-M 10. ■, Room temperature, ■, 4°C. 
Data are the mean o f  3 replicates ± SD.
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6.3.4 Effect of Endotrap purification on activity, endotoxin content and 
microbial content of Ps. aeruginosa phase cocktails
All phage cocktails showed no microbial contamination according to 
pharmacopeial standards (data not shown).
When endotoxin levels were assessed using the Endosafe PTS LAL kinetic 
assay, crude phage cocktails showed large amounts of endotoxin to be present 
(>5 Logio EU/mL; Table 6.3). Following purification via passage through the 
Endotrap system, there was a small drop in endotoxin levels (approximately 
0.2 Logio EU/mL) that was non-significant when compared to crude phage 
cocktails (P=0.327). This level of endotoxin far exceeds the pharmacopeia 
required levels (<0.2 EU/mL) and as such would fail quality assurance.
The assessment of both purified and non-purified phage preparations on the 
Bioscrcen C analyser shows a small decrease but non-significant (P>0.05) in 
the level of activity of the phages in terms of Logio reductions at 8 and 20 h 
(Table 6.3). This is potentially due to the small reduction (P=0.124) in the 
phage content of preparations following passage through the Endotrap system. 
It should also be noted that the phage activity presented here is slightly lower 
than previously described (Chapters 4 and 5) but is not significantly different to 
previously reported activity (P>0.05).
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Recovery (Logio Bioscreen C Assay Endotoxin 
Levels (Logio 
EU/mL)
PFU/mL) Logio Reduction Time1
(min)8 h 20 h
Crude Preparation
11.02(0.07) 1.85(0.11) 1.84 (0.19) >1200 6.05(0.06)
“Purified” Preparation
10.81(0.18) 1.78(0.12) 1.77(0.29) >1200 5.81(0.37)
Table 6.3: Activity of Ps. aeruginosa cocktails following purification on the 
Endotrap Blue system against Ps. aeruginosa strain PAOl. Data are the 
mean of 3 replicates (±SD). Time taken to increase O D 4 2 0 -5 8 0 n m  by 0.1 above 
the original O D 4 2 o - 5 8 0 n m -
6.4 Discussion
6.4.1 Preparation of phage cocktails for delivery
The use of nebulised antibiotics for the treatment of Ps. aeruginosa infections 
in CF patients is well established and has been shown to have some impact on 
bacterial levels within sputum samples of CF patients (Herrmann et al., 2010). 
In the current investigation we have shown that the delivery of a bacteriophage 
based preparation can be readily achieved, and that viable phages can be 
recovered following delivery. The deposition of phage observed here (Figure
6.4) shows that although phage will be retained by upper airways, as is the case 
with antibiotics and other nebulised products (Sermet-Gaudelus et al., 2002). 
Sufficient phage will reach the targeted areas (i.e. the secondary and terminal 
bronchi) to potentially establish a self replicating phage infection.
The deposition and subsequent recovery of viable phage from a simulated lung
model has demonstrated that shear stress and nebulisation of phage particles
via a jet nebuliser does not have a severe effect on the ability of phages to
replicate for the phages used in this investigation. However, different phages
could potentially be more susceptible to damage and loss of viability. In order
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to mitigate this risk a number of strategies could be introduced to encapsulate 
phage particles that have successfully been used for nebulisation including the 
use of chitosan-alginate microbeads (Ma et al., 2008) and PEGylation (Mok et 
al., 2007).
The surface of Ps aeruginosa biofilms has been shown to demonstrate 
negatively charged residues within the exopolysaccharide layer of biofilms (i.e. 
alginate), that have been shown to bind cationic antibiotics e.g. 
aminoglycosides (Slack and Nichols, 1981). In this chapter we have 
demonstrated that wild type phages (i.e. non- PRE treated phages) also have a 
negative surface charge, which may limit the binding potential of phages to 
host bacterial cells and as a consequence diminish their activity. The small, 
although statistically insignificant decrease in the negative charges of phage, 
following treatment with PRE to select for more active phages, may in part 
explain this enhanced activity as it would reduce repulsion between phage and 
host cells. However, due to the relatively small change in charge, further 
experimentation should be carried out in order to determine if this effect is real 
or merely an artefact.
6.4.2 Quality control of phage preparations
Although the described phage cocktail reaches compliance levels in terms of 
bacterial numbers for BP (British Pharmacopeia, 201 Id) this is for non-sterile 
manufactured products only. Due to the nature of pharmacopeia compliance, 
many of the phage preparations currently undergoing clinical trials (Wright et 
al., 2009) or currently licensed for use (e.g. ListShield™, Intralytix, USA) are 
for topical use or within the food industry only. For approval for the use in the 
food industry, the Listshield™ product has demonstrated that the phage 
cocktail used is at little or no risk of causing adverse side effects (a single 
protein showed some homology to wheat protein but not enough to induce an 
allergic response) and that no potentially pathogenic sequences for Listeria 
reside within the phage genome (Food and Drug Administration, 2006).
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Although the information is unavailable within the public domain, stability 
studies would have been carried out to ascertain the “shelf-life” of the product.
However, for topical applications, in order to pass British Pharmacopeia 
standards (British Pharmacopeia, 201 Id), products only need to demonstrate 
bacterial levels o f less than 100 CFU/mL and with all products a 
stability/preservative efficacy test o f the product would be performed. For 
preparations that are to be used intravenously, microbiological quality 
assurance will be based around sterility testing (British Pharmacopeia, 2011b) 
rather than the methods used in the current investigation. In this chapter we 
have demonstrated the ease at which phage preparations could meet the 
requirements for non-sterile topical applications. However, for use as a 
nebulised product, stricter controls including endotoxin levels would have to be 
met.
As demonstrated here, the production of endotoxin from the lysis of the 
Pseudomonas represents a major stumbling block for the further development 
of phage products beyond topical applications. For determination of endotoxin 
levels within phage preparations only animal models have been used to provide 
an indication (Merabishvili et al., 2009). Here, the use of the pharmacopeia 
“gold standard” LAL assay (British Pharmacopeia, 201 lc and 201 lg) has been 
used to quantify endotoxin levels in both crude and “purified” phage cocktails 
resulting in unacceptable endotoxin levels (Table 6.3). The LAL assay not 
only provides quantitative data with regards to the total endotoxin levels within 
samples, but also is more sensitive than animal models. However, the LAL 
assay used here required the dilution of samples that were above the detection 
threshold of the cartridge (1 EU/mL), requiring the extrapolation of endotoxin 
levels from a positive result.
The purification of phage preparations with the Endotrap Blue system has
previously been demonstrated to be effective at reducing endotoxin levels in
phage preparations (Merabishvili et al., 2009). In the current investigation
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endotoxin levels were not significantly altered by passage through this system. 
The low reduction in endotoxin content observed here may be in part due to 
saturation of the column with endotoxin, in which case the column would need 
to be increased in size or samples passed through multiple columns to reduce 
endotoxin levels to the required level. However, this would increase any final 
cost for industrial applications. For laboratory scale preparation, caesium 
chloride gradients and PEG precipitations have been demonstrated to purify 
phages (Gill and Hyman, 2010) although this would be impractical for 
industrial applications.
6.4.3 Summary
This chapter illustrates the range of quality control issues that need to be 
addressed in the formulation of phage based products in particular endotoxin 
levels within phage preparations. There will be a need to ensure consistency in 
performance and stability; the data obtained for the phage cocktail 
demonstrates wide limits (up to a 6 month shelf life at both room temperature 
and 4°C storage with no significant loss of activity; a high endotoxin content 
that far exceeds acceptable standards etc). This investigation has also 
demonstrated that a non-encapsulated phage cocktail can be deposited 
throughout a simulated lung and that to enhance deposition in the target areas 
further, alterations to the size of aerosolized particles produced by nebulisers 
would have to be made.
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Chapter 7 
General discussion
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7.1 General discussion
7.1.1 Phage as antimicrobial agents
Since their initial discovery phage preparations have been used as a mechanism 
for the treatment of bacterial infection (Rutter et al., 2010). Although in 
clinical use within the former Soviet Union for over half a century, a lack of 
comprehensive information on the efficacy and safety of bacteriophage 
products, coupled with the wide availability of antibiotics, limited their impact 
and dispersal within the Western world (Hanlon, 2007). Today, with a well 
publicised and documented rise in bacterial resistance to antibiotics, alternative 
strategies are being sought to treat bacterial infection including the use of 
phage preparations.
It is currently believed that phage represent the most abundant organism on 
Earth with approx. 1031 PFU existing (Hanlon, 2007). This abundance of 
phage means that lytic phages against most bacterial species are relatively easy 
to isolate, with a few notable exceptions (e.g. C. difficile). Within the current 
investigation, phage therapy has been described as the use of a replicating lytic 
phage that can infect and destroy bacteria. These types of preparations are 
amongst the simplest to produce in a crude form via a simple centrifugation 
and filtration step, and have been established as safe for use within the food 
industry (e.g. Listshield, Intralytix Inc.). The use of lytic phage allows for a 
single dose to set up a self-replicating infection that, in theory, should continue 
until all the target bacteria are destroyed, while leaving the non-targeted 
bacteria intact.
Another approach to phage therapy is the induction of lysogenic phages. 
Traditionally this is accomplished through the use of mitomycin C. However, it 
has been demonstrated in Ps. aeruginosa that many antibiotics can induce 
lysogenic phages including those more commonly used for the treatment of Ps. 
aeruginosa infections in CF patients (Fothergill et al., 2011). Induction of 
lysogenic phages with mitomycin C from the Ps. aeruginosa strains used in the
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current investigation revealed the presence of inducible lysogenic phages in 10 
of the 14 strains (Jones, 2009). Currently this approach is only used by one 
commercial company, Novolytics, to induce lysogenic phages then modifies 
them to remove both lysogenic properties and potentially hazardous sequences 
using a proprietary process called ABSEPT. Although the induction of 
lysogenic phages would allow for synergy between antibiotic and phage 
therapy it is not without its risks (Table 7.1), as the induction of lysogenic 
phages may carry virulence factors for the bacterial hosts with it.
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Advantages Disadvantages
•Self-Replicating • Limited Efficacy
•Highly abundant for most • Quality control issues
organisms particularly in gram-
Lytic Phage • Highly specific negative organisms
• Easy to produce in most • Highly specific
cases • Requires time to lyse cells
• Development of resistance 
by the host
• Difficult to commercialise
• Short time to lysis • Only effective against Gram
• Existing GM technology can positive and non-
be adapted to produce lysins intracellular organisms
Lysins • Low development of •  Potentially highly specific
resistance • High initial investment
• Can be isolated from lytic • Protein based therefore
and lysogenic phages cleared from the body easily 
• Need multiple doses
Induction of • Induction with common • Induction and transfer of
lysogenic antibiotics can provide pathogenic regions e.g.
phage synergy between antibiotics toxin production
and phage • Potential toxicity following
• Antibiotic efficacy and use of high antibiotic
safety well established
• Currently possible with 
right antibiotics
•  Broad spectrum
concentrations
Table 7.1: Summary of different approaches to phage therapy
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Alternatives to the use of phages involving the synthesis of phage lysins are 
actively being pursued (Daniel et al., 2010). Although lysins remove potential 
hurdles involving the use of actively replicating lytic phages, they have only 
been shown to be effective against Gram-positive organisms such as Staph, 
aureus (Daniel et al., 2010). The use o f lysins within the clinical setting would 
require multiple molecular techniques in order to produce an engineered 
bacterium that could express the lysin in high quantities (Pastagia et al., 2011). 
This would subsequently then require extraction and purification before 
efficacy and safety testing could be undertaken.
Currently a number of companies are undertaking research into phage 
preparations (Table 7.2). Despite the focus of this investigation on the use of 
phage to treat a systemic infection, phage preparations can be applied to a 
variety of different fields, from water and industrial decontamination (Table
7.2) to the oil industry.
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Company Product Name/Type Target organism Industrial
area
Intralytix SalmShieldIM Salmonella serotypes Food
Inc. SAP-1OOTM Staphylococcus aureus Human
Health
ABPP-100TM Acinetobacter
baumannii
Human
Health
Novolytics Unknown: No 
product name 
available
Staphylococcus aureus Human
Health
Omnilytics Unknown: No 
product name
Bacillus anthracis Human
Health
available Ps. aeruginosa
Enterobacter
aerogenes
Food and
Water
Paper
Fcolyse Unknown: No Sulphate reducing Oil and
Inc. product name 
available
bacteria Water
Table 7.2: Summary table of phage based products currently under 
development by commercial companies.
Preparations based upon whole lytic phage (including phage cocktail), although 
patentable for a particular application, are relatively easy to circumvent due to 
the high abundance of other lytic phages. In order to successfully patent a 
phage preparation containing lytic phages, the patent should be targeted at 
extra components (e.g. cocktail + antibiotics) or a specific process in the 
manufacture (e.g. reduction of endotoxin content) or delivery (e.g. 
nebulisation). Bacterial lysins and also potentially genetically modified phage 
are highly patentable, as patents could target specific gene sequences and also 
expression vectors.
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7.1.2 Treatment of Ps. aeruQinosa infections in CF patients 
Currently the treatment of Ps. aeruginosa infections in CF patients is reliant 
upon the use of antibiotics (Chapter 5 ;Table 5.1) that is often frustrated if not 
resulting in complete failure by the formation of biofilms within the lung and 
the reduction of bacterial metabolic activity reducing sensitivity to antibiotics 
(Abdi-Ali et al., 2006). The potential advantages of phage preparations over 
traditional antibiotic therapy have been discussed elsewhere in some detail 
(Chapter 1; Table 1.7).
This investigation has shown that with the addition of antibiotics to a phage 
cocktail the level of bacterial reduction in certain Ps. aeruginosa biofilms can 
be increased. The addition of a phage cocktail to individual antibiotics (i.e. 
CIP and TOB) did improve the overall bactericidal activity against PAOl 
biofilm, but not against other bacterial strains (Table 7.3). This may be in part 
due to the relative activity of phages against biofilms and a lack of penetration 
into the biofilm layer and the presence of persistor cells within the biofilm 
matrix (Donlan, 2009). The high level of activity exhibited by the use of 
antibiotics only is due to the high concentration used based upon MIC levels 
for Ps. aeruginosa (Andrews, 2009). The activity of the cocktail in 
combination with antibiotics and antibiotics alone could be better distinguished 
by using concentrations that reflect the in use concentrations for the treatment 
of Ps. aeruginosa in CF patients (Chapter 5; Table 5.1).
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Treatment Bacterial strain (Log i0 CFU)
PAOl NCTC P8959 C2238
Untreated 7.47 (0.21) 7.35 (0.27) 7.47 (0.15) 7.35 (0.29)
Cocktail + CIP <2 4.66 (0.15) 6.23 (0.20) 6.33 (0.28)
Cocktail + TOB <2 4.65 (0.31) 6.08 (0.07) 5.35 (0.05)
CIP only 3.36 (0.05) 4.65 (0.59) 4.19(0.31) 4.81 (0.26)
TOB only 3.62 (0.48) 4.47 (0.35) 3.49 (0.30) 5.45 (0.16)
Table 73 : Summary of the bacterial content of Ps. aeruginosa biofilms 
following 20 h exposure to the described phage cocktail in combination 
with antibiotics. CIP- ciprofloxacin (1 mg/L), TOB- tobramycin (4 mg/L).
7.1.3 Assessment of phage activity
Currently the assessment of phage activity relies on assays such as the streak 
test or a spot assay that rely upon the formation of plaques within a lawn or 
streak of bacteria (Merabishvili et a l., 2009). These methods are simple to 
perform but provide only a yes/no assessment o f activity with any indication of 
the relative resistance of the organisms being tested against, or taking into 
account, the relative replication rates of the target bacteria.
The current investigation has shown the development of an alternative assay 
based upon optical density for the initial screening of phages using the 
Bioscrecn C analyser. This assay is not only quantitative and able to look at 
the reduction in bacterial content compared to an uninoculated control, but also 
can investigate the relative resistance and regrowth of a phage resistant 
subpopulation of bacteria (Cooper et al., 2011).
This method has been shown to be particularly useful in distinguishing 
between subtle differences in activity that are found in phage cocktails 
(Chapter 4; Tables 7a and 7b) that cannot be distinguished between with plaque
based assays.
165
The addition of “acceptance” criteria to the Bioscreen C assay has allowed for 
minimum levels of activity to be set based upon the literature (for Logio 
reductions; Hanlon et al., 2001; Atterbury et al., 2007; Fu et al., 2010) and 
antibiotic dosing times (for the calculation of bacterial regrowth; (Van Zanten 
et al., 2007; McCoy et al., 2008). For the criteria used approx. 50% of strains 
failed to meet the acceptable level of activity (Table 7.4). However, by 
reducing the acceptance criteria to require only a 1 Logio reduction in bacterial 
content at 8 h and 20 h approximately 20% more strains showed the required 
level of reduction. What is interesting to note however is the small increase in 
the number of strains meeting required levels of activity in the cocktail 
containing components (Table 7.4; antibiotics, alginate lyase or ambroxol 
hydrochloride). By increasing the level of activity that each phage is required 
to possess, the assay is required to discriminate between different phages 
ensuring that only highly active phage will be accepted.
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Treatment Acceptance criteria
type Logio reduction Time
8 h 20 h
Established criteria
Acceptance levels >2 >2 >480
Single phage 42.3 49.2 58.1
% Strains meeting Cocktail 46.4 66.1 60.7
required levels Cocktail + 40.0 75.0 85.0
Components
Modified criteria
Acceptance levels >1 >1 >240
Single phage 61.3 81.5 71.8
% Strains meeting Cocktail 69.6 87.5 66.1
required levels Cocktail + 75.0 80.0 85.0
Components
Table 7.4: Established and modified acceptance criteria for Bioscreen C 
assessment of phage activity. Table is based on both single phages and phage 
combinations against the 14 strains tested in this investigation. *: Time taken to 
increase OD42o-5sonm by 0.1 above the original OD42o-580nm-
This investigation has also shown the ability to directly quantify bacterial 
surv ivors following the addition of a phage cocktail through the addition of a 
selective virucide. Although the cocktail described here (Table 7.5) has shown 
a limited activity against biofilms of Ps. aeruginosa, including clinical isolates 
from CF patients, initial preliminary work involving single phages showed 
damage to the biofilm layer after 20 h exposure to phage (Figure 7.1). The 
potential number of phages in the environment (1031 PFU; Hanlon, 2007) 
would allow for a large scale screening process to be undertaken in order to 
successfully determine the most effective phage candidates for future cocktails.
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Biofilm type Bacterial strain (Logio reduction)
PAOl NCTC 10332 P8959 C2238
CDFF 0.70 (0.13) 0.06 (0.07) 0.68 (0.11) -
Sedimentary 3.48(1.29) 0.51 (1.69) 0.14(0.17) 0.16(0.29)
Table 7.5: Summary of reduction in bacterial content of the described 
phage cocktail against biofilms of Ps, aeruginosa following 20h exposure.
Cocktail contained equal parts GL-1, GL-1 2.5 and LP-M 10.
7.1.3.1 Limitations of the assessment o f lvtic activity of bacteriophages 
As previously discussed (Chapters 4 and 5), the current assessment of lytic 
activity using OD represents a step toward a rapid, standardised, quantitative 
method for phage activity; however, there are a number of limitations which 
first must be addressed.
Chief amongst these is the use of OD as a mechanism for determining bacterial 
content as numerous factors can interfere with this, including bacterial debris 
and non-lysed bacterial cells. These factors in turn affect the sensitivity and the 
range at which lytic activity can be accurately calculated resulting in an 
underestimation of activity.
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Figure 7.1: Effect of phage addition to 96 h PAOl CDFF biofilms 
following 20 h of exposure to LP-M 15 phage, a) PBS treated, b) and c) LP-
M 15 phage treated. Scale bars are included on each image.
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7.1.4 Delivery and formulation of phage preparations
The use of nebulised antibiotic solutions for the treatment of Ps. aeruginosa 
infections of CF is well established (Tramper-Stranders et a l , 2010) and 
previously discussed. Nebulised or dry powdered formulations would possess 
numerous advantages over other delivery vectors (Chapter 1; Table 1.4).
In the current investigation it has been shown that bacteriophages can be 
successfully delivered and recovered following nebulisation with no significant 
loss of phage viability (approx. 0.1 Logio PFU). The use of nebulised phages 
has been described within the literature (Huff et al., 2003; Golshahi et al., 
2008) and shown to be effective in vitro and in animal models. In the study by 
Huff and colleagues (2003), it was shown that nebulised delivery of a lytic E. 
coli phage could reduce mortality in broiler chickens compared to controls.
The encapsulation of phage (Mok et al., 2007; Ma et al., 2008) possesses a 
number of advantages and disadvantages (Table 7.6). Encapsulation would 
allow for greater product stability and a reduction of shear stress resulting from 
the nebulisation process, potentially increasing the number of viable phage to 
the target site. In the current investigation it was shown that encapsulation of 
the phage cocktail used would not be necessary as the individual phage 
components were shown to be stable at both room temperature and 4°C (< 1.5 
Logio reduction following 180 days storage). In addition, following 
nebulisation, nearly all phage were recovered and their viability maintained 
(Chapter 6; Section 6.3.2). It should be noted that the stability of any phage 
preparations should be evaluated as standard practice and as such may require 
encapsulation to preserve activity.
However, any encapsulating material would need to account for the charge of 
the phage particle as this would potentially have a serious impact on the ability 
of the phage to attach to target cells. While alginate microspheres (Ma et al., 
2008) would be of little use for delivery of Ps. aeruginosa phages in CF 
patients, particularly if an alginate lyase was used to disrupt the biofilm layer,
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as the alginate lyase could potentially degrade the microspheres before 
delivery. The use of PEG could potentially provide the answer (Mok et al.,
2007), by hiding the phage particles from immune cells and increasing 
stability.
Advantages Disadvantages
• Encapsulation can allow for more • Increased particle size could lead
specific targeting of the phage to deposition in the wrong parts of
cocktail the lung
• Increased product stability • Encapsulation material could lead
to decreased availability of phage
• Could reduce immune response to • Would increase the time taken to
phage particularly for use in IV establish a self replicating
preparations infection
• Poor encapsulation material
choice could reduce phage
binding
Table 7.6: Summary of the advantages and disadvantages of phage 
encapsulation.
7.1.5 General conclusions
This thesis sought to characterise, assess and enhance the lytic activity of four 
Ps. aeruginosa phages (i), assess the activity of a cocktail of phages against 
biofilms of Ps. aeruginosa including clinically relevant strains (ii) introducing 
other components into the phage cocktail including antibiotics, alginate lyase 
and ambroxol hydrochloride (iii) and to investigate quality control issues 
surrounding the delivery of a cocktail of phage (iv).
The initial investigation into the host range and activity of the Ps. aeruginosa 
phages used here showed immense potential and high levels of activity when 
assessed by both broth and by plaque based assays. This activity was then
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improved upon for a number of strains following selection based upon time, 
with some strains showing a reduction in activity.
Although the current investigation has highlighted the potential for phage 
preparations to be used against biofilms of Ps. aeruginosa in CF patients the 
level of activity would need to be substantially increased in order to be a viable 
alternative to antibiotics. This substantial increase could be achieved by the 
screening for more active phage using both the streak test and the Bioscreen C 
assay (Table 7.7). This would not only allow for the selection of more active 
phages but also aid in the refinement of the assessment criteria. Phages could 
also be enhanced further using selective virucides previously discussed 
(Chapter 4). However, further investigation into the mechanism behind the 
enhancement should be undertaken.
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Method Advantages Disadvantages
PRE Enhancement against a Mechanism behind the
Treatment single strain can increase 
activity against multiple 
strains
enhancement is unknown
“Natural” selection on the Can reduce activity against
basis of infection time other strains
Genetic Can be used to turn Increases difficulty to pass
modification lysogenic phage into lytic 
phage
regulation
Can remove pathogenic Expensive and requires
sequences from potential genome sequencing
candidates
Requires propriety 
technology e.g. ABSEPT 
process (Novolytics, UK)
Increased Easiest to perform Labour and time intensive
screening
Potentially increase the Lytic phage may not exist
number of phages available for certain organisms
Table 7.7: Summary table of potential improvements for increasing phage 
activity.
The current investigation has shown the need for further research into aspects 
of quality assurance that would surround phage preparations. Here it has been 
shown that despite the ability to meet the Pharmacopeia based requirements for 
a number of types of product (Table 7.8), the level of endotoxins present far 
exceeds acceptable limits and therefore in its current form the preparation 
would be limited to arenas in which endotoxin levels were not monitored.
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Criteria
Application
Microbiology content* 
(CFU/mL or CFU/g) 
TAMCC TYMCd
Endotoxin
contentb
(EU/mL) Other
This Absence of Staph.
investigation NDC ND >5 LoglO aureus and Ps. 
aeruginosa
Aqueous oral 
preparations
102 10' Absence of E. coli
Transdermal
patches
102 10* Absence of Staph, 
aureus and Ps. 
aeruginosa
Inhalation
usef
102 10l Absence of Staph, 
aureus, Ps. 
aeruginosa and 
bile tolerant gram 
negative bacteria
Parenteral
Preparations
0 0 0.2 See British 
Pharmacopeia 
(201 l)g
Table 7.8: Summary of the different regulatory requirements by 
application compared to the current investigation. a: Based on British 
Pharmacopeia (201 Id )b: Based on British Pharmacopeia (201 lc and 201 lg) °: 
Total aerobic microbe count, d: Total Yeast and Moulds count, : Not detected, 
d: Not for nebulised delivery.8: Based on British Pharmacopeia (201 If)-
1 7 4
Currently the majority of phage research being undertaken centres around 
topical applications (e.g. for use in infected bums, acne treatment etc) and 
around the food industry applications. However, some research into the 
prevention of biocorrosion and water treatment is also being undertaken (Table
7.2). This is in part to meet less stringent criteria that are required within the 
topical application (Table 7.8), whereas for use for systemic applications much 
stricter requirements are required to be met (British Pharmacopeia, 201 lb).
7.2 Future work
7.2.1 Creation of a co-culture model of Ps. aeruginosa and CF cell lines
In order to provide a more representative system which better mimics the in 
vivo conditions of a CF lung, a co-culture between a mucus producing CF cell 
line and Ps. aeruginosa could be used. This system has been used in the 
modelling of pulpal infection by Streptococcus anginosus (Roberts et al.,
2008). Although this system would not account for the three dimensional 
structure usually seen in the lung, it would produce a characteristic thick mucus 
layer and provide a more representative picture of the CF lung.
7.2.2 Screening a larger range of Ps. aeruginosa phages and Ps. aerusinosa 
strains and optimisation of the Bioscreen C assay
The current investigation has established the host range and lytic potential of 
four Ps. aeruginosa phages and has demonstrated how this host range and 
activity can be changed and altered by the application of a selective virucide.
The screening of a larger range of phages will allow for the selection of a more 
active cocktail with an enhanced host range. The Bioscreen C method 
described here can rapidly and quantitatively assess phage based on multiple 
criteria, including the reduction of bacterial content and the regrowth of 
resistant sub-populations compared to the qualitative assessment provided by 
plaque based assays. This would be done in order to minimise the potential for
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a subpopulation to develop and also increase the activity of cocktail selected 
phage, which could then transfer to increased activity against biofilms.
The Bioscreen C assay as described in the current investigation relies upon the 
conversion of optical density to bacterial number from an OD/TVC graph. 
This conversion has its limitations as OD values above approx. 0.8 are non 
linear in nature and as such could lead to an underestimation of phage activity 
(Cooper et al., 2011). In order to increase the accuracy and sensitivity of the 
Bioscreen assay a metabolic assay for measuring bacterial viability (Kuda and 
Yano, 2003; Cerca et al., 2005) or potentially bioluminescent mutants 
(Marques et al. 2005; Jassim and Griffiths, 2007; Thom et al., 2007) could be 
incorporated. However, particularly with the use of mutants, these may not be 
wholly representative of clinical isolates.
The application of “acceptance” criteria to the data generated by the Bioscreen 
C assessment of phage activity is currently based upon Pseudomonas phages 
only and, in a number of cases, the phages tested here failed to meet the 
required acceptance criteria for further testing. In order to refine these criteria, 
other bacterial species such as staphlococci etc should be tested against, as 
should an increased number of Pseudomonas phages.
7.2.3 Alternative formulations and efficacy of nebulised phage preparations 
In this investigation we have shown that the individual components of a phage 
cocktail are stable in suspension and remain viable for a period of 6 months. 
The production of a dry powder formulation of phage has been shown to be 
possible (Puapermpoonsiri et al.y 2009; Golshahi et al., 2010), which possess a 
number of advantages over liquid formulations (Table 7.9).
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Advantages Disadvantages
Liquid Less complicated to produce Endotoxin content
formulation than dry powder Potentially more
Less processing required to susceptible to storage
produce final product conditions
Dry powdered Increased stability of final Endotoxin content
formulation product More complicated to
Can increase phage produce
concentration within powders Loss of activity during 
lyophilisation 
Will require stabilising 
agents in order to protect 
the phage
Table 7.9: Summary of liquid formulation versus dry powdered 
formulation.
Although Ps. aeruginosa is the main infectious agent within CF patients, 
colonizing up to 80% of sufferers by the age of 20 (Hassett et a l , 2009), the 
presence of other infectious agents such a B. cepacia complex increases both 
mortality and morbidity (Waine et al., 2007). Cocktail of phages to target 
multiple potential pathogens are currently well researched, particularly for 
topical applications such as infected bums. However, cocktails of phages that 
target Ps. aeruginosa and also include phages that target emerging pathogens 
such as Inquilinus limosus (Herasimenka et al., 2007), could potentially reduce 
the bacterial load of CF patients prior to the establishment of a persistent
infection.
This investigation has demonstrated how a cocktail of Ps. aeruginosa phages 
can be successfully delivered into a simulated lung using a jet nebuliser and 
viability o f recovered phage assessed. In order to further develop a successful 
phage preparation, different types of nebuliser should be assessed to determine
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their usefulness in delivering phage preparations. Although this would 
determine the efficacy of the delivery options, it would not determine the 
activity of those preparations following delivery against biofilms of Ps. 
aeruginosa. As such it is recommended that biofilms of Ps. aeruginosa 
clinical isolates are evaluated for their susceptibility to nebulised phage.
7.2.4 Development of new deovrogenation strategies
The presence of endotoxin within phage cocktails remains one of the main 
stumbling blocks for the successful implementation of phage products beyond 
topical applications and use within the food industry. Endotoxin removal via 
the Endotrap affinity column has been shown to be effective in reducing the 
endotoxin content of a phage preparation containing both staphylococci and 
Pseudomonas phages (Merabishvili et al., 2009), although endotoxin levels 
were assessed using a rabbit pyrogenicity test. The current investigation has 
shown passage of a Pseudomonas phage cocktail through the Endotrap system 
did not reduce the endotoxin content o f the cocktail sufficiently to be in line 
with pharmacopeia standards when assessed using the gold standard LAL 
assay.
Current dcpyrogenation methods, such as dry heat treatment (200°C for approx. 
1 h) and repeated acid/base washes are incompatible for biologically active 
products such as phages. As such alternative methods would need to be 
developed which would preserve the biological activity of phage while 
reducing the endotoxin content to acceptable levels.
178
Chapter 8 
References
ABDI-ALI, A., MOHAMMADI-MEHR, M. & AGHA ALAEI, Y. (2006) 
Bactericidal activity of various antibiotics against biofilm-producing 
Pseudomonas aeruginosa. International Journal o f  Antimicrobial Agents, 27, 
196-200.
ACCURSO, F.J. (2007). Update in Cystic Fibrosis 2006. American Journal o f  
Respiratory and Critical Care Medicine 175, 754-757.
ADAMS, M.H. (1959). Bacteriophage. New York: Interscience Publishers Inc, 
p. 7.
ALCORN, J.F. & WRIGHT, J.R. (2004) Degradation of Pulmonary Surfactant 
Protein D by Pseudomonas aeruginosa Elastase Abrogates Innate Immune 
Function. Journal o f  Biological Chemistry, 279, 30871-30879.
ALLEN, L., DOCKRELL, D.H., PATTERY, T., LEE, D.G., CORNELIS, P., 
HELLEWELL, P.G. & WHYTE, M.K B. (2005) Pyocyanin Production by 
Pseudomonas aeruginosa Induces Neutrophil Apoptosis and Impairs 
Neutrophil-Mediated Host Defenses In Vivo. Journal o f  Immunology, 174, 
3643-3649.
ALAOUI-EL-AZHER, M., JIA, J., LIAN, W. & JIN, S. (2006) ExoS of 
Pseudomonas aeruginosa induces apoptosis through a Fas receptor/caspase 8- 
independent pathway in HeLa cells. Cellular Microbiology, 8, 326-338.
ALVAREZ-ORTEGA, C. & HARWOOD C.S. (2007) Responses of 
Pseudomonas aeruginosa to low oxygen indicate that growth in the cystic 
fibrosis lung is by aerobic respiration. Molecular Microbiology 65, 153-165.
ANDREWS, J.M. (2009). BSAC standardized disc susceptibility testing 
method (version 8). Journal o f  Antimicrobial Chemotherapy 64, 454-489.
180
ARMSTRONG, D., BELL S., ROBINSON, M., BYE, P., ROSE, B., 
HARBOUR, C., LEE, C., SERVICE, H., NISSEN, M., SYRMIS, M. & 
WAINWRIGHT, C. (2003). Evidence for Spread of a Clonal Strain of 
Pseudomonas aeruginosa among Cystic Fibrosis Clinics. Journal o f Clinical 
Microbiology 41, 2266-2267.
ARRINGTON-SANDERS, R., YI, M., TSEVAT, J., WILMOTT, R.W., 
MRUS, J.M. & BRITTO, M.T. (2006) Gender differences in health-related 
quality of life of adolescents with cystic fibrosis. Health and Quality o f Life 
Outcomes, 4, 5.
ATTERBURY, R.J., VAN BERGEN, M.A.P., ORTIZ, F., LOVELL, M.A., 
HARRIS, J.A., DE BOER, A., WAGENAAR, J.A., ALLEN, V.M. & 
BARROW, P.A. (2007) Bacteriophage Therapy To Reduce Salmonella 
Colonization of Broiler Chickens. Applied and Environmental Microbiology, 
73, 4543-4549.
BARROW, P.A. & SOOTHILL, J.S. (1997) Bacteriophage therapy and 
prophylaxis: rediscovery and renewed assessment of potential. Trends in 
Microbiology 5, 268-71.
BEATTY, A.L., MALLOY, J.L. & WRIGHT, J.R. (2005) Pseudomonas 
aeruginosa Degrades Pulmonary Surfactant and Increases Conversion In Vitro. 
American Journal o f  Respiratory Cell and Molecular Biology, 32, 128-134.
BHOGAL H. (2010) Enhancement of Bacteriophage against Pseudomonas 
aeruginosa strains isolated from Cystic Fibrosis Patients. Undergraduate 
Project Report, Cardiff, UK
181
BIANCHI, S.M., PRINCE, L.R., MCPHILLIPS, K., ALLEN, L., MARRIOTT, 
H.M., TAYLOR, G.W., HELLEWELL, P.G., SABROE, I., DOCKRELL, 
D.H., HENSON, P.W. & WHYTE, M.K.B. (2008) Impairment of Apoptotic 
Cell Engulfment by Pyocyanin, a Toxic Metabolite of Pseudomonas 
aeruginosa. American Journal o f  Respiratory and Critical Care Medicine, 177, 
35-43.
BOE, J., O'DRISCOLL, B.R. & DENNIS, J. H. (2004) Practical Handbook o f  
Nebulizer Therapy, London, Taylor and Francis Group pic
BOROWITZ, D., DURIE, P R., CLARKE, L.L., WERLIN, S.L., TAYLOR, 
S.J., SEMLER, J., LISLE, R.C.D., LEWINDON, P., LICHTMAN, S.M., 
SINAASAPPEL, M., BAKER, R.D., BAKER, S. S.,VERKADE, H.J., LOWE, 
M E., STALLINGS, V.A., JANGHORBANI, M., BUTLER, R. & HEUBI, J. 
(2005) Gastrointestinal Outcomes and Confounders in Cystic Fibrosis [Special 
Feature: Special Report]. Journal o f  Pediatric Gastroenterology and Nutrition, 
41,273-285
BOYLE, M.P. (2007). Adult Cystic Fibrosis. Journal o f  the American Medical 
Association 298, 1787-1793.
BRADLEY, D. (1967) Ultrastructure of bacteriophage and bacteriocins. 
Bacteriological Reviews. 31, 230-341.
BRENNAN, A.L., GYI, K.M., WOOD, D.M., JOHNSON, J., HOLLIMAN, 
R., BAINES, D.L., PHILLIPS, B.J., GEDDES, D.M., HODSON, M E. & 
BAKER, E.H. (2007). Airway glucose concentrations and effect on growth of 
respiratory pathogens in cystic fibrosis. Journal o f  Cystic Fibrosis 6, 101-109.
182
BRITISH NATIONAL FORMULARY (2011). 3.7 Mucolytics. [Online] 
Available at:
http://bnf.org/bnf/bnf761 /3059.htm?q=anti%20mucolytics&t=search&ss=text& 
p=l
BRITISH PHARMACOPEIA (2011a). Appendix XVIII Methods o f  
Sterilisation (Methods o f  Preparation o f  Sterile Products). [Online] Available 
at:
http://www.pharmacopoeia.co.uk/bp2011 /ixbin/bp.cgi?a=display&id=876
British Pharmacopeia (2011b). Volume V Appendix XVI A. Test for Sterility. 
[Online] Available at:
http://www.pharmacopoeia.co.uk/bp2011 /ixbin/bp.cgi?a=display&r=c_OtUQ3 
20k&n= 180&id=900&tab=search&all=yes
BRITISH PHARMACOPEIA (2011c). Appendix XIV C. Test for Bacterial 
Endotoxins (LAL Test). [Online] Available at:
http://www.pharmacopoeia.co.uk/bp201 l/ixbin/bp.cgi?a=display&id=922
BRITISH PHARMACOPEIA (201 Id). Volume V Appendix XVI D.
Microbiological Quality o f  Non-Sterile Pharmaceutical Preparations and 
Substances fo r Pharmaceutical Use. [Online]. Available at: 
http://www.pharmacopoeia.co.uk/bp2011 /ixbin/bp.cgi?a=display&r=TUwB4X 
0A0DR&n=33&id=897&tab=search
BRITISH PHARMACOPEIA (201 le). Volume V Appendix XVI B.
Microbiological Examinations o f  Non-Sterile Products. [Online] Available at: 
http://www.pharmacopoeia.co.uk/bp201 l/ixbin/bp.cgi?a=display&r=TUwB4X 
0A0DR&n=32&id=899&tab=search
183
BRITISH PHARMACOPEIA (201 If). Volume III Formulated Preparations: 
General Monographs (PARENTERAL PREPARATIONS). [Online] Available 
at: http://www.pharmacopoeia.co.uk/bp201 l/ixbin/bp.cgi?a=display&id=6373
BRITISH PHARMACOPEIA (201 lg). Volume V Supplementary Chapters: SC 
I C Bacterial Endotoxin Testing. [Online] Available at: 
http://www.pharmacopoeia.co.uk/bp201 l/ixbin/bp.cgi?a==display&id=840
CANTON, R., COBOS, N., GRACIA, J., BAQUERO, F., HONORATO, J., 
GARTNER, S., ALVAREZ, A., SALCEDO, A., OLIVER, A., GARCIA- 
QUETGLAS, E. (2005). Antimicrobial therapy for pulmonary pathogenic 
colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis 
patients. European Society o f  Clinical Microbiology and Infectious Diseases. 
11,690-703.
CARTERSON, A.J., HONER ZU BENTRUP, K., OTT, C M., CLARKE, 
M.S., PIERSON, D.L., VANDERBURG, C.R., BUCHANAN, K.L., 
NICKERSON, C.A. & SCHURR, M.J. (2005). A549 Lung Epithelial Cells 
Grown as Three-Dimensional Aggregates: Alternative Tissue Culture Model 
for Pseudomonas aeruginosa Pathogenesis. Infection and Immunity 73, 1129- 
1140.
CERCA, N., MARTINS, S., CERCA, F., JEFFERSON, K.K., PIER, G.B., 
OLIVEIRA, R. & AZEREDO, J. (2005) Comparative assessment of antibiotic 
susceptibility of coagulase-negative staphylococci in biofilm versus planktonic 
culture as assessed by bacterial enumeration or rapid XTT colorimetry. Journal 
o f  Antimicrobial Chemotherapy, 56, 331-336.
1 8 4
CEYSSENS, P.-J., MESYANZHINOV, V., SYKILLINDA, N., BRIERS, Y., 
ROUCOURT, B., LAVIGNE, R., ROBBEN, J., DOMASHIN, A., 
MIROSHNIKOV, K., VOLCKAERT, G. & HERTVELDT, K. (2008). The 
Genome and Structural Proteome of YuA, a New Pseudomonas aeruginosa 
Phage Resembling M6. Journal o f  Bacteriology 190, 1429-1435.
CHIANG, P. & BURROWS, L.L. (2003) Biofilm Formation by Hyperpiliated 
Mutants of Pseudomonas aeruginosa. Journal o f Bacteriology, 185, 2374- 
2378.
CLARK, J.R. & MARCH, J.B. (2006) Bacteriophages and biotechnology: 
vaccines, gene therapy and antibacterials. Trends in Biotechnology, 24, 212- 
218.
COMOLLI, J. C., WAITE, L.L., MOSTOV, K.E. & ENGEL, J.N. (1999) Pili 
Binding to Asialo-GMl on Epithelial Cells Can Mediate Cytotoxicity or 
Bacterial Internalization by Pseudomonas aeruginosa. Infection and. Immunity, 
67,3207-3214.
COOPER, C.J., DENYER, S.P. & MAILLARD, J-Y. (2011) Rapid and 
quantitative automated measurement of bacteriophage activity against cystic 
fibrosis isolates of Pseudomonas aeruginosa. Journal o f Applied Microbiology, 
110, 631-640.
COURTNEY, J.M., DUNBAR, K.E.A., MCDOWELL, A., MOORE, J.E., 
WARKE, T.J., STEVENSON, M. & ELBORN, J.S. (2004) Clinical outcome 
o f Burkholderia cepacia complex infection in cystic fibrosis adults. Journal o f  
Cystic Fibrosis, 3, 93-98.
185
CUZICK, A., STIRLING, F.R., LINDSAY, S.L. & EVANS, T.J. (2006) The 
Type III Pseudomonal Exotoxin U Activates the c-Jun NH2-Terminal Kinase 
Pathway and Increases Human Epithelial Interleukin-8 Production. Infection 
and Immunity, 74, 4104-4113.
DANIEL, A., EULER, C., COLLIN, M., CHAHALES, P., GORELICK, K. J. 
& FISCHETTI, V. A. (2010) Synergism between a Novel Chimeric Lysin and 
Oxacillin Protects against Infection by Methicillin-Resistant Staphylococcus 
aureus. Antimicrobial Agents and Chemotherapy, 54, 1603-1612.
DEL POZO, J.L. & PATEL, R. (2007) The Challenge of Treating Biofilm- 
associated Bacterial Infections. Clinical Pharmacology and Therapeutics, 82, 
204-209.
DI, A., BROWN, M E., DERIY, L.V., LI, C., SZETO, F.L., CHEN, Y., 
HUANG, P., TONG, J., NAREN, A.P., BINDOKAS, V., PALFREY, H.C. & 
NELSON, D.J. (2006) CFTR regulates phagosome acidification in 
macrophages and alters bactericidal activity. Nature Cell Biology, 8,933-943.
DODGE, J.A., LEWIS, P.A., STANTON, M. & WILSHER, J. (2007). Cystic 
fibrosis mortality and survival in the UK: 1947-2003. European Respiratory 
Journal 29, 522-526.
DONLAN, R. M. (2009) Preventing biofilms of clinically relevant organisms 
using bacteriophage. Trends in Microbiology, 17, 66-72.
DULON, S., LEDUC, D., COTTRELL, G.S., D’ALAYER, J., HANSEN, K. 
K., BUNNETT, N.W., HOLLENBERG, M.D., PIDARD, D. & CHIGNARD, 
M. (2005) Pseudomonas aeruginosa Elastase Disables Proteinase-Activated 
Receptor 2 in Respiratory Epithelial Cells. American Journal o f  Respiratory 
Cell and Molecular Biology, 32,411-419.
186
EDWARDS, K.J. & SAUNDERS, N.A. (2001). Real-time PCR used to 
measure stress-induced changes in the expression of the genes of the alginate 
pathway of Pseudomonas aeruginosa. Journal o f  Applied Microbiology 91, 29- 
37.
ERTESVAG, H., HOIDAL, H.K., SKJAK-BRAEK, G. & VALLA, S. (1998) 
The Azotobacter vinelandii mannuronan C-5-epimerase AlgEl consists of two 
separate catalytic domains. Journal o f  Biological Chemistry, 273, 30927-32.
EUTAMENE, H., THEODOROU, V., SCHMIDLIN, F., TONDEREAU, V., 
GARCIA-VILLAR, R., S AL V ADOR-C ARTIER, C., CHOVET, M., 
BERTRAND, C. & BUENO, L. (2005) LPS-induced lung inflammation is 
linked to increased epithelial permeability: role of MLCK. European 
Respiratory Journal, 25, 789-796.
FAHY, J.V., YUAN, S., COVINGTON, J., HAROLD, R. & SOLON, M. 
(2010). Rheological Properties Of Cystic Fibrosis Sputum And Effects Of 
Mucolytic Agents. American Journal o f  Respiratory and Critical Care 
Medicine, 181, A 1823-.
FESTINI, F., BUZZETTI, R., BASSI, C., BRAGGION, C., SALVATORE, D., 
TACCETTI, G. & MASTELLA, G. (2006) Isolation measures for prevention 
of infection with respiratory pathogens in cystic fibrosis: a systematic review. 
Journal o f  Hospital Infection, 64, 1 -6.
FOKINE, A., KOSTYUCHENKO, V.A., EFIMOV, A.V., KUROCHKINA, 
L.P., SYKILINDA, N.N., ROBBEN, J., VOLCKAERT, G., HOENGER, A., 
CHIPMAN, PR ., BATTISTI, A.J., ROSSMANN, M.G. & 
MESYANZHINOV, V.V. (2005) A Three-dimensional Cryo-electron 
Microscopy Structure of the Bacteriophage OKZ Head. Journal o f  Molecular 
Biology, 352, 117-124.
187
FONSECA, A.P. & SOUSA, J.C. (2007) Effect of shear stress on growth, 
adhesion and biofilm formation of Pseudomonas aeruginosa with antibiotic- 
induced morphological changes. International Journal o f Antimicrobial 
Agents, 30, 236-41
FOOD AND DRUG ADMINISTRATION (2006). Agency Response Letter 
GRAS Notice No. GRN 000198. [Online] Available at: 
http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallyRecognizedasS 
afeGRAS/GRASListings/ucm 154675.htm
FOOD AND DRUG ADMINISTRATION (2011). FDA clears first test to 
quickly diagnose and distinguish MRS A and MSSA. [Online] Available at: 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm254512 
.htm
FOTHERGILL, J.L., PANAGEA, S., HART, C.A., WALSHAW, M.J., PITT, 
T.L. & WINSTANLEY, C. (2007). Widespread pyocyanin over-production 
among isolates of a cystic fibrosis epidemic strain. BMC Microbiology 7, 45- 
55.
FOTHERGILL, J. L., MOWAT, E., WALSHAW, M. J., LEDSON, M. J., 
JAMES, C. E. & WINSTANLEY, C. (2011) Effect of Antibiotic Treatment on 
Bacteriophage Production by a Cystic Fibrosis Epidemic Strain of 
Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 55, 426- 
428.
FU, W., FORSTER, T., MAYER, O., CURTIN, J.J., LEHMAN, S.M. & 
DONLAN, R.M. (2010) Bacteriophage Cocktail for the Prevention of Biofilm 
Formation by Pseudomonas aeruginosa on Catheters in an In Vitro Model 
System. Antimicrobial Agents and Chemotherapy, 54, 397-404.
188
FUX, C.A., COSTERTON, J.W., STEWART, P.S. & STOODLEY, P. (2005) 
Survival strategies of infectious biofilms. Trends in Microbiology, 13, 34-40.
G ACES A, P. (1992) Enzymatic degradation of alginates. International Journal 
o f  Biochemistry, 24, 545-552
GAIDA, W., KLINDER, K., ARNDT, K. & WEISER, T. (2005) Ambroxol, a 
Nav 1.8-preferring Na+ channel blocker, effectively suppresses pain symptoms 
in animal models of chronic, neuropathic and inflammatory pain. 
Neuropharmacology, 49, 1220-1227.
GARCIA-MEDINA, R., DUNNE, W.M., SINGH, P.K. & BRODY, S.L. 
(2005). Pseudomonas aeruginosa Acquires Biofilm-Like Properties within 
Airway Epithelial Cells. Infection and Immunity 73, 8298-8305.
GEISER, T.K., KAZMIERCZAK, B.I., GARRITY-RYAN, L.K., MATTHAY, 
M.A. & ENGEL J.N. (2001) Pseudomonas aeruginosa ExoT inhibits in vitro 
lung epithelial wound repair. Cellular Microbiology, 3, 223-236
GIBSON, R.L., BURNS, J.L. & RAMSEY, B.W. (2003). Pathophysiology and 
Management of Pulmonary Infections in Cystic Fibrosis. American Journal o f  
Respiratory and Critical Care Medicine 168, 918-951.
GILL J.J. & HYMAN P. (2010). Phage Choice, Isolation, and Preparation for 
Phage Therapy. Current Pharmaceutical Biotechnology 11,2-14
GLONTI, T., CHANISHVILI, N. & TAYLOR, P.W. (2010). Bacteriophage- 
derived enzyme that depolymerizes the alginic acid capsule associated with 
cystic fibrosis isolates of Pseudomonas aeruginosa. Journal o f  Applied 
Microbiology, 108, 695-702.
189
GOLSHAHI, L., SEED, K.D., DENNIS, J J .  & FINLAY W.H. (2008) Toward 
Modem Inhalational Bacteriophage Therapy: Nebulization of Bacteriophages 
o f Burkholderia cepacia complex. Journal o f  Aerosol Medicine and Pulmonary 
Drug Delivery, 21, 351-360
GOLSHAHI, L., LYNCH, K.H., DENNIS, J.J. & FINLAY W.H. (2010) In 
vitro lung delivery of bacteriophages KS4-M and OKZ using dry powder 
inhalers for treatment of Burkholderia cepacia complex and Pseudomonas 
aeruginosa infections in cystic fibrosis. Journal o f Applied Microbiology, 110, 
106-117.
GOMEZ, M.I. & PRINCE, A. (2007) Opportunistic infections in lung disease: 
Pseudomonas infections in cystic fibrosis. Current Opinion in Pharmacology, 
7, 244-251.
GOODERHAM, W.J., BAINS, M., MCPHEE, J.B., WIEGAND, I. & 
HANCOCK, R.E.W. (2008). Induction by Cationic Antimicrobial Peptides and 
Involvement in Intrinsic Polymyxin and Antimicrobial Peptide Resistance, 
Biofilm Formation, and Swarming Motility of PsrA in Pseudomonas 
aeruginosa. Journal o f  Bacteriology. 190, 5624-5634.
GOULD, M.P., GREENE, J.A., BHOJ, V., DEVECCHIO, J.L. & HEINZEL, 
F.P. (2004) Distinct Modulatory Effects of LPS and CpG on IL- 18-Dependent 
IFN- {gamma} Synthesis. Journal o f  Immunology, 172, 1754-1762.
HAGENS, S., HABEL, A., VON AHSEN, U., VON GABAIN, A. & BLASI, 
U. (2004) Therapy of Experimental Pseudomonas Infections with a 
Nonreplicating Genetically Modified Phage. Antimicrobial Agents and 
Chemotherapy., 48, 3817-3822.
190
HAAGENSEN, J.A.J., KLAUSDEN, M., ERNST, R.K., MILLER, S.I., 
FOLKESSON, A., TOLKER-NEILSEN, T. & MOLIN, S. (2007). 
Differentiation and Distribution of Colistin- and Sodium Dodecyl Sulfate- 
Tolerant Cells in Pseudomonas aeruginosa Biofilms. Journal o f Bacteriology. 
189, 28-37.
HALL-STOODLEY, L., COSTERTON, J.W. & STOODLEY, P. (2004) 
Bacterial biofilms: from the natural environment to infectious diseases. Nature 
Reviews Microbiology, 2, 95-108.
HANLON, G.W., DENYER, S.P., OLLIFF, C.J. & IBRAHIM, L.J. (2001) 
Reduction in Exopolysaccharide Viscosity as an Aid to Bacteriophage 
Penetration through Pseudomonas aeruginosa Biofilms. Applied and 
Environmental Microbiology, 67, 2746-2753.
HANLON, G.W. (2007) Bacteriophages: an appraisal of their role in the 
treatment of bacterial infections. International Journal o f Antimicrobial 
Agents, 30, 118-128.
HANTASH, F., REDMAN, J., STARN, K., ANDERSON, B., BULLER, A., 
MCGINNISS, M., QUAN, F., PENG, M., SUN, W. & STROM, C. (2006) 
Novel and recurrent rearrangements in the CFTR gene: clinical and laboratory 
implications for cystic fibrosis screening. Human Genetics, 119, 126-136.
HARRISON-BALESTRA, C., CAZZANIGA, A.L., DAVIS, S.C. & MERTZ, 
P.M. (2003). A wound-isolated Pseudomonas aeruginosa grows a biofilm in 
vitro within 10 hours and is visualized by light microscopy. Dermatologic 
Surgery 29, 631-635.
191
HASSETT, D. J., SUTTON, M. D., SCHURR, M. J., HERR, A. B., 
CALDWELL, C. C. & MATU, J. O. (2009) Pseudomonas aeruginosa hypoxic 
or anaerobic biofilm infections within cystic fibrosis airways. Trends in 
Microbiology, 17, 130-138.
HEALTH PROTECTION AGENCY. (2010) Pseudomonas spp. and 
Stenotrophomonas maltophilia bacteraemia in England, Wales, and Northern 
Ireland, 2006 to 2010 [Online] Available at: 
http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1309968922480
HENTZER, M., TEITZEL, G.M., BALZER, G.J., HEYDORN, A., MOLIN, 
S., GIVSKOV, M. & PARSER, M.R. (2001). Alginate Overproduction Affects 
Pseudomonas aeruginosa Biofilm Structure and Function. Journal o f  
Bacteriology 183, 5395-5401.
HERASIMENKA, Y., CESCUTTI, P., IMPALLOMENI, G. & RIZZO, R. 
(2007) Exopolysaccharides produced by Inquilinus limosus, a new pathogen of 
cystic fibrosis patients: novel structures with usual components. Carbohydrate 
Research, 342, 2404-15.
HERRMANN, G., YANG, L., WU, H., SONG, Z., WANG, H., HA.IBY, N., 
ULRICH, M., MOLIN, S.R., RIETHMULLER, J. & DORING, G. (2010). 
Colistin-Tobramycin Combinations Are Superior to Monotherapy Concerning 
the Killing of Biofilm Pseudomonas aeruginosa. Journal o f  Infectious 
Diseases, 202, 1585-1592.
HERTVELDT, K., LAVIGNE, R., PLETENEVA, E., SERNOVA, N., 
KUROCHKINA, L., KORCHEVSKII, R., ROBBEN, J., MESYANZHINOV, 
V., KRYLOV, V.N. & VOLCKAERT, G. (2005) Genome Comparison of 
Pseudomonas aeruginosa Large Phages. Journal o f  Molecular Biology, 354, 
536-545.
192
HO, S-A., LEE, T.W.R., DENTON, M., CONWAY, S.P. & BROWNLEE, 
K.G. (2009) Regimens for eradicating early Pseudomonas aeruginosa infection 
in children do not promote antibiotic resistance in this organism. Journal o f  
Cystic Fibrosis, 8, 43-46.
H0IBY, N., BJARNSHOLT, T., GIVSKOV, M., MOLIN, S. & CIOFU, O. 
(2010). Antibiotic resistance of bacterial biofilms. International Journal o f  
Antimicrobial Agents, 35, 322-332.
HOLLAND, S.J., SANZ, C. & PERHAM, R.N. (2006) Identification and 
specificity of pilus adsorption proteins of filamentous bacteriophages infecting 
Pseudomonas aeruginosa. Virology, 345, 540-548.
HOPE, C.K. & WILSON, M. (2006) Biofilm structure and cell vitality in a 
laboratory model of subgingival plaque. Journal o f  Microbiological Methods, 
66, 390-398.
HOSEIN, I. (2007). Current Use o f  Antibiotics fo r Pseudomonas aeruginosa 
infection o f  CFpatients. Personal Communication.
HUFF, W. E., HUFF, G. R., RATH, N. C., BALOG, J. M. & DONOGHUE, A. 
M. (2003) Evaluation of aerosol spray and intramuscular injection of 
bacteriophage to treat an Escherichia coli respiratory infection. Poultry 
Science, 82, 1108-1112.
HULL, R., BROWN, F. & PAYNE C. (1990). Virology, Directory and 
Dictionary o f  Animal, Bacterial and Plant Viruses. London. The Macmillan 
Press.
INTRALYTIX INC. (2011). Press release -  02/08/2011. [Online] Available at: 
http://www.intralytix.com/Intral_News_PR020811 .htm
193
ISHIMOTO, K.S. & LORY, S. (1989). Formation of Pilin in Pseudomonas 
aeruginosa requires the Alternative sigma Factor (RpoN) of RNA Polymerase. 
Proceedings o f  the National Academy o f  Sciences o f the United States o f  
America, 86, 1954-1957.
1WAMOTO, Y., ARAKJ, R., IRIYAMA, K., ODA, T., FUKUDA, H., 
HAYASH1DA, S. & MURAMATSU, T. (2001) Purification and 
characterization of bifunctional alginate lyase from Alteromonas sp. strain no. 
272 and its action on saturated oligomeric substrates. Bioscience, 
Biotechnology and Biochemistry. 65, 133,
JASSIM, S. A., DENYER, S. P. & STEWART, G. S. A. B. (1995) Virus 
Breeding. IN INTERNATIONAL & 9523848, P. A. N. W. (Eds.).
JASSIM, S.A.A. & GRIFFITHS, M.W. (2007) Evaluation of a rapid microbial 
detection method via phage lytic amplification assay coupled with Live/Dead 
fluorochromic stains. Letters in Applied Microbiology, 44, 673-678.
JENKINS, C.E., SWIATONIOWSKI, A., ISSEKUTZ, A.C. & LIN, T-J.
(2004) Pseudomonas aeruginosa Exotoxin A Induces Human Mast Cell 
Apoptosis by a Caspase-8 and -3-dependent Mechanism. Journal o f  Biological 
Chemistry, 279,37201-37207.
JESAITIS, A.J., FRANKLIN, M.J., BERGLUND, D., SASAKI, M., LORD, 
C.I., BLEAZARD, J.B., DUFFY, J.E., BEYENAL, H. AND 
LEWANDOWSKI, Z. (2003). Compromised Host Defense on Pseudomonas 
aeruginosa Biofilms: Characterization of Neutrophil and Biofilm Interactions. 
Journal o f  Immunology, 171, 4329-4339.
JONES H. (2009) Prevalence and activity of prophages within Pseudomonas 
aeruginosa strains isolated from Cystic Fibrosis patients. Undergraduate 
Project Report, Cardiff, UK
194
JONES, J.B., JACKSON, L.E., BALOGH, B., OBRADOVIC, A., IRIARTE, 
F.B. & MOMOL, M.T. (2007) Bacteriophages for Plant Disease Control. 
Annual Review o f  Phytopathology, 45, 245-262.
JONES, A.M., GOV AN, J.R.W., DOHERTY, C.J., DODD, M.E., ISALSKA,
B.J., STANBRIDGE, T.N. AND WEBB, A.K. (2001). Spread of a 
multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis 
clinic. The Lancet, 358, 557-558.
KALANTR1, S., PAI, M., PASCOPELLA, L., RILEY, L. & REINGOLD, A. 
(2005) Bacteriophage- based tests for the detection of Mycobacterium 
tuberculosis in clinical specimens: a systematic review and meta- analysis. 
BMC Infectious Diseases, 5, 59.
KIESEWETTER, S., MACEK, M., DAVIS, C., CURRISTIN, S.M., CHU,
C.S., GRAHAM, C., SHRIMPTON, A.E., CASHMAN, S.M., TSUI, L. C., 
MICKLE, J., AMOS, J., HIGHSMITH, W.E., SHUBER, A., WITT, D.R., 
CRYSTAL, R.G. & CUTTING, G.R. (1993) A mutation in CFTR produces 
different phenotypes depending on chromosomal background. Nature Genetics, 
5, 274-278.
KEREM, B.S., ZIELENSKI, J., MARKIEWICZ, D., BOZON, D., GAZIT, E., 
YAHAV, J., KENNEDY, D., RIORDAN, J R., COLLINS, F.S., ROMMENS, 
J.M. & TSUI, L-C. (1990) Identification of mutations in regions corresponding 
to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. 
Proceedings o f the National Academy o f  Sciences o f the United States o f 
America, 87, 8447-51.
KILLC, N.K. & DCjNMEZ, G. (2008). Environmental conditions affecting 
exopolysaccharide production by Pseudomonas aeruginosa, Micrococcus sp., 
and Ochrobactrum sp. Journal o f  Hazardous Materials 154, 1019-1024.
195
KING, S.J., TOPLISS, D.J., KOTSIMBOS, T., NYULASI, I.B., BAILEY, M., 
EBELING, P.R. & WILSON, J.W. (2005) Reduced bone density in cystic 
fibrosis: AF508 mutation is an independent risk factor. European Respiratory 
Journal, 25, 54-61.
KIPNIS, E., SAWA, T. & WIENER-KRONISH, J. (2006) Targeting 
mechanisms of Pseudomonas aeruginosa pathogenesis. Medecine et Maladies 
Infectieuses, 36, 78-91.
KIRISITS, M.J., PROST, L., STARKEY, M. & PARSEK, M.R. (2005) 
Characterization of colony morphology variants isolated from Pseudomonas 
aeruginosa biofilms. Applied and Environmental Microbiology, 71, 4809-21.
KNEZEVIC, P. & PETROVIC, O. (2008) A colorimetric microtiter plate 
method for assessment of phage effect on Pseudomonas aeruginosa biofilm. 
Journal o f  Microbiological Methods, 74, 114-118.
KNUTSON, C.A. & JEANES, A. (1968) A new modification of the carbazole 
analysis: application to heteropolysaccharides. Analytical Biochemistry, 24, 
470-81.
KUDA, T. & YANO, T. (2003) Colorimetric alamarBlue assay as a bacterial 
concentration and spoilage index of marine foods. Food Control, 14,455-461.
KURAHASHI, K , OTA, S., NAKAMURA, K., NAGASHIMA, Y., 
YAZAWA, T., SATOH, M., FUJITA, A., KAMIYA, R., FUJITA, E., BABA, 
Y., UCHIDA, K , MORIMURA, N., ANDOH, T. & YAMADA, Y. (2004) 
Effect of lung-protective ventilation on severe Pseudomonas aeruginosa 
pneumonia and sepsis in rats. American Journal o f  Physiology - Lung Cellular 
and Molecular Physiology, 287, L402-L410.
196
KUTTER, E., DE VOS, D., GV AS ALIA, G., ALAVIDZE, Z., GOGOKHLA, 
L., KUHL, S., & ABDEDON, S.T. (2010). Phage Therapy in Clinical Practice: 
Treatment of Human Infections. Current Pharmaceutical Biotechnology, 11, 
69-86
KWAN, T., LIE, J., DU BOW, M., GROS, P. & PELLETIER, J. (2006). 
Comparative Genomic Analysis of 18 Pseudomonas aeruginosa 
Bacteriophages. Journal o f Bacteriology. 188, 1184-1187.
LAMBERT, P.A. (2002) Mechanisms of antibiotic resistance in Pseudomonas 
aeruginosa. Journal o f  the Royal Society o f  Medicine, 95, Suppl 41, 22-6.
LAMB1ASE, A., RAIA, V., PEZZO, M., SEPE, A., CARNOVALE, V. & 
ROSSANO, F. (2006) Microbiology of airway disease in a cohort of patients 
with Cystic Fibrosis. BMC Infectious Diseases, 6, 4.
LAMFON, H., PORTER, SR.,  MCCULLOUGH, M. & PRATTEN, J. (2004) 
Susceptibility of Candida albicans biofilms grown in a constant depth film 
fermcntor to chlorhexidine, fluconazole and miconazole: a longitudinal study. 
Journal o f  Antimicrobial Chemotherapy, 53, 383-385.
LANDRY, R.M., AN, D., HUPP, J.T., SINGH, P.K. & PARSER, M.R. (2006). 
Mwcm-Pseudomonas aeruginosa interactions promote biofilm formation and 
antibiotic resistance. Molecular Microbiology 59, 142-151.
LANG, L.H. (2006) FDA Approves Use of Bacteriophages to be Added to 
Meat and Poultry Products. Gastroenterology, 131, 1370.
LAU, G.W., HASSETT, D.J., RAN, H. & KONG, F. (2004) The role of 
pyocyanin in Pseudomonas aeruginosa infection. Trends in Molecular 
Medicine, 10, 599-606.
197
LAVIGNE, R., NOBEN, J-P., HERTVELDT, K., CEYSSENS, P-J., BRIERS, 
Y., DUMONT, D., ROUCOURT, B., KRYLOV, V.N., MESYANZHINOV, 
V.V., ROBBEN, J. & VOLCKAERT, G. (2006). The structural proteome of 
Pseudomonas aeruginosa bacteriophage O KMV. Microbiology 152, 529-534.
LEE, B., HAAGENSEN, J.A.J., CIOFU, O., ANDERSEN, J.B., HOIBY, N. & 
MOLIN, S. (2005) Heterogeneity of Biofilms Formed by Nonmucoid 
Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis. Journal 
o f  Clinical Microbiology, 43, 5247-5255.
LEWIS, D.A., JONES, A., PARKHILL, J., SPEERT, D P., GOV AN, J.R., 
L1PUMA, J.J., LORY, S., WEBB, A.K. & MAHENTHIRALINGAM, E.
(2005). Identification of DNA markers for a transmissible Pseudomonas 
aeruginosa cystic fibrosis strain. American Journal o f  Respiratory Cell and 
Molecular Biology 33, 56-64.
LI, F., YU, J., YANG, H., WAN, Z. & BAI, D. (2008). Effects of ambroxol on 
alginate of mature Pseudomonas aeruginosa biofilms. Current Microbiology 
57, 1-7.
LYCZAK, J.B., CANNON, C.L. & PIER, G.B. (2002) Lung infections 
associated with cystic fibrosis. Clinical Microbiology Reviews, 15, 194-222.
MA, L., CHI, Z., LI, J. & WU, L. (2008) Overexpression of alginate lyase of 
Pseudoalteromonas elyakovii in & Escherichia coli, purification, and 
characterization of the recombinant alginate lyase. World Journal o f  
Microbiology and Biotechnology, 24, 89-96.
MAILLARD, J-Y., HANN, A C., BEGGS, T.S., DAY, M.J., HUDSON,
R.A. & RUSSELL, A.D. (1995) Electronmicroscopic investigation of the 
effects of biocides on Pseudomonas aeruginosa PAO bacteriophage 
FI 16. Journal o f  Medical Microbiology, 42, 415-420.
198
MAILLARD, J-Y., BEGGS, T.S., DAY, M.J., HUDSON, R.A. & RUSSELL, 
A.D. (1996). The effect of biocides on proteins of Pseudomonas aeruginosa 
PAO bacteriophage FI 16. Journal o f  Applied Bacteriology 80, 291-295.
MALERBA, M. & RAGNOLI, B. (2008) Ambroxol in the 21st century: 
pharmacological and clinical update. Expert Opinion on Drug Metabolism & 
Toxicology, 4, 1119-1129.
MALLOY, J.L., VELDHUIZEN, R A W . ,  THIBODEAUX, B.A., 
O'CALLAGHAN, R.J. & WRIGHT, J.R. (2005) Pseudomonas aeruginosa 
protease IV degrades surfactant proteins and inhibits surfactant host defense 
and biophysical functions. American Journal o f  Physiology Lung Cellular and 
Molecular Physiology, 288, L409-418.
MARQUES, C.N.H., SALISBURY, V.C., GREENMAN, J., BOWKER, K. E. 
& NELSON, S. M. (2005) Discrepancy between viable counts and light output 
as viability measurements, following ciprofloxacin challenge of self- 
bioluminescent Pseudomonas aeruginosa biofilms. Journal o f  Antimicrobial 
Chemotherapy, 56, 665-671.
MARZA, J.A.S., SOOTHILL, J.S., BOYDELL, P. & COLLYNS, T.A. (2006) 
Multiplication of therapeutically administered bacteriophages in Pseudomonas 
aeruginosa infected patients. Bums, 32, 644-646.
MCCORMICK, J., GREEN, M.W., MEHTA, G., CULROSS, F. & MEHTA, 
A. (2002) Demographics of the UK cystic fibrosis population: implications for 
neonatal screening. European Journal o f  Human Genetics, 10, 583-90.
199
MCCOY, K.S., QUITTNER, A.L., OERMANN, C.M., GIBSON, R.L., 
RETSCH-BOGART, G.Z. & MONTGOMERY, A.B. (2008) Inhaled 
Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic 
Fibrosis. American Journal o f  Respiratory and Critical Care Medicine, 178, 
921-928.
MCDOWELL, A., MAHENTHIRALINGAM, E., DUNBAR, K.E.A., 
MOORE, J.E., CROWE, M. & ELBORN, J.S. (2004) Epidemiology of 
Burkholderia cepacia complex species recovered from cystic fibrosis patients: 
issues related to patient segregation. Journal o f  Medical Microbiology, 53, 
663-668.
MCVAY, C.S., VELASQUEZ, M. & FRALICK, J.A. (2007) Phage Therapy 
o f Pseudomonas aeruginosa Infection in a Mouse Bum Wound Model. 
Antimicrobial Agents and Chemotherapy, 51, 1934-1938.
MERABISHVILI, M., PIRNAY, J-P., VERBEKEN, G., CHANISHVILI, N., 
TEDIASHVILI, M., LASHKHI, N., GLONTI, T., KRYLOV, V., MAST, J., 
VAN PARYS, L., LAVIGNE, R., VOLCKAERT, G., MATTHEUS, W., 
VERWEEN, G., DE CORTE, P., ROSE, T., JENNES, S., ZIZI, M., DE VOS,
D. & VANEECHOUTTE, M. (2009) Quality-Controlled Small-Scale 
Production of a Well-Defined Bacteriophage Cocktail for Use in Human 
Clinical Trials. PLoS ONE, 4, e4944.
MILES, A., MAILLARD, J-Y., HANN, A.C., BEGGS, T.S., DAY, M.J., 
HUDSON, R.A. & RUSSELL, A.D. (1995). Electronmicroscopic investigation 
of the effects of biocides on Pseudomonas aeruginosa PAO bacteriophage 
FI 16. Journal o f  Medical Microbiology 42, 415-420.
MILES A. A. & MISRA, J.O. (1938). The estimation of the bacteriacidal power 
of the blood. Journal o f Hygiene 38, 732-749.
200
MOK, H., PARK, J. & PARK, T. (2007) Microencapsulation of PEGylated 
Adenovirus within PLGA Microspheres for Enhanced Stability and Gene 
Transfection Efficiency. Pharmaceutical Research, 24, 2263-2269.
MOREAU-MARQUIS, S., STANTON, B.A. & O'TOOLE, G.A. (2008). 
Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. 
Pulmonary Pharmacology & Therapeutics 21, 595-599.
MOSKOWITZ, S.M., FOSTER, J.M., EMERSON, J. & BURNS, J.L. (2004) 
Clinically Feasible Biofilm Susceptibility Assay for Isolates of Pseudomonas 
aeruginosa from Patients with Cystic Fibrosis. Journal o f  Clinical 
Microbiology, 42, 1915-1922.
MOSKOWITZ, S.M., CHMIEL, J.F., STERNEN, D.L., CHENG, E., 
GIBSON, R.L., MARSHALL, S.G. & CUTTING, G.R. (2008). Clinical 
practice and genetic counselling for cystic fibrosis and CFTR-related disorders. 
Genetics in Medicine 10, 851-868.
MULCAHY, L.R., BURNS, J.L., LORY, S. & LEWIS, K. (2010). Emergence 
of Pseudomonas aeruginosa Strains Producing High Levels of Persister Cells 
in Patients with Cystic Fibrosis. Journal o f  Bacteriology, 192, 6191-6199.
NAKA1, T. & PARK, S.C. (2002) Bacteriophage therapy of infectious diseases 
in aquaculture. Research in Microbiology, 153, 13-18.
NIVENS, D.E., OHMAN, D.E., WILLIAMS, J. & FRANKLIN, M.J. (2001) 
Role of Alginate and Its O Acetylation in Formation of Pseudomonas 
aeruginosa Microcolonies and Biofilms. Journal o f Bacteriology, 183, 1047- 
1057.
201
OCHS, M., NYENGAARD, J R., JUNG, A., KNUDSEN, L., VOIGT, M., 
WAHLERS, T., RICHTER, J. & GUNDERSEN, H.J.G. (2004). The Number 
of Alveoli in the Human Lung. American Journal o f Respiratory and Critical 
Care Medicine 169, 120-124.
OFFICE OF NATIONAL STATISTICS (2010). Interim Life Tables. [Online] 
Available at: http://www.statistics.gov.uk/StatBase/Product.asp?vlnk= 14459
O'MAY, C.Y., REID, D.W. & KIROV, S.M. (2006). Anaerobic culture 
conditions favor biofilm-like phenotypes in Pseudomonas aeruginosa isolates 
from patients with cystic fibrosis. FEMS Immunology & Medical Microbiology 
48, 373-380.
OSMAN, L.P., ROUGHTON, M., HODSON, M.E. & PRYOR, J.A. (2010). 
Short-term comparative study of high frequency chest wall oscillation and 
European airway clearance techniques in patients with cystic fibrosis. Thorax, 
65, 196-200.
O'SULLIVAN, B.P., ZWERDLING, R.G., DORKIN, H.L., COMEAU, A. M. 
& PARAD, R. (2006) Early pulmonary manifestation of cystic fibrosis in 
children with the AF508/R117H-7T genotype. Pediatrics, 118, 1260-5.
O’SULLIVAN, D.M., MCHUGH, T.D. & GILLESPIE, S.H. (2010) Mapping 
the fitness of Mycobacterium tuberculosis strains: a complex picture. Journal 
o f Medical Microbiology, 59, 1533-1535.
PAI, M., KALANTRI, S., PASCOPELLA, L., RILEY, L.W. & REINGOLD, 
A.L. (2005) Bacteriophage-based assays for the rapid detection of rifampicin 
resistance in Mycobacterium tuberculosis', a meta-analysis. Journal o f  
Infection, 51, 175-87.
202
PASTAGIA, M., EULER, C., CHAHALES, P., FUENTES-DUCULAN, J., 
KRUEGER, J. G. & FISCHETTI, V. A. A. (2011) Novel Chimeric Lysin 
Shows Superiority to Mupirocin for Skin Decolonization of Methicillin- 
Resistant and -Sensitive Staphylococcus aureus Strains. Antimicrobial Agents 
and Chemotherapy, 55, 738-744.
PETERS, A.C. & WIMPENNY, J.W.T. (1988) A constant-depth laboratory 
model film fermentor. Biotechnology and Bioengineering, 32, 263-270.
PIER, G.B. (2007) Pseudomonas aeruginosa lipopolysaccharide: A major 
virulence factor, initiator of inflammation and target for effective immunity. 
International Journal o f Medical Microbiology, 297, 277-295.
PITT, T.L. (1986) Biology of Pseudomonas aeruginosa in relation to 
pulmonary infection in cystic fibrosis. Journal o f  Royal Society o f  Medicine, 
79, Suppl 12, 13-8.
PLATT, M.D., SCHURR, M.J., SAUER, K., VAZQUEZ, G., KUKAVICA- 
IBRUU, I., POTVIN, E., LEVESQUE, R.C., FEDYNAK, A., BRINKMAN, 
F.S.L., SCHURR, J., HWANG, S.-H., LAU, G.W., LIMBACH, P.A., ROWE, 
J.J., LIEBERMAN, M.A., BARRAUD, N., WEBB, J., KJELLEBERG, S., 
HUNT, D.F. & HASSETT, D.J. (2008). Proteomic, Microarray, and Signature- 
Tagged Mutagenesis Analyses of Anaerobic Pseudomonas aeruginosa at pH 
6.5, Likely Representing Chronic, Late-Stage Cystic Fibrosis Airway 
Conditions. Journal o f  Bacteriology 190, 2739-2758.
POOLMAN, E.M. AND GALVANI, A.P. (2007). Evaluating candidate agents 
of selective pressure for cystic fibrosis. Journal o f the Royal Society Interface 
4,91-98.
PRITT, B., O'BRIEN, L. & WINN, W. (2007). Mucoid Pseudomonas in cystic 
fibrosis. American Journal o f  Clinical Pathology 128, 32-34.
203
PUAPERMPOONSIRI, U., SPENCER, J. & VAN DER WALLE, C. F. (2009) 
A freeze-dned formulation of bacteriophage encapsulated in biodegradable 
microspheres. European Journal o f  Pharmaceutics and Biopharmaceutics, 72, 
26-33.
PUREVDORJ-GAGE, B., COSTERTON, W.J. AND STOODLEY, P. 2005). 
Phenotypic differentiation and seeding dispersal in non-mucoid and mucoid 
Pseudomonas aeruginosa biofilms. Microbiology 151, 1569-1576.
RATJEN, F. & DORING, G. (2003) Cystic fibrosis. The Lancet, 361, 681-9.
RHOADS, D.D., WOLCOTT, R.D., KUSKOWSKI, M.A., WOLCOTT, B.M., 
WARD, L.S. & SULAKVELDZE, A., (2009). Bacteriophage therapy of 
venous leg ulcers in humans: results of a phase I safety trial. Journal o f Wound 
Care 18, 237 - 243
ROBERTS, J.L., WILLIAMS, D.W., WADDINGTON, R., DENYER, S.P., 
MAILLARD, J-Y., SLOAN, A.J. (2008). Modification of Culture Conditions 
to Support an Ex-Vivo Co-Culture System. I ADR, Toronto
ROGERS, G.B., CARROLL, M.P., SERISIER, D.J., HOCKEY, P.M., 
KEHAGIA, V., JONES, G.R. & BRUCE, K.D. (2005) Bacterial activity in 
cystic fibrosis lung infections. Respiratory Research, 6,49.
ROSSMANN, M.G., MESYANZHINOV, V.V., ARISAKA, F. & LEEMAN, 
P.G. (2004) The bacteriophage T4 DNA injection machine. Current Opinion in 
Structural Biology, 14, 171-180.
RUBIN, B.K. (2007) Mucus structure and properties in cystic fibrosis. 
Paediatric Respiratory Reviews, 8, 4-7.
204
RYDER, C., BYRD, M. & WOZNIAK, D J. (2007). Role of polysaccharides 
in Pseudomonas aeruginosa biofilm development. Current Opinion in 
Microbiology 10, 644-648.
SADIKOT, R.T., BLACKWELL, T.S., CHRISTMAN, J.W. & PRINCE, A.S. 
(2005) Pathogen-Host Interactions in Pseudomonas aeruginosa Pneumonia. 
American Journal o f  Respiratory and Critical Care Medicine, 171, 1209-1223.
SALUNKHE, P., SMART, C.H.M., MORGAN, J.A.W., PANAGEA, S., 
WALSHAW, M.J., HART, C.A., GEFFERS, R., TUMMLER, B. & 
WINSTANLEY, C. (2005). A Cystic Fibrosis Epidemic Strain of 
Pseudomonas aeruginosa Displays Enhanced Virulence and Antimicrobial 
Resistance. Journal o f  Bacteriology 187, 4908-4920.
SAIMAN, L. & SIEGEL, J. (2004). Infection control in cystic fibrosis. Clinical 
Microbiology Reviews 17, 57-71.
SANSONI, P., VESCOVINI, R., FAGNONI, F., B1ASINI, C., ZANNI, F., 
ZANLARI, L., TELERA, A., LUCCHINI, G., PASSERI, G., MONTI, D., 
FRANCESCHI, C. & PASSERI, M. (2008) The immune system in extreme 
longevity. Experimental Gerontology, 43, 61-65.
SE1FART, C., CLOSTERMANN, U., SE1FART, U., MULLER, B., 
VOGELMEIER, C., VON W1CHERT, P. & FEHRENBACH, H. (2005) Cell- 
specific modulation of surfactant proteins by ambroxol treatment. Toxicology 
and Applied Pharmacology, 203, 27-35.
SERMET-GAUDELUS, I., LECOCGUIC, Y., FERRONI, A., CLAIRICIA, 
M., BARTHE, J., DELAUNAY, J., BROUSSE, V. & LENOIR, G. (2002) 
Nebulized Antibiotics in Cystic Fibrosis. Pediatric Drugs, 4, 455-467.
205
SERMET-GAUDELUS, I., RENOUIL, M., FAJAC, A., BIDOU, L., 
PARBAILLE, B., PIERROT, S., DAVY, N., BISMUTH, E., REINERT, P., 
LENOIR, G., LESURE, J., ROUSSET, J. & EDELMAN, A. (2007) In vitro 
prediction of stop-codon suppression by intravenous gentamicin in patients 
with cystic fibrosis: a pilot study. BMC Medicine, 5, 5.
SETHI, S. & MURPHY, T.F. (2008). Infection in the Pathogenesis and Course 
of Chronic Obstructive Pulmonary Disease. New England Journal o f Medicine 
359, 2355-2365.
SHAFIKHANI, S.H. & ENGEL, J. (2006) Pseudomonas aeruginosa type III- 
secreted toxin ExoT inhibits host-cell division by targeting cytokinesis at 
multiple steps. Proceedings o f the National Academy o f Sciences, 103, 15605- 
15610.
SHIMIZU, E., OJIMA, T. & NISHITA, K. (2003) cDNA cloning of an 
alginate lyase from abalone, Haliotis discus hannai. Carbohydrate Research, 
338, 2841-2852.
SLACK, M.P.E., NICHOLS, W.W., (1981). The penetration of antibiotics 
through sodium alginate and through the exopolysaccharide of a mucoid strain 
of P. aeuroginosa. The Lancet, 318, 502-503.
SMART, C.H.M., SCOTT, F.W., WRIGHT, E.A., WALSHAW, M.J., HART,
C.A., PITT, T.L. & WINSTANLEY, C. (2006) Development of a diagnostic 
test for the Midlands 1 cystic fibrosis epidemic strain of Pseudomonas 
aeruginosa. Journal o f  Medical Microbiolgy, 55, 1085-1091.
SMITH, A.W. (2005) Biofilms and antibiotic therapy: Is there a role for 
combating bacterial resistance by the use of novel drug delivery systems? 
Advanced Drug Delivery Reviews, 57, 1539-1550.
206
SOUTHERN, K.W., MUNCK, A., POLLITT, R., TRAVERT, G., ZANOLLA, 
L., DANKERT-ROELSE, J. & CASTELLANI, C. (2007) A survey of newborn 
screening for cystic fibrosis in Europe. Journal o f Cystic Fibrosis, 6, 57-65.
SRIRAMULU, D.D., LUNSDORF, H., LAM, J.S. & ROMLING, U. (2005). 
Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for 
the cystic fibrosis lung. Journal o f  Medical Microbiology 54, 667-676.
STEWART, G.S.A.B., JASSIM, S.A.A., DENYER, S.P., NEWBY, P., 
LINLEY, K., & DHIR, V.K. (1998) The specific and sensitive detection of 
bacterial pathogens within 4 h using bacteriophage amplification. Journal o f  
Applied Microbiology, 84, 777-783.
STOVER, C.K., PHAM, X.Q., ERWIN, A.L., MIZOGUCHI, S.D., 
WARRENER, P., HICKEY, M.J., BRINKMAN, F.S.L., HUFNAGLE, W.O., 
KOWALIK, D.J., LAGROU, M., GARBER, R.L., GOLTRY, L., 
TOLENTINO, E., WESTBROCK-WADMAN, S., YUAN, Y., BRODY, L.L., 
COULTER, S.N., FOLGER, K.R., KAS, A., LARBIG, K., LIM, R., SMITH, 
K., SPENCER, D., WONG, G.K.S., WU, Z., PAULSEN, I T., REIZER, J., 
SAIER, M.H., HANCOCK, R.E.W., LORY S. & OLSON, M.V. (2000). 
Complete genome sequence of Pseudomonas aeruginosa PAOl, an 
opportunistic pathogen. Nature, 406, 959-964.
SULAKVELIDZE, A., ALAVIDZE, Z. & MORRIS, J.G., JR. (2001) 
Bacteriophage therapy. Antimicrobial Agents and Chemotherapy, 45, 649-59.
TAORI, S.K., HALL, V. & POXTON, I.R. (2010) Changes in antibiotic 
susceptibility and ribotypes in Clostridium difficile isolates from southern 
Scotland, 1979-2004.. Journal o f  Medical Microbiology, 59, 338-344.
207
TATE, S., MACGREGOR, G., DAVIS, M., INNES, J.A. & GREENING, A.P. 
(2002). Airways in cystic fibrosis are acidified: detection by exhaled breath 
condensate. Thorax 57, 926-929.
THORN, R.M.S., NELSON, S.M. & GREENMAN, J. (2007) Use of a 
Bioluminescent Pseudomonas aeruginosa Strain within an In Vitro 
Microbiological System, as a Model of Wound Infection, To Assess the 
Antimicrobial Efficacy of Wound Dressings by Monitoring Light Production. 
Antimicrobial Agents and Chemotherapy, 51, 3217-3224.
TRAMPER-STRANDERS, G. A., WOLFS, T. F. W., VAN HAREN 
NOMAN, S., VAN AALDEREN, W. M. C., NAGELKERKE, A. F., 
NUUSINK, M., KIMPEN, J. L. L. & VAN DER ENT, C. K. (2010) Controlled 
trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas 
aeruginosa infection in children with cystic fibrosis. Thorax, 65, 915-920.
TSENG, J., DO, J., WIDDICOMBE, J.H. & MACHEN, T.E. (2006) Innate 
immune responses of human tracheal epithelium to Pseudomonas aeruginosa 
flagellin, TNF-a, and IL-lbeta. American Journal o f  Physiology, 290, C678- 
690.
UCHIMURA, K., MIYAZAKI, M., NOGI, Y., KOBAYASHI, T. & 
HORIKOSHI, K. (2010). Cloning and Sequencing of Alginate Lyase Genes 
from Deep-Sea Strains of Vibrio and & Agarivorans and Characterization of a 
New Vibrio Enzyme. Marine Biotechnology, 12, 526-533.
UCL EASTMAN DENTAL INSTITUTE. (2010) IN VITRO MODELS: 
BIOFILMS AND ECOLOGY. [Online] Available at:
http://www.ucl.ac.uk/eastman/research/MD/biofilms_ecology_models/index.ht
ml
208
USHER, L.R., LAWSON, R.A., GEARY, I., TAYLOR, C.J., BINGLE, C. D., 
TAYLOR, G.W. & WHYTE, M.K.B. (2002) Induction of Neutrophil 
Apoptosis by the Pseudomonas aeruginosa Exotoxin Pyocyanin: A Potential 
Mechanism of Persistent Infection. Journal o f  Immunology, 168, 1861-1868.
USOV, A. (1999). Alginic acids and alginates: analytical methods used for 
their estimation and characterisation of composition and primary structure. 
Russian Chemical Reviews, 68, 957
VALENZA, G., TAPPE, D., TURNWALD, D., FROSCH, M., KONIG, C., 
HEBESTREIT, H. & ABELE-HORN, M. (2008) Prevalence and antimicrobial 
susceptibility of microorganisms isolated from sputa of patients with cystic 
fibrosis. Journal o f  Cystic Fibrosis, 7, 123-127.
VANCE, R.E., RIETSCH, A. & MEKALANOS, J.J. (2005) Role of the Type 
III Secreted Exoenzymes S, T, and Y in Systemic Spread of Pseudomonas 
aeruginosa PAOl In Vivo. Infection and. Immunity, 73, 1706-1713.
VAN DE VOSSE, E., ALI, S., VISSER, A., SURJADI, C., WIDJAJA, S., 
VOLLAARD, A. & DISSEL, J. (2005). Susceptibility to typhoid fever is 
associated with a polymorphism in the cystic fibrosis transmembrane 
conductance regulator (CFTR). Human Genetics 118, 138-140.
VAN ZANTEN, A.R.H., OUDUK, M., NOHLMANS-PAULSSEN, M.K.E., 
VAN DER MEER, Y.G., GIRBES, A.R.J. & POLDERMAN, K.H. (2007) 
Continuousvs.intermittent cefotaxime administration in patients with chronic 
obstructive pulmonary disease and respiratory tract infections: 
pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical 
efficacy. British Journal o f Clinical Pharmacology, 63, 100-109.
209
VERKMAN, A.S. (2001) Lung disease in cystic fibrosis: is airway surface 
liquid composition abnormal? American Journal o f Physiology - Lung Cellular 
and Molecular Physiology, 281, L306-308.
VICKERY, K., PAJKOS, A. & COSSART, Y. (2004) Removal of biofilm 
from endoscopes: evaluation of detergent efficiency. American Journal o f 
Infection Control, 32, 170-176.
WAGNER, V. & IGLEWSKI, B. (2008) P. aeruginosa Biofilms in CF 
Infection. Clinical Reviews in Allergy and Immunology, 35, 124-134.
WAINE, D.J., WHITEHOUSE, J. & HONEYBOURNE, D. (2007) Cross­
infection in cystic fibrosis: The knowledge and behaviour of adult patients. 
Journal o f  Cystic Fibrosis, 6, 262-266.
WATANABE, R., MATSUMOTO, T., SANO, G., ISHII, Y., TATEDA, K., 
SUMIYAMA, Y., UCHIYAMA, J., SAKURAI, S., MATSUZAKI, S., IMAI, 
S. & YAMAGUCHI, K. (2007) Efficacy of bacteriophage therapy against gut- 
derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrobial 
Agents and Chemotherapy, 51,446-52.
WHITCHURCH, C.B., TOLKER-NIELSEN, T., RAGAS, P.C. & MATTICK, 
J.S. (2002). Extracellular DNA Required for Bacterial Biofilm Formation. 
Science 295, 1487.
WILLIAMS, G.J. & STICKLER, D.J. (2008) Effect of triclosan on the 
formation of crystalline biofllms by mixed communities of urinary tract 
pathogens on urinary catheters. Journal o f  Medical Microbiology, 57, 1135- 
1140.
210
WOOD, L.F., LEECH, A.J. & OHMAN, D.E. (2006). Cell wall-inhibitory 
antibiotics activate the alginate biosynthesis operon in Pseudomonas 
aeruginosa: roles of a22 (AlgT) and the AlgW and Prc proteases. Molecular 
Microbiology 62, 412-426.
WORLITZSCH, D., TARRAN, R., ULRICH, M., SCHWAB, U., CEKICI, A., 
MEYER, K.C., BIRRER, P., BELLON, G., BERGER, J., WEISS, T., 
BOTZENHART, K., YANKASKAS, J.R., RANDELL, S., BOUCHER, R.C. 
& DORING, G. (2002). Effects of reduced mucus oxygen concentration in 
airway Pseudomonas infections of cystic fibrosis patients. Journal o f Clinical 
Investigation 109, 317-325.
WRIGHT, A., HAWKINS, C.H., ANGGARD, E.E. & HARPER, D.R. (2009) 
A controlled clinical trial of a therapeutic bacteriophage preparation in chronic 
otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report 
of efficacy. Clinical Otolaryngology, 34, 349-357.
YAHR, T.L., VALLIS, A.J., HANCOCK, M.K., BARBIERI, J.T., & FRANK,
D.W. (1998) ExoY, an adenylate cyclase secreted by the Pseudomonas 
aeruginosa type III system. Proceedings o f  the National Academy o f Sciences 
USA, 95. 13899-13904.
YAMASAKI, M., MORIWAKI, S., MIYAKE, O., HASHIMOTO, W., 
MURATA, K. & MIKAMI, B. (2004) Structure and Function of a 
Hypothetical Pseudomonas aeruginosa Protein PA1167 Classified into Family 
PL-7: A NOVEL ALGINATE LYASE WITH A p-SANDWICH FOLD. 
Journal o f  Biological Chemistry, 279, 31863-31872.
YU, Y., CHENG, A.S., WANG, L., DUNNE, W.M. & BAYLISS, S.J. (2007) 
Hot tub folliculitis or hot hand-foot syndrome caused by Pseudomonas 
aeruginosa. Journal o f  American Academy o f  Dermatology, 57, 596-600.
211
ZANIN, I. C.J., GONCALVES, R.B., JUNIOR, A.B., HOPE, C.K. & 
PRATTEN, J. (2005) Susceptibility of Streptococcus mutans biofilms to 
photodynamic therapy: an in vitro study. Journal o f Antimicrobial
Chemotherapy, 56, 324-330.
ZHANG, S., MCCORMACK, F.X., LEVESQUE, R.C., O’TOOLE, G.A., & 
LAU, G.W. (2007). The Flagellum of Pseudomonas aeruginosa Is Required 
for Resistance to Clearance by Surfactant Protein A. PLOS ONE, 2, e564
ZIMMERLI, W. & OCHSNER, P.E. (2003) Management of Infection 
Associated with Prosthetic Joints. Infection, 31, 99-108.
212
Chapter 9 
Appendix
213
2Q
Applied Microbiology
Journal of Applied Microbiology ISSN 1364-5072
ORI GI NAL ARTICLE
Rapid and quantitative automated measurement of 
bacteriophage activity against cystic fibrosis isolates of
Pseudom onas aeruginosa
CJ.  Cooper, S.P. Denyer and  J.-Y. Maillard
Welsh School of Pharmacy, Cardiff University, Cardiff, Wales, UK
Keywords
bacteriophage, lytic activity. Pseudomonas 
aeruginosa
Correspondence
Jean-Yves Maillard, Welsh School of 
Pharmacy, Redwood Building, King Edward 
VII Avenue, Cardiff, CF10 3NB, UK.
E-mail maillardjOcardiff ac.uk
2010/0676: received 23 April 2010, revised 
and accepted 15 November 2010
doi: 10 111 \f\ 1365-2672.2010.04928 x
Abstract
Introduction: Pseudomonas aeruginosa is an opportunistic pathogen and is the 
main cause of respiratory infection in cystic fibrosis patients. Most strains pre­
valent within the UK are resistant to two or more antibiotics leading to the 
search for new therapeutic strategies including the use of bacteriophages. 
Methods and Results: The infectivity of four bacteriophages was increased 
using an enhancement protocol based on the use of pomegranate rind extract. 
Their efficacy against 14 Ps. aeruginosa strains was measured using a qualitative 
streak test and a novel quantitative assay based on the Bioscreen C microbial 
growth analyzer. Streak test analysis illustrated an increase in the lytic activity 
of enhanced bacteriophages, whereas Bioscreen analysis showed that both 
enhanced and unenhanced bacteriophages failed to meet acceptable levels of 
activity in c. 50% of strains tested.
Conclusions: The quantitative Bioscreen C analyzer showed comparable but 
not identical results in phage activity and identified significant bacterial re­
growth by 20 h postinfection.
Significance and Impact of the Study: With the resurgence of interest in bacte­
riophage therapy against infectious bacterial diseases, a rapid high throughput 
quantitative method for screening phage activity and bacterial resistance is 
required. The use of the Bioscreen C analyzer meets these criteria and was 
shown to be more stringent than the traditional streak test.
Introduction
Pseudomonas aeruginosa, an environmentally ubiquitous 
organism, is an opportunistic human pathogen that plays 
a key role in Cystic Fibrosis (CF) patients with around 
80% of patients colonized by the age of 20 years (Saiman 
and Siegel 2004). With an increase in the level of anti­
biotic resistance over the past decade, there has been a 
renewed interest in alternatives to antibiotic therapy. 
Although in clinical use in Eastern Europe, bacteriophage 
therapy has only recently begun to attract attention in the 
West with a number of new products being licenced or 
currently in clinical trials (Merabishvili et a l 2009).
To successfully produce whole phage based therapeutics, 
a number of criteria must be met. These include the ability 
to infect a range o f bacterial strains as well as the ability to 
reduce the overall level o f infection (Hanlon 2007). One of
two distinct approaches may be undertaken to create such 
a phage preparation: genetic modification (GM) of the 
phage genome to broaden specificity and to increase activ­
ity, or the selective breeding of phage, isolating the most 
infectious. The former of these two approaches is undoubt­
edly attractive allowing the ability to not only increase the 
rate and overall level of bacterial kill but also to provide 
genes that when expressed would enhance phage virulence, 
e.g., biofilm penetration through the production of an algi­
nate lyase (Hanlon et al. 2001). However, products based 
on genetically modified (GM) phages might be more 
difficult to bring to market due to the level o f regulation 
surrounding GM organisms. The latter approach on the 
other hand allows for the selection of more virulent phages 
on the basis of infectivity (Jassim et al. 1995).
The activity of phages is generally measured using tra­
ditional plating on agar of target bacteria where infection
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will be identified by plaque production (Adams 1959). 
Plaque morphologies and counts, however, vary yielding 
a subjective end point. The traditional streak assay, which 
relies on such a protocol is limited in its capacity and 
does not provide evidence for the emergence of bacterial 
resistance and re-growth (Merabishvili et al. 2009). Both 
phage induced lysis and bacterial re-growth can be 
followed by turbidometric measurements, offering an 
alternative and potentially high throughput method 
(Maillard et al. 1996).
In the present study, the efficacy o f a novel high through­
put method for measuring phage activity was tested against 
four Ps. aeruginosa phages and 14 strains o f Ps. aeruginosa 
including isolates from CF patients. Phage activity was 
concurrendy tested with a traditional streak test.
Materials and Methods
Host cells and bacteriophage cultures
Bacterial strains were kindly provided by Dr E Mahen- 
thiralingam (School o f Biosciences, Cardiff University, 
Cardiff, UK) (Table 1). Ps. aeruginosa PAOl was obtained 
from the National Collection o f Industrial and Marine 
Bacteria (NCIMB, Aberdeen, UK). Ps. aeruginosa NCTC 
10332 (reference strain) was obtained from the Health 
Protection Agency (London, UK). Four bacteriophages, 
C10176-Large (C10176-L), C10176-Small (C10176-S), 
GL-1 and L-Phage-Medium (LP-M), were kindly 
provided by Prof. GW Hanlon (School o f Pharmacy, 
University o f Brighton, Brighton, UK). Bacterial strains 
and bacteriophages were stored at -80°C  in 10% glycerol.
Bacterial cultures were routinely prepared in tryptone soy 
broth (TSB; Oxoid Ltd, Cambridge, UK) and incubated 
at 37°C for 24 h. Cultures were centrifuged at 2600 g, 
resuspended in tryptone sodium chloride (TSC; 1 g I-1 
tryptone, 9 25 g I-1 NaCl) to a standardized optical 
density at 600 nm (OD60o) corresponding to 1-3 x  108 
CFU ml-1. Bacteriophage suspensions were routinely pre­
pared using the soft overlay agar method (Adams 1959) 
with Ps. aeruginosa PAOl used as the host. Five ml of 
phosphate buffered saline (PBS; Sigma, Dorset, UK) was 
used to remove the sloppy agar layer containing the 
phage. The phage suspension was then centrifuged at 
11 000 g  for 15 min at 4°C and passed through 0-45 and 
0 2 fim  membrane filters (Millipore, Cork, Ireland).
Preparation o f pomegranate rind extract
Pomegranate rind extract (PRE) was kindly provided by 
David Houston (Welsh School o f Pharmacy, Cardiff 
University, Cardiff, UK) and prepared as described in 
Stewart et al. (1998). Briefly, PRE was diluted by adding 
1-3 ml o f PRE in 8-7 ml o f X buffer immediately prior to 
use and 8 3 ml added to 16*7 ml o f a freshly prepared 
ferrous sulfate solution (4*8 mmol I-1 FeS04.7H20 ) .  The 
solution was protected from light.
Enhancement o f Ps. aeruginosa bacteriophage activity
The phage enhancement principle used in this study is 
based on the selection o f the more virulent phage on the 
basis o f  invasion time. The enhancement protocol was 
adapted from Jassim et al. (1995) and is shown in Fig. 1.
Table 1 Pseudomonas aeruginosa strains used in this investigation
Strain name Source Comment
NCTC 10332 NCTC Also known as ATCC 10145. Quality control strain for API products. 
Not producing alginate (Edwards and Saunders 2001)
PA01 Clinical, nonCF Ps. aeruginosa genome sequencing strain (Stover et al. 2000)
C3652* CF Epidemic Manchester CF strain type (Jones et al. 2001)
C3719* CF Epidemic Manchester CF strain type (Jones etal. 2001)
C3786* CF Melbourne Ps. aeruginosa CF strain -  unique (Armstrong etal. 2003)
LES 400* CF Liverpool epidemic strain- Hypervirulent Strain predominant 
epidemic strain in the UK (Salunkhe et al. 2005; Fothergill ef al. 2007)
Midlands-1-9245 (Mids-1) CF Midland 1 epidemic strain
P8959* CF Liverpool epidemic strain- predominant epidemic 
strain in the UK (Fothergill et al. 2007)
C1913* CF A55 unique- Unique genotype from Vancouver patients (Lewis ef al. 2005)
C2238* CF A61 unique- Unique genotype from Vancouver patients (Lewis ef al. 2005)
C2846* CF A55 unique-Unique genotype from Vancouver patients (Lewis ef al. 2005)
C3597# CF Nonepidemic Manchester CF strain type (Jones etal. 2001)
C4503* CF A55 unique- Unique genotype from Vancouver patients (Lewis ef al. 2005)
PAK-SR Research Strain Streptomycin” parent of Fla-/Pil- mutants of PAK. Sm50
Strains indicated by * are epidemic CF strains. ♦ nonepidemic CF strains.
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The initial exposure time (referred to as enhancement 
time) was 15 min and subsequently shortened to 10, 5 
and 2 5 min.
Streak test assay
The following methodology was adapted from (Merabish- 
vili et al. 2009). Ten microlitres o f bacterial suspension 
(c. 1 x 108 CFU ml-1) was streaked over the surface o f a 
100 x  100 mm square petri dish (Sterilin Ltd, Caerphilly, 
UK) that was previously divided into a 5 x 5 grid and air 
dried at room temperature for 15 min. Ten microlitres of 
bacteriophage suspension (c. 1 x  107 PFU ml-1) was then 
spotted onto each intersection and air dried at room tem­
perature for 1 h. PBS was used as a negative control. 
Plates were incubated at 37°C for 3 h and a primary 
assessment for activity was made on the basis o f the
Bacterial host 
suspension (PAO l) 
10 pi of 109 CFU m l-1
Initial phage 
suspension 
(unenhanced)
10 pi of 1012 PFU m h1
15 min enhancement time1
2 -3  min contact time
Incubation for 3 -5  h at 37 °C
Selection step 
Addition of PRE (144 pi)
Isolation of phages 
(in this schematic 15 min enhancement time)
Neutralisation of PRE 
Addition of 2% (v/v) Tween 80 in X-buffer 
(144 pi)
Propagation of “enhanced” phages 
Addition of 0-1 ml P A O l1 (108 CFU ml~1) and 2-3 
ml TSB
Figure 1 Schematic representation of bacteriophage enhancement 
using pomegranate rind extract. 1:Contact time between phages and 
bacterial suspension varied (i.e. enhancement time of 2-5, 5, 10 and 
15 min were used; see text).
extent of phage lysis. A secondary reading was performed 
after a further incubation for 18 h at room temperature 
and a score of ‘O’ (no plaque) to ‘+5’ (confluent lysis) 
was attributed (Merabishvili et al. 2009) (Fig. 2). Ten sep­
arate experiments were conducted and a final score out of 
a maximum value of 50 was calculated.
Bioscreen assay
Three hundred and fifty microlitres of a bacterial suspen­
sion in TSB (c. 1 x 108 CFU ml-1) was added to each 
well o f a 100 well honeycomb plate (Oy Growth Curves 
AB Ltd, Helsinki, Finland) with TSB used as a negative 
control. To each well, 50 pi of standardized bacteriophage 
suspension (10*1 PFU ml-1) was added. This phage/bac­
terial cell ratio was determined in preliminary experi­
ments to give the most appropriate phage activity, 
without directly lysing the bacterial cell on initial contact, 
thus allowing phage replication inside the host. To 
increase the reproducibility of the reading, a total of 10 
wells for each phage were inoculated for each honeycomb 
plate. The plates were then incubated at 37°C for 20 h 
and turbidity recorded using a wideband filter (420- 
580 nm) with readings taken every 15 min in a Bioscreen 
C analyzer (Oy Growth Curves AB Ltd, Helsinki, 
Finland). Each reading was preceded by a 10 s shaking 
cycle. A total o f three independent experiments were per­
formed using fresh bacterial cultures and phage cultures
Figure 2 Example of a phage streak test plate at secondary reading 
stage. Cl -  confluent lysis (+5), 01 -  overgrowth, bacterial line 
completely broken, presence of singular bacterial colonies on spot 
(+4), Sd -  Semi-confluent lysis- bacterial line not completely broken 
(+3), NTV -  Multiple small phage plaques (+2), + / -  Bacterial line just 
affected i.e. little observable disruption to bacterial line (+1) and 
Ng-negative (0).
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for each repeat. Once completed, the mean optical density 
(out o f 10 wells) for each sample at each sampling time 
was calculated. Bacterial number at 8 and 20 h incubation 
time was calculated using a standard graph plotting opti­
cal density reading vs CFU ml-1. Reduction in bacterial 
number (expressed as Log10 reduction) following phage 
exposure was calculated by comparing bacterial number 
recovered after 8 and 20 h incubation from wells exposed 
to phage and those not exposed to phages (control) 
(Fig. 3).
For this study, phage activity with the Bioscreen C ana­
lyser was measured against set ‘acceptance’ values attrib­
uted to two main parameters: (i) a > 2 logl0 decrease in 
bacterial number after 8 and 20 h (i.e. measurement of  
bactericidal efficacy) and (ii) a time of >480 min to reach 
a OD420_580 of 0 1 above the original OD42o_58o (measure­
ment o f bacterial re-growth postphage infection) (Fig. 3 
and Table 2). Other parameters were also calculated but 
did not contribute to the assessment of phage efficacy. 
These included the measurement of phage initial lytic 
activity indicated by a decrease in OD420_58o within 
30 min of phage addition (Fig. 3) and the calculation of 
the lytic slope, which indicates the rate of bacterial lysis. 
The attribution o f set ‘acceptance’ values (Table 2) was 
based on a review of the literature for phage activity 
(Hanlon et al. 2001; Atterbury et al. 2007; Fu et al. 2010) 
and antibiotic dosing times (Van Zanten et al. 2007; 
McCoy et al. 2008).
1 9
15
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.2 . 0-6 TJ
<  0-5 
0-4 
0-3 
0 2
0 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200
Time (min)
Figure 3 Representative change in bacterial growth patterns of Pseudomonas aeruginosa strain C1913 following treatment with original and 
enhanced C10176-S bacteriophage (a and b) bacterial reduction at 8 and 20 h respectively, (c) time taken for the OD42&. 580 to increase by 0-1 
above the initial OD420-s8o Phage treated samples are the mean of three replicates; untreated samples are the mean of six replicates. (#) 
Untreated Cultures; (■) nonPRE treated phage and (A) PRE treated phage
Statistical analysis
Data were analysed for significant differences using a one­
way a n o v a  in Minitab 15 (Minitab Ltd, Coventry, UK).
Results
Assessment of phage activity using the streak test 
method
Phage activity was enhanced against Ps. aeruginosa PAOl. 
Phages showing an increase in activity were then tested 
against the different clinical isolates.
The streak test showed an increase in the level of 
lytic activity o f the four phages against Ps. aeruginosa 
PAOl (Table 3). The largest level of increased lytic 
activity against PAOl was after the first enhancement 
step of 15 min (data not shown). The further enhance­
ment steps following 10, 5 and 2 5 min contact time 
lead to smaller increases in activity (data not shown). 
Ultimately, the maximum level o f lytic activity against 
PAOl was reached after the final enhancement time of 
2 5 min for all phages, except for GL-1, for which a 
maximum activity was reached after the enhancement 
time o f 5 min (Table 3). When used against all bacte­
rial isolates, the highest increase in activity was 
observed for C10176-L and LP-M and the smallest for 
GL-1. For some bacterial strains, notably for the CF
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Table 2 Summary of the lytic assessment 
criteria of Pseudomonas aeruginosa 
bacteriophages from Bioscreen C assessment
Evaluation criteria
log ,0 reduction
8 hours 20 hours
Time* (min)
Additional criterion
Lysisf (min)
'Acceptance' valuet >2 >2 >480 £30
Phage Treatment
No of bacterial strains meeting the 
acceptance value out of 14
GL-1 Non-PRE 3 3 8 7
C10176-S treated 3 4 8 7
C10176-L 6 6 8 7
LP-M 7 10 8 7
GL-1 PRE 7 7 7 4
C10176-S treated 6 6 8 4
C10176-L 6 7 6 4
LP-M 7 6 6 4
*Time taken to increase OD42o-s8o by 0-1 above the original OD4 2 0 _580 
fTime taken to induce a lytic slope 
tSet 'acceptance' value (see text)
Tabla 3 Comparison of lytic activity of 
phages against Pseudomonas aeruginosa 
PAOl between the streak test method and 
the Bioscreen C analyzer
Bioscreen C analyser
log i0 reduction (CFU ml"1)
Phage treatment (score out of 50) 8 hours 20 hours P-values* (minutes)
C10176-L
Nonef 20 2 06 ± 0-50 2 28 ± 0-89 0-724 >1200
PRE§ (2-5)f 48 3 14 ± 0-10 3-20 ± 0-46 0-834 >1200
C10176-S
None 29 2 04 ± 0-52 2 31 ± 0-83 0-662 >1200
PRE (2-5) 47 3-14 ± 0-10 3 23 ± 0-52 0-668 >1200
GL-1
None 20 1 -95 ± 0 51 1-24 ± 1-10 0-367 815 ± 670
PRE (5) 46 2-66 ± 0-25 2-72 ± 0-13 0-712 >1200
PRE (2-5) 43 3-15 ± 0-11 3 -18 ± 0 -40 0-905 >1200
LP-M
None 30 2-01 ± 0-45 2 28 ± 0-89 0-667 >1200
PRE (2-5) 45 3 01 ± 0-30 2-97 ± 0-55 0-917 >1200
Data are based upon the means of three replicates.
*P-values showing differences in logio reduction at 8 and 20 h. 
fTime taken to increase OD4 2 o_5 8o by 0-1 above the original OD420_s8o 
{None: phage not treated with PRE (i.e. original phage).
§PRE: phage exposed to PRE.
^(time): phage-bacteria contact time (min) before exposure to PRE (see text).
epidemic strain Midlands-1, no increase in phage acti­
vity was observed, whereas only LP-M phage showed 
some increase in activity against CF nonepidemic strain 
C4503 (Tables 4-7). Overall, C10176-L and LP-M 
showed increased levels o f activity against 11 strains, 
C10176-S against 10 strains and GL-1 against six strains 
(Tables 4-7). Surprisingly, all enhanced phages showed 
decreased levels o f activity against Midlands-1 (data not 
shown). Finally, the nonepidemic CF bacterial strains
were overall more susceptible to the enhanced phages 
when compared to epidemic strains.
Assessment o f phage activity using the Bioscreen C 
m ethod
When PAOl was challenged with phages, a lytic slope 
was observed within 30 min o f the initial inoculation 
for original phages and immediately upon exposure for
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Table 4 Summary table of Bioscreen C Data for Pseudomonas aeruginosa strains exposed to C10176-L phage
Original phage Enhanced phage
Streak test
Bioscreen C analyser Bioscreen C analyser
-------  Streak test
Bacterial strain (score out of 50) Log,0 reduction* Timef (minutes) (score/50) Log 10 reduction* Timef (minutes)
10332 10 0-90 ± 0 78 205 ± 10 21 (10)f 1 -90 ± 0-65 180 ± 40
C36S2 10 0-94 ±0-14 590 ± 85 36 (10) 1-06 ± 0 15 1005 ± 340
C3719 0 0-85 ± 0-05 565 ± 10 25(10) 1 05 ± 015 >1200
C3786 44 2 58 ± 105 130 ± 10 -§ 2-74 ± 0-60 140 ± 10
LES-400 10 1-09 ± 0-18 1155 ± 80 29 (2-5) 0-88 ± 0-27 860 ± 280
Mids-1 10 ND^ i 105 ± 45 - ND 140 ± 25
P89S9 10 1-99 ±0-20 1180 ± 35 27(10) 1 72 ± 0-46 770 ± 285
C1913 0 4-36 ± 1 79 345 ± 55 22 (2-5) 3-57 ± 2-24 240 ± 50
C2238 0 0-59 ± 0-07 865 ± 135 49 (5) 0-59 ± 0  14 790 ± 325
C2846 20 2 39 ± 0-95 305 ± 30 24(10) 3-04 ± 0 83 205 ± 40
C3597 47 3 78 ± 0-82 570 ± 210 50(10) 2-47 ± 0-09 185 ± 40
C4S03 20 0-07 ± 0-04 130 ± 10 - 0-95 ± 1-70 380 ± 440
PAK-SR 16 2 90 ± 0-22 1085 ± 150 40 (15) 3-05 ± 0-26 1000 ± 165
Data shown are the mean of three replicates. Bold typeface indicates significant differences.
•Logip reduction m bacterial number at 8 h
fTime taken to increase OD42o-seo by 0-1 above the original OD420-S80
t(time) phage-bacteria contact time (mm) before exposure to PRE (see text)
§Dashes indicate no increase or decrease in lytic activity
r ND no reduction in bacterial content determined
TabU 5 Summary table of Bioscreen C Data for Pseudomonas aeruginosa strains exposed to C10176-S phage
Original phage Enhanced phage
Bioscreen C analyser Bioscreen C analyser
Ctrpak tfKt Streak test
Bacterial strain
</ll COK ICjI
(score out of 50) Log10 reduction* Timef (minutes) (max. 50) Log 10 reduction* Timef (minutes)
10332 14 0-47 ± 0-78 220 ± 30 27 (15)t 1-64 ± 1 20 180 ± 25
C36S2 30 0-97 ± 0-24 900 ± 520 40 (10) 0-95 ± 0-37 558 ± 200
C3719 30 0-89 ± 0-24 890 ± 540 31 (15) 0-77 ± 0-31 485 ± 170
C3786 9 0 87 ± 1 31 100 ± 25 45 (2-5) 3 32 ± 0 80 145 ± 10
LES-400 14 0-91 ± 0-24 805 ± 280 30 (2-5) 1 50 ± .121 980 ± 330
Mids-1 18 ND§ 95 ± 30 _«• ND 140 ± 25
P8959 22 1-96 ± 0-2 1100 ± 85 - 1-81 ± 0-08 825 ± 145
C1913 30 1 50 ± 033 200 ± 30 - 4 49 ± 105 425 ± 285
C2238 8 0-56 ±0-11 805 ± 50 40 (10) 0-62 ±0-13 865 ± 340
C2846 25 0-76 ± 0-67 215 ± 25 30 (10) 2-73 ± 1 52 215 ± 50
C3597 2 3 73 ± 0-78 500 ± 280 46(5) 3-39 ± 0-59 895 ± 295
C4503 30 ND 140 ± 10 - 0-81 ± 1 63 370 ± 435
PAK-SR 24 2-84 ± 0-26 1095 ± 160 46(5) 3-04 ± 0-35 1025 ± 100
Data shown are the mean of three replicates. Bold typeface indicates significant differences. 
*Logio reduction in bacterial number at 8 h.
fTime taken to increase OD4 2 0-S8 0  by 0-1 above the original OD4 2 0 -5 8 0  
t(time): phage-bacteria contact time (min) before exposure to PRE (see text).
§ND: no reduction in bacterial content determined.
•■Dashes indicate no increase or decrease in lytic activity.
enhanced phages. However, there was no significant 
(P > 0 05) change in the rate o f OD42o-58o decrease per 
minute between original and enhanced phages (data 
not shown). A lytic slope was not necessarily observed
with all CF isolates exposed to the parent or enhanced 
phages (data not shown). Where a decrease OD42o_58o 
was noted (against Ps. aeruginosa LES400, P8959 and 
PAK-SR), there was no statistically significantly
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Tabl* 6 Summary table of Bioscreen C Data for Pseudomonas aeruginosa strains exposed to GL-1 phage
Bacterial strain
Original phage Enhanced phage
Streak test 
(score out of 50)
Bioscreen C analyser
Streak test 
(max. 50)
Bioscreen C analyser
Log 10 reduction* Timef (minutes) Log10 reduction* Timef (minutes)
10332 35 0-99 ± 0-74 230 ± 35 - t 2 09 ± 0-98 180 ± 25
C3652 34 1 -23 ± 0-17 885 ± 295 38 (10)§ 0-90 ± 0-20 505 ± 140
C3719 46 0-93 ±0-17 585 ± 130 - 0-79 ± 0-20 455 ± 160
C3786 44 0 77 ± 0-67 110 ± 30 - 2-72 ± 1-43 145 ± 10
LES-400 30 109 ± 0-13 1185± 25 34 (2-5) 0-97 ± 0-21 940 ± 80
Mids-1 30 NDC 85 ± 20 - ND 140 ± 25
P89S9 35 1 79 ± 0-34 905 ± 175 - 1 95 ± 0 07 915 ± 25
C1913 6 3 30 ± 0 85 310 ± 20 22 (2-5) 506 ± 0 33 345 ± 90
C2238 23 0-51 ± 0 08 765 ± 70 40 (10) 0-57 ± 0-16 840 ± 240
C2846 35 0 97 ± 050 240 ± 15 - 2 90 ± 0 08 345 ± 275
C3597 50 3-80 ± 0-78 560 ± 185 - 2-98 ±0-19 495 ± 300
C4S03 34 ND 140 ± 20 - 0-90 ± 1-52 350 ± 400
PAK-SR 30 2 78 ± 0 23 >1200 46 (2-5) 2-98 ± 0 31 1020 ± 40
Data shown are the mean of three replicates Bold typeface indicates significant differences 
•Log 10 reduction in bacterial number at 8 h
fTime taken to increase OD42o-sso by 0-1 above the original OD420-s8o 
fDashes indicate no increase or decrease in lytic activity, 
i  (time) phage-bacteria contact time (mm) before exposure to PRE (see text)
• ND no reduction in bacterial content determined
difference (P > 0 05) between original and enhanced 
phages (data not shown). In the strains where no lytic 
slope was observed (e.g. C1913), the growth pattern of 
the bacterial isolates was dramatically altered by the 
phage (example in Fig. 3) and the final OD42<v_58o at 
20 h was lower following exposure to enhanced phages. 
It has to be noted that as our protocol is based on 
OD reading, bacterial cell debris following lysis might 
have contributed somewhat to the OD values recorded 
and as such might have masked initial cell lysis follo­
wing initial phage interaction/replication in their host. 
However, the presence o f cell debris cannot explain 
solely the dramatic change in bacterial growth pattern 
recorded following phage treatment.
When the phage bactericidal activity to PAOl was eval­
uated, enhanced phages showed a significantly higher 
(P <  0 05) level o f bacterial reduction compared to their 
original counterparts at both 8 and 20 h (Table 3). There 
was no significant difference (P > 0 05) in the reduction 
o f  bacterial number after 8 and 20 h incubation 
(Table 3). There was, however, a significant difference 
(P = 0034) between the efficacy o f the original and 
enhanced phages at 8 h and these results were in accor­
dance to those obtained from the streak test (Table 3). In 
the case o f GL-1 where a 5 min PRE treatment yielded 
the highest score by streak test, there was no significant 
difference (P > 0 05) in phage activity between the 5 and 
2 5 min enhancement time (Table 3) when measured with
the Bioscreen. Furthermore, in PAOl, there was no signif­
icant difference in bacterial re-growth following original 
and enhanced phage exposure (Table 3).
There was generally no significant difference (P > 0 05) 
in activity between original and enhanced phages at 8 h 
exposure against CF isolates (Tables 4-7), with the excep­
tion o f Ps. aeruginosa C3786 and C1913 exposed to 
C10176-S (Table 4) and C1913 and C2846 challenged 
with GL-1 (Table 6). After 8 h  incubation at 37°C, all 
bacterial strains showed a reduction in bacterial number 
when exposed to original or enhanced phages with the 
exception o f  Midlands-1.
Following exposure to phages, all bacterial strains 
showed an eventual increase in OD42o_58o (Tables 4-7). 
This OD420_58o increase is indicative o f bacterial 
re-growth and potentially indicates the presence of 
resistant bacteria to the phage. However, the extent of  
OD 42o_58o increase varied between bacteria/phage combi­
nations. In the majority o f cases, the time taken to 
increase the OD420- 5so by 01 above the initial OD 420_58o 
was reduced when bacteria were exposed to enhanced 
phage (Tables 4-7).
Comparison o f activity between the streak test and the 
Bioscreen C
Overall, there was some correlation between the streak 
test assay and the Bioscreen C assay against PAOl, where
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Table 7 Summary table of Bioscreen C Data for Pseudomonas aeruginosa strains exposed to LP-M phage
Onginal phage Enhanced phage
Bioscreen C analyser Bioscreen C analyser
Bacterial strain (score out of 50) Log 10 reduction* Timet (minutes) (max. 50) Log10 reduction* Timef (minutt
10332 32 0-87 ± 0-56 200 ± 20 - t 2-01 ± 0-80 170 ± 30
C3652 22 1 08 ± 0 02 880 ± 280 35 (10)§ 0-92 ± 0-32 505 ± 275
C3719 20 0-95 ± 0-24 >1200 31 (10) 0-76 ± 0-29 450 ±250
C3786 40 3 03 ± 1-02 130 ± 20 42 (2-5) 2-70 ± 0-99 140 ± 10
LES-400 30 1-08 ± 0-19 1155 ± 80 - 0-91 ± 0-23 940 ± 320
Mids-1 10 NDC 115 ± 40 - ND 135 ± 15
P8959 20 2 03 ± 01 7 >1200 26 (10) 1 76 ± 0-28 830 ± 285
C1913 0 5-57 ± 0-45 545 ± 115 22 (10) 4-84 ± 0-86 350 ± 205
C2238 20 0-77 ± 0 09 >1200 50 (5) 0 51 ± 017 705 ± 370
C2846 43 3 00 ± 0 36 305 ± 10 50 (10) 3 01 ± 0-31 200 ± 40
C3597 43 3 90 ± 0-82 605 ± 8 5 50(10) 2-66 ± 0-26 220 ± 60
C4503 10 ND 130 ± 10 21 (10) 0-83 ± 1-54 335 ± 360
PAK-SR 4 2 95 ± 0-26 995 ± 75 42 (2-5) 2-85 ± 0-33 950 ± 55
Data shown are the mean of three replicates Bold typeface indicates significant differences.
*log,0 reduction in bacterial number at 8 h.
fTime taken to increase O D 4 2 0 - S 8 0  by 0-1 above the original OD42a-s8o 
{Dashes indicate no increase or decrease in lytic activity.
I (time) phage-bacteria contact time (mm) before exposure to PRE (see text)
CND no reduction in bacterial content determined
all enhanced phages with the exception o f GL-1 showed 
the highest reduction o f bacterial number with the 
Bioscreen C (Table 3). This fact corresponded to the 
highest scores achieved with the streak test (Table 3). 
However, with enhanced GL-1, the largest reduction in 
bacterial number was obtained after an enhancement 
time o f 2 5 min, compared to the highest score on the 
streak test that was obtained after a 5 min enhancement 
(Table 3). When comparing the time taken for PAOl to 
re-grow to an OD42&-580 value o f 01  higher than the 
initial OD 42<>-580> ft was found that for all phages, 
except GL-1, bacteria treated with both original and 
enhanced phages took >1200 min to reach this value 
(Table 3).
When the activity o f phages was assessed against CF 
isolates, the level o f correlation between the streak test 
and the reduction o f bacterial number from the Bioscreen 
C method depended upon phage/bacterial strain. A good 
correlation was observed with LP-M and two strains, 
C10176-L and five strains, GL-1 and six strains and 
C10176-S and seven strains (Tables 4-7). For all the 
other phage/bacteria combinations, however, the level o f  
reduction in bacterial number at 8 h was not significantly 
different (P > 0 05) when exposed to the original or the 
enhanced phages.
When phage performance was compared to the set 
‘acceptance’ values, it was observed that an ‘acceptable’ 
status was achieved against 50% or less strains (Table 2). 
However, enhanced phages appeared to have a better
activity than the original phage although bacterial 
re-growth was faster in many bacteria.
Discussion
With the renewed interest in bacteriophage therapy for a 
variety o f conditions ranging from Ps. aeruginosa infec­
tions in cystic fibrosis patients to the use o f bacterio­
phages to reduce the level of Salmonella colonization of 
broiler chickens (Atterbury et al. 2007), there is a need 
for a high throughput method, which is both sensitive 
and quantitative.
Although a successful phage product does not hinge on 
the initial screening of activity, the selection o f phages 
may be enhanced by efficient and quantitative screening 
methods to ensure maximum activity against the widest 
host range. Here, we have shown that both the streak 
plate method and the Bioscreen method produced similar 
results, at least with phages showing a large increase in 
activity. Although the streak test provides adequate quali­
tative data for initial screening in the form o f a single 
number, it does not provide the quantitative data that 
would be needed to select phages for practical applica­
tions. Conversely, the data generated by the Bioscreen C 
analyser allows for the assessment o f multiple criteria. 
These criteria, however, should not be taken individually, 
but should instead be combined, and phages selected on 
the basis o f increased characteristics between all criteria 
combined. Our assay relied on the calculation o f bacterial
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number from a pre-established OD/TVC graph. Such 
extrapolation o f bacterial number has its limitation as the 
OD/TVC graph is not linear above an OD value o f c. 0 8. 
At best, this limitation means that our bacterial number 
calculated from OD value >0 8 might have been underes­
timated. However, the conversion o f OD value in bacte­
rial number, and the subsequent calculation o f Log,0 
reduction, enables the direct comparison o f phage activity 
between strains that show different growth kinetic to be 
established. Our method aimed to provide criterion to 
compare phage activity against multiple bacterial strains 
that might show different growth characteristic. Although, 
the conversion o f OD values to bacterial number has its 
drawbacks, our results proved to be reproducible and 
enabled phage activity to be effectively compared.
In this manuscript, two methods were compared and 
some similarities were observed. It has to be noted that 
the parameters used in the two methodologies were 
different, notably the different phage: bacteria ratio, 
the incubation temperature following exposure and the 
media. These parameters might have contributed to the 
differences in results observed. The parameters used with 
the Bioscreen were developed in preliminary experiments 
and chosen as they provided the best results. The parame­
ters used in the traditional streak test are those described 
in the literature and used routinely. The main objective 
of this paper was to report an automated method to 
improve on the traditional streak test. The main practical 
difference between the two methods remains with the 
number o f  bacteria/phage combination that can be tested. 
With the streak test, a maximum of four phage combina­
tions and one set o f  controls (five replicates per bacterial 
line) against a single bacterial species could be tested in 
any one experiment. However, with the Bioscreen assum­
ing the same number o f replicates, a maximum of 18 
phage combinations could be investigated showing that 
the Bioscreen has a higher throughput. In addition, the 
Bioscreen method provided important quantitative infor­
mation on bacterial re-growth following phage exposure 
over a 20 h period.
In this study, four Ps. aeruginosa bacteriophages were 
confirmed to possess activity against multiple strains of 
Ps. aeruginosa including some o f the more prevalent 
strains within the UK (Salunkhe et al. 2005; Fothergill 
et al. 2007). Result variability is most probably caused by 
the inherent variability that is associated with both bacte­
rial and bacteriophage growth despite initial standardiza­
tion o f bacterial content. The differences in susceptibility 
of the phages may be a result in part to the binding effi­
cacy o f the phage to the target cell (Hart et a l  1994) and 
also the growth rates o f the strains tested. The nature o f  
the PRE treatment also accounts for a lack o f increase in 
both rate and level o f  kill as it was originally designed to
select bacteriophages on the basis o f invasion time rather 
than other factors (Jassim et al. 1995).
The use o f the Bioscreen C analyzer produced a quick 
real-time assessment o f bacteriophage activity. It allows 
the rapid visualization o f bacterial lysis demonstrating 
phage activity although measurement of the rate o f lysis 
was shown not to be a reliable criterion for the compari­
son o f lytic activity. Measurement o f OD in the Bioscreen 
assay is automated and does not rely on human qualita­
tive assessment on plaque formation as in the streak assay 
(Merabishvili et al. 2009) and was shown to be more 
stringent compared to the streak test and provided quan­
titative results within 8 h. In comparison, the streak test 
method can take up to 24 h (Merabishvili et al. 2009). 
The Bioscreen method could be further refined with the 
use o f metabolic assays to assess the level o f bacterial 
viability (Kuda and Yano 2003; Cerca et al. 2005) or 
potentially bioluminescent mutants (Marques et al. 2005; 
Jassim and Griffiths 2007; Thorn et al. 2007), which pro­
vide direct measurements of bacterial viability, ultimately 
increasing the sensitivity o f this OD-based quantitative 
assay.
The set ‘acceptance’ values used in this study aim to 
ensure that selected phages possess acceptable properties 
to be used for therapy. The phages used in this study 
meet these criteria in 50% or less o f strains tested, imply­
ing that their activity is not yet sufficient to be applied to 
therapeutics. These ‘acceptance’ values were set after a 
review o f the literature and taken into account antibiotic 
dosing to prevent bacterial re-growth. It is conceivable 
that our values are too stringent and might need to be 
revised. To this aim the testing of phages that are cur­
rently undergoing licencing or already licenced for human 
applications would be of benefit.
The Bioscreen method is an in vitro set up and phage 
behaviour in vitro  might be different from their behaviour 
in situ. The chemical and physical parameters used in the 
Bioscreen set up (e.g. growth media, temperature; % 
C 0 2) can be modified to represent better conditions 
found in practice.
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